W.-H. Boehncke · H.H. Radeke (Eds.) Biologics in General Medicine
W.-H. Boehncke · H.H. Radeke (Eds.)
Biologics in G...
156 downloads
2490 Views
6MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
W.-H. Boehncke · H.H. Radeke (Eds.) Biologics in General Medicine
W.-H. Boehncke · H.H. Radeke (Eds.)
Biologics in General Medicine With 51 Figures in 95 Parts and 23 Tables
Prof. Dr. med. Wolf-Henning Boehncke MA Department of Dermatology Clinic of the Johann-Wolfgang-Goethe-University Theodor-Stern-Kai 7 60590 Frankfurt Prof. Dr. med. Heinfried H. Radeke Dr.-Hans-Schleussner-Foundation Immune Pharmacology pharmazentrum frankfurt, Bldg. 75, Room 103 Johann-Wolfgang-Goethe-University Theodor-Stern-Kai 7 60590 Frankfurt
ISBN 978-3-540-29017-9
Springer-Verlag Berlin Heidelberg New York
Library of Congress Control Number: 2006938888 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. Springer is a part of Springer Science+Business Media http://www.springer.com ˇ Springer-Verlag Berlin Heidelberg 2007 Printed in Germany The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature. Editor: Dr. Ute Heilmann Desk Editor: Dörthe Mennecke-Bühler Copy-editing: WS Editorial Ltd, Shrewsbury, UK Production Editor: Joachim W. Schmidt Cover design: eStudio Calamar, Spain Typesetting: FotoSatz Pfeifer GmbH, D-82166 Gräfelfing Printed on acid-free paper – 21/3150 – 5 4 3 2 1 0
Preface
The idea for this book was born during the symposium on biologics organized by ZAFES (Center for Drug Research, Development and Safety at the University of Frankfurt am Main) in September 2005. Highly distinguished researchers specializing in the field of biologics had gathered together to exchange information on this relatively new subject. Realizing that this symposium was one of the few sources of condensed information on biologics, it became obvious that we had to create a means of informing an interested wider circle of scientists and especially general clinicians. Therefore, the editors of this book suggested to the researchers at the symposium and also to prominent scientists and clinicians involved in the development and application of biologics as their major field of interest the idea of assembling this compendium. We received an overwhelmingly positive response – thankfully also from the publisher – most being more than willing to support this innovative project with highly relevant chapters on the latest state of the art. As we were eager to fill the information gap with up-to-date knowledge, the project had to be finished within the shortest time possible. To all experienced with editing this was obviously a challenge and we are very thankful to all the contributors that our timeline had to be extended by only a few months. This book represents a collection of the most recent knowledge on biologics written by people who have been active in the field for many years. Wolf-Henning Boehncke Heinfried H. Radeke
Contents
1 1.1 1.2
Introduction: Definition and Classification of Biologics W.-H. Boehncke, H.H. Radeke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
I
Development and Pre-clinical Pharmacology of Biologics
2
Infliximab: From the Idea to the Product M. Wiekowski, Ch.E. Antoni . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.1 Characteristics and Biological Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.1.1 Antibody Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.1.2 Other Mechanisms of Infliximab Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.2 Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.3 Therapeutic Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.4 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.4.1 Pharmacokinetics in Rheumatoid Arthritis Patients . . . . . . . . . . . . . . . . . . . 2.4.2 Pharmacokinetics in Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.4.3 Pharmacokinetics in Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.4.4 Pharmacokinetics in Pediatric Crohn’s Patients . . . . . . . . . . . . . . . . . . . . . . . 2.5 Relationship Between Infliximab Concentration and Clinical Response . . . 2.6 Antibody Formation Against Infliximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.6.1 HACA Formation and Clinical Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 Infusion Reactions/Delayed Hypersensitivity Reactions . . . . . . . . . . . . . . . . 2.8 Alternative Routes of Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.9 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3.1 3.1.1 3.1.2 3.1.3 3.1.4 3.2 3.3 3.3.1
Adalimumab J. Salfeld, H. Kupper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pharmacology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mode of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adalimumab Comparisons with Infliximab and Etanercept . . . . . . . . . . . . . Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pivotal Studies in Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adalimumab Plus Methotrexate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 5 5 5 6 6 7 7 9 9 9 10 10 11 11 11 12 12
14 15 15 16 16 16 18 18 19
VIII
Contents
3.3.2 Monotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.3.3 Adalimumab Plus Traditional DMARDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.3.4 Early Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.4 Pivotal Studies in Psoriatic Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.5 Pivotal Study in Ankylosing Spondylitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.6 Future Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.6.1 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.6.2 Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.7 Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.8 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19 22 22 23 25 25 25 25 26 27 28
4
Etanercept Ch.T. Molta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1 Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.1 Absorption . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.2 Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.3 Metabolism and Elimination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.4 Age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.5 Gender . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.6 Patients with Renal or Hepatic Insufficiency . . . . . . . . . . . . . . . . . . . . . . . . . 4.2.7 Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.3 Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.3.1 Mode of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.3.2 Pharmacodynamics in Disease States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.4 Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Key References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
32 32 32 32 34 34 34 34 34 35 35 35 36 38 40 40 40
5
Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development S. Jahn, K. Schmitt-Rau . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.2 Development and Characterization of the Antibody . . . . . . . . . . . . . . . . . . . 5.3 Efalizumab: From Mode of Action to the Treatment of Psoriasis . . . . . . . . . 5.3.1 Psoriasis: Prevalence, Characteristics and Therapeutic Options . . . . . . . . . 5.3.2 Pathogenesis of Psoriasis: Targets for Efalizumab . . . . . . . . . . . . . . . . . . . . . 5.3.3 Efalizumab: Mechanism of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.4 Pharmacology and Toxicology of Efalizumab . . . . . . . . . . . . . . . . . . . . . . . . . 5.4.1 Preclinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.4.2 Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.4.3 Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.5 Indication(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
42 42 43 44 44 45 46 47 47 47 48 49 49 49
Contents
6
Monoclonal Antibody Targeted Radiation Cancer Therapy L.M.M. Keller, C.A. Boswell, D.E. Milenic, Erik D. Brady, Martin W. Brechbiel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2 Introduction and Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.3 The Radioisotope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.4 Linking the Radionuclide to Protein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.5 The Protein Vehicle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50 50 50 51 54 56 57 57
7
The Production of Biopharmaceuticals B. Hughes, L.E. Hann . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.2 The Success of Modern Biotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3 The Science and Technology Behind Modern Biopharmaceuticals . . . . . . . 7.4 Process Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.5 Biopharmaceutical Manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.6 Quality Assurance and Quality Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.7 Facility Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.8 Biosimilar Products (or Follow-on Biologics) . . . . . . . . . . . . . . . . . . . . . . . . . 7.9 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Key References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Full Reference List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II
59 59 60 61 62 63 64 64 65 65 65 66
Disease-Specific Applications and Clinical Trials
8
Treating Autoimmune Bullous Skin Disorders with Biologics R. Eming, A. Niedermeier, M. Pfütze, A. Jacobi, M. Hertl . . . . . . . . . . 8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.1.1 Autoimmune Bullous Skin Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.1.2 Immune Pathogenesis of Bullous Autoimmune Disorders . . . . . . . . . . . . . . 8.2 Rituximab (Anti-CD20 Monoclonal Antibody) in the Treatment of Autoimmune Bullous Skin Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2.1 Biological Activity of Rituximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2.2 Clinical Experience with Rituximab Therapy . . . . . . . . . . . . . . . . . . . . . . . . . 8.2.3 Rituximab in Pemphigus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2.4 Rituximab in Epidermolysis Bullosa Acquisita . . . . . . . . . . . . . . . . . . . . . . . . 8.2.5 Toxicity of Rituximab Treatment and Adverse Effects . . . . . . . . . . . . . . . . . . 8.2.6 Contraindications for Treatment with Rituximab . . . . . . . . . . . . . . . . . . . . . 8.3 Inhibitors of TNF- [ in the Treatment of Autoimmune Bullous Skin Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.3.1 Central Role of TNF- [ in Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.3.2 Inhibition of TNF- [ by Biologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.3.3 Inhibition of TNF- [ in Pemphigus Vulgaris . . . . . . . . . . . . . . . . . . . . . . . . . . 8.3.4 Inhibition of TNF- [ in Bullous Pemphigoid . . . . . . . . . . . . . . . . . . . . . . . . . . 8.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69 69 69 71 72 72 73 73 74 76 76 76 76 77 78 79 79 80
IX
X
Contents
9
Biologics in Psoriasis W.A. Myers, W.-H. Boehncke, A.B. Gottlieb . . . . . . . . . . . . . . . . . . . . 9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.1.1 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.1.2 Mechanism of Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2 Etanercept . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2.1 Structure and Mode of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2.2 Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . 9.2.3 Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2.4 Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.2.5 Off-Label Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3 Efalizumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3.1 Structure and Mode of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3.2 Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . 9.3.3 Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3.4 Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.3.5 Off-Label Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4 Alefacept . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4.1 Structure and Mode of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4.2 Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . 9.4.3 Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4.4 Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4.5 Off-Label Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.5 Infliximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.6 Adalimumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
81 81 81 85 86 86 86 87 88 89 89 89 89 90 91 92 92 92 93 93 94 95 95 95 96
10
Biologic Agents in Psoriatic Arthritis Ph. Mease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.2 Classification and Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.3 Genetic Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.4 Immunopathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.5 Clinical Features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.6 Outcome Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.7 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.8 Biologic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.8.1 Etanercept . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.8.2 Infliximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.8.3 Adalimumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.9 Other Biologic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.9.1 Alefacept . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.9.2 Efalizumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.9.3 Abatacept . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.10 Other Potential Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.11 Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.12 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
97 97 97 97 98 98 101 101 102 102 103 104 105 105 106 106 106 107 107 108
Contents
11
Biologic Therapies for Rheumatoid Arthritis Targeting TNF-␣ and IL-1 P.C. Taylor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 11.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 11.2 Biologic Therapies Targeting TNF- [ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 11.2.1 Rationale for TNF Blockade in the Treatment of Rheumatoid Arthritis 111 11.2.2 Clinical Studies of Anti-TNF Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 11.2.3 Safety of Biologic TNF Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 11.2.4 Infectious Complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 11.2.5 Congestive Cardiac Failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 11.2.6 Solid Tumours and Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 11.2.7 Other Toxicity Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 11.2.8 Injection Site Reactions or Infusion-Related Reactions . . . . . . . . . . . . . . 117 11.2.9 Mechanism of Action of TNF Blockade . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 11.3 Targeting IL-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 11.4 Combination Anti-cytokine Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 11.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 12
Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists J. Salfeld, P. Rutgeerts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.1 Clinical Features of Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.2 Pathogenesis of Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3 Biologics for Use in Crohn’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.1 TNF Antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.2 Selective Adhesion Molecule Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.3 Anti-IL-12/IL-23 Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.4 Anti-IFN- * Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.5 Anti-IL-6 Receptor Monoclonal Antibody . . . . . . . . . . . . . . . . . . . . . . . . . 12.3.6 Miscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.4 Biologics in Ulcerative Colitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.5 Summary and Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
124 124 124 126 130 134 135 136 136 137 137 137 138
13
Multiple Sclerosis: New Immunobiologics R. Gold, R. Hohlfeld . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.2 Immunopathogenesis of Multiple Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . 13.3 Prominent Failure of TNF- [ Targeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.4 Adverse Reactions in Highly Efficacious Anti- [ 4-Integrin Therapy with Natalizumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.5 Currently Investigated Monoclonal Antibodies . . . . . . . . . . . . . . . . . . . . . 13.5.1 Anti-CD52 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.5.2 Anti-CD25 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.5.3 Anti-CD20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.5.4 Other Therapeutic Monoclonal Antibodies . . . . . . . . . . . . . . . . . . . . . . . . 13.6 Conclusions and Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
141 141 141 142 143 144 144 144 145 145 145 146
XI
XII
Contents
14
Biologics in Cutaneous Lymphoma M. Beyer, Ch. Assaf, W. Sterry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.2 Cutaneous T-Cell Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.2.1 Cutaneous B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3 Biologics in the Treatment of CTCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3.1 DAB389-Interleukin-2 (DAB389IL-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3.2 Alemtuzumab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3.3 Rituximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3.4 90Y-Ibritumomab Tiuxetan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.3.5 Histone Deacetylase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
147 147 148 149 149 149 150 150 151 152 152
15
Biologics in Targeted Cancer Therapy D. Schrama, J.C. Becker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.2 Chemoimmunoconjugates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.3 Immunotoxins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.4 Antibody-Cytokine Fusion Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.5 Evolving Approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III
153 153 154 156 157 160 162 163
Safety and Perspectives
16
Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies Ch.K. Schneider, J. Löwer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 16.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 16.2 Intervention with Pleiotropic Cytokine Pathways . . . . . . . . . . . . . . . . . . . 170 16.3 Intervention with Adhesion Molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171 16.4 Intervention with Growth Factor Receptors . . . . . . . . . . . . . . . . . . . . . . . . 172 16.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173 17
New Biological Therapeutics in the Genome Age T.N.C. Wells, S. Schnieper-Samec . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 17.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 17.2 Early Biotechnology Production of Human Cytokines and Hormones . . 176 17.3 Finding New Cytokine Orphans in the Human Genome: Early Excitement from Expressed Sequence Tags . . . . . . . . . . . . . . . . . . . . . . . . 177 17.4 Assembling the Complete Protein Collection: The Serono Secretome . . 177 17.5 Moving from the Protein to the Biological Activity: The Post-Genome Era . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .178 17.6 Strategies for Blocking Responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 17.6.1 Monoclonal Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 17.6.2 Receptor Fusion Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 17.6.3 Protein Antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 17.6.4 Small Molecules: The Convenience of an Oral Medicine . . . . . . . . . . . . . 180 17.7 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
Contents
18
Evidence Based Medicine’s Perspective on Biologics B. Rzany, A. Nast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18.1 What is EBM? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18.2 EBM Steps to Treating an Individual Patient . . . . . . . . . . . . . . . . . . . . . . . . 18.3 German S3 Guideline for the Treatment of Plaque Psoriasis . . . . . . . . . . . . 18.4 EBM and Biologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18.5 Where Do Biologics Stand Among Other Systemic Treatments of Psoriasis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
184 184 184 185 185 186 186
Subject Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
XIII
List of Contributors
Christian E. Antoni, MD Department of Clinical Immunology, Schering-Plough Research Institute 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA Chalid Assaf, MD Cutaneous Lymphoma Section, Department of Dermatology and Allergy, Skin Cancer Center Charit´e, Charit´e-Universitätsmedizin Berlin Fabeckstr. 60 – 62, 14195 Berlin, Germany Jürgen C. Becker, Prof. Dr. med., PhD Department of Dermatology, University of Würzburg Josef-Schneider Str. 2, 97080 Würzburg, Germany Marc Beyer, Dr. Department of Dermatology and Allergy, Skin Cancer Center Charit´e, Charit´eUniversitätsmedizin Berlin, Fabeckstr. 60 – 62, 14195 Berlin, Germany Wolf-Henning Boehncke, Prof. Dr. med., MA Department of Dermatology, Johann-Wolfgang-Goethe-University Theodor-Stern-Kai 7, 60590 Frankfurt, Germany C. Andrew Boswell, PhD Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive, Bethesda, MD 20892, USA Erik D. Brady, PhD Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive, Bethesda, MD 20892, USA Martin W. Brechbiel, PhD Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive, Building 10, Room 1B40, Bethesda, MD 20892-1088, USA Rick Davis, MS, RPh Complete Healthcare Communications, Inc., One Dickinson Drive Chadds Ford PA 19317, USA
XVI
List of Contributors
Rüdiger Eming, MD Department of Dermatology and Allergology, University Hospital, Philipps-University of Marburg, Deutschhausstraße 9, 35033 Marburg, Germany Ralf Gold, MD Experimentelle und Klinische Neuroimmunologie, Institut für MS-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung, Waldweg 33, 37073 Göttingen, Germany Alice B. Gottlieb, MD, PhD Department of Dermatology, Tufts-New England Medical Center 750 Washington Street, Boston, MA 02111, USA Louane E. Hann, PhD Wyeth BioPharma, One Burtt Road, Andover, MA 01810, USA Michael Hertl, MD Department of Dermatology and Allergology, Philipps University Deutschhausstraße 9, 35033 Marburg, Germany Reinhard Hohlfeld, Prof. Institute for Clinical Neuroimmunology, Klinikum Großhadern Ludwig Maximilians University, Marchioninistraße 15, 81366 Munich, Germany Brendan Hughes, PhD The Wyeth BioPharma Campus at Grange Castle, Grange Castle International Business Park, Clondalkin, Dublin 22, Ireland Arnd Jacobi, MD Department of Dermatology and Allergology, Philipps University Deutschhausstraße 9, 35033 Marburg, Germany Sigbert Jahn, MD, PhD Serono GmbH, Freisinger Str. 5, 85716 Unterschleißheim, Germany Lanea M.M. Keller, MS Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive, Bethesda, MD 20892, USA Hartmut Kupper, Dr. Abbott GmbH & Co., Knollstraße 50, 67061 Ludwigshafen, Germany Johannes Löwer, Prof. Dr. med. Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe (Federal Agency for Sera and Vaccines), Paul-Ehrlich-Straße 51 – 59, 63225 Langen, Germany Philip J. Mease, MD Division of Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, WA, USA; Seattle Rheumatology Associates, 1101 Madison St., Suite 1000, Seattle, WA 98104, USA Diane E. Milenic, MS Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive, Bethesda, MD 20892, USA
List of Contributors
Charles T. Molta, MD Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA Wendy A. Myers, MD UMDNJ-Robert Wood Johnson Medical School, Psoriasis Center of Excellence One Robert Wood Johnson Place, PO Box 19, New Brunswick, NJ 08903-0019, USA Alexander Nast, Dr. med. Division of Evidence-Based Medicine (dEBM), Klinik für Dermatologie, Charit´e-Universitätsmedizin Berlin, Campus Charit´e Mitte Schumannstr. 20/21, 10117 Berlin, Germany Andrea Niedermeier, MD Department of Dermatology and Allergology, Philipps University Deutschhausstraße 9, 35033 Marburg, Germany Martin Pfütze, MD Department of Dermatology and Allergology, Philipps University Deutschhausstraße 9, 35033 Marburg, Germany Heinfried H. Radeke, Prof. Dr. med. Dr.-Hans-Schleussner-Foundation Immune Pharmacology, pharmazentrum frankfurt, Bldg. 75, Room 103, Johann-Wolfgang-Goethe-University Theodor-Stern-Kai 7, 60590 Frankfurt, Germany Berthold Rzany, Prof. Dr. med., ScM Division of Evidence-Based Medicine (dEBM), Klinik für Dermatologie, Charit´e-Universitätsmedizin Berlin, Campus Charit´e Mitte Schumannstr. 20/21, 10117 Berlin, Germany Paul Rutgeerts, Prof. University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium Jochen Salfeld, Dr. Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA Karlheinz Schmitt-Rau, PhD Serono GmbH, Freisinger Str. 5, 85716 Unterschleissheim, Germany Christian Schneider, Dr. Mono- and Polyclonal Antibodies Section, Paul-Ehrlich-Institut, Bundesamt für Sera und Impfstoffe (Federal Agency for Sera and Vaccines) Paul-Ehrlich-Straße 51 – 59, 63225 Langen, Germany Sonia Schnieper-Samec, PhD Serono International, 15bis ch. des Mines, 1211 Geneva, Switzerland David Schrama, PhD Department of Dermatology, University of Würzburg Josef-Schneider Str. 2, 97080 Würzburg, Germany Wolfram Sterry, Prof. Department of Dermatology and Allergy, Skin Cancer Center Charit´e Charit´e-Universitätsmedizin Berlin, Fabeckstr. 60 – 62, 14195 Berlin, Germany
XVII
XVIII List of Contributors Peter C. Taylor, MA, PhD, FRCP The Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, London, W6 8LH, UK Timothy N.C. Wells, PhD Serono International, 15bis ch. des Mines, 1211 Geneva, Switzerland Maria Wiekowski, PhD Department of Immunology, Schering-Plough Research Institute 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
Chapter 1
Introduction: Definition and Classification of Biologics W.-H. Boehncke, H.H. Radeke
1.1 Aims Many chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and Crohn’s disease to name just a few are caused by an overreactive immune system. Carrier substances that falsely inform the body about an ongoing infection are produced in large quantities. The immune system answers by starting a strong immune response. The body’s own tissues are attacked and continuously destroyed. Specific models of reaction have to be understood to find a possible key to altering this perpetual process of destruction. On the other hand, the immune system may overlook the destructive process of cancer by neglecting its surveillance task, by allowing itself to be fooled by the tumor cell’s deceiving tactics. Here specific biologic reagents are needed to jump-start the immune reaction or simply for highly specific targeting of drugs to kill specifically the tumor. The development of biologics has both of these aims in mind. By definition biologics are proteins and/or derivatives thereof that modulate the immune system, downregulate the inflammatory response or support tumor specific defenses. Biologics – also known as “biologicals” or “recombinant therapeutics” – do not represent one homogeneous group of drugs. Monoclonal antibodies, fusion proteins (along with other proteins, toxins and radionucleotides) and recombinant proteins, growth factors, anti- and pro-angiogenic factors, and expression vectors generating proteins in situ may all be included as members of this class of pharmaceuticals. These drugs are designed to resemble or exploit substances that occur naturally in the body and are thereby able to influence the immune response. Advances in biotechnology and molecular biology have made their
production possible and further advances are necessary to widen their field of use. Part I of the book describes the process of development of biologics, starting with the rationales of the research labs of public institutions and also of the pharmaceutical industry. As we have limited our focus to drugs having reached clinical use, the pre-clinical part is also biased towards the success stories: It starts by defining this class of medications, which are not always recognizable as a group. The development and preclinical pharmacology of biologics are exemplified by looking at infliximab, adalimumab, etanercept and efalizumab. Part I also provides introductions to monoclonal antibody targeted radiation cancer therapy and the details of the production process, safety precautions and – last but not least – the profit margins necessary for the manufacture of biopharmaceuticals. In order to understand the background and possible problems with biologics at a more detailed level, the pre-clinical descriptions in Part I are followed by details of their clinical use in Part II. This part describes clinical studies and practical experience by presenting disease-specific applications and clinical trials. Biologics today have a broad use in medicine mainly in a group of diseases referred to as “immune-mediated inflammatory diseases” (IMIDs), comprising psoriasis and psoriatic arthritis, rheumatoid arthritis, colitis and multiple sclerosis, but also in the treatment of tumors of the skin and other organ systems. Moreover, they continue to find their way into other medical fields. Biologic therapies for rheumatoid arthritis targeting TNF- [ and IL-1 are extensively covered, and the treatments of psoriasis and psoriatic arthritis are also examined in detail. Close attention is then given to the use of biologics such as anti-TNF and the new anti-IL12p40 antibody in gastroenterology. A growing and promising use of biologics is coming up in neurology,
1
2
1 Introduction: Definition and Classification of Biologics
especially for the treatment of multiple sclerosis. Finally, more and more biologics are being successfully applied in the fight against cancer. In some types of cancer, biologics already have a solid basis as treatment, and other types of cancer are still being evaluated to identify the most suitable molecular target to start biologic therapy. Part III of this book highlights safety aspects and future perspectives, attempting to look into the future by defining possible new targets for biologic therapy. New biological therapeutic strategies in the genome age are discussed and suggested improvements for the safety of biologics are outlined. As biologics are proteins they are theoretically able to activate the immune system themselves and might cause adverse reactions such as antibody formation, which in turn may lead to allergies or neutralization of the drug. Finally, we provide a distillation of the evidence from the point of view of evidence based medicine.
1.2 Perspectives The development of biologics is still a young branch of the medical and pharmaceutical field. Further research and a wider usage of these substances will be necessary to fully explore their potential. Only by continuously expanding our knowledge about disease driving molecules and the pathomechanisms involved will science be able to extend the field of biological therapy. In fact, the application of biologics has in itself already unraveled new insights into disease processes. Clearly it is not within the scope of this book to evaluate the chances of even more advanced drug systems on the verge of clinical use, e.g., immune liposomes carrying highly active small molecules to the targets presently covered by biologics or nanoparticles targeting gene activity modifiers. Biologics are already widely recognized as milestones in the history of pharmacology. In the near future we will learn whether they will accompany us for long, as many think, or – as others feel – they will soon leave the stage like dinosaurs and be succeeded by those small molecules. More likely, particularly successful biologics will be applied more widely, will become more affordable and will be here to stay. In this case, this kind of textbook will be only the first of a continuing series....
Part I
Development and Pre-clinical Pharmacology of Biologics
I
Chapter 2
Infliximab: From the Idea to the Product M. Wiekowski, Ch. E. Antoni
2.1 Characteristics and Biological Activity 2.1.1 Antibody Characteristics Infliximab is a monoclonal antibody that neutralizes the cytokine tumor necrosis factor (TNF)- [ by binding selectively and with high affinity to soluble and membrane-bound TNF- [ . Infliximab does not bind to TNFq (lymphotoxin [ ), a related cytokine that utilizes the same receptors as TNF- [ . Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytokine TNF- [ . Infliximab was developed by fusing the TNF- [ binding site of the murine antibody A2 to the constant region of human IgG1 κ immunoglobulin. This created a chimeric antibody with an acceptable immunogenic and pharmacokinetic profile (Knight et al. 1993). Infliximab binds the trimeric form of soluble TNF- [ with an affinity of Kd 100 pM but also binds to its monomeric form (Scallon et al. 1995, 2002). Although the trimeric form of TNF- [ is the bioactive form, binding of TNF- [ monomers might be clinically important by slowing down or even preventing the formation of trimeric TNF- [ . When testing the binding affinity of infliximab on a cell line that expresses only membrane-bound recombinant human TNF- [ , the affinity of the antibody to TNF- [ was about twofold higher when compared to the affinity to soluble TNF- [ (Kd 46 pM) (Scallon et al. 1995). In addition, the binding affinities of the dimeric F(ab’)2 fragment were 50-fold higher than that of the monomeric FAB fragment (Scallon et al. 1995). This verified that the strong avidity of the antibody binding to TNF- [ is in part based on the bivalent interaction of the antibody with its ligand.
The stability of the infliximab-TNF- [ complex was confirmed by its slow dissociation rate. In fact, no dissociation of infliximab was observed within 4 h from soluble or within 2 h from membrane-bound TNF- [ in an in vitro assay (Scallon et al. 2002). 2.1.2 Other Mechanisms of Infliximab Activity Binding and neutralization of soluble TNF- [ is probably not the only activity mediated by infliximab. Indeed, in vitro assays have shown that infliximab also binds to membrane-bound TNF- [ and induces cell death (Scallon et al. 1995). However, clinical observations suggest that infliximab mediated cytotoxicity in vivo is limited. Infliximab infusions are very well tolerated and patients do not experience a cell lysis syndrome (Scallon et al. 1995). Similarly, the number of circulating mononuclear cells does not decrease following infliximab infusions. In contrast, programmed cell death (apoptosis) has been observed in Crohn’s patients treated with infliximab within 24 h of a single infusion. In these patients a significant increase in the number of apoptotic T cells was noted in the lamina propria. Interestingly, infliximab dependent apoptosis of T cells appears to be restricted to activated T cells since in an in vitro experiment infliximab only lysed activated, but not resting, Jurkat (a T-cell line) cells (ten Hove et al. 2002). These experiments suggest that the efficacy of infliximab observed in chronic inflammatory conditions is not only mediated through the neutralization of TNF- [ , but also through other activities like induction of cell death in selected cells.
2
6
2 Infliximab: From the Idea to the Product
infliximab
membrane-bound forms of TNF-α
soluble TNF-α
Fig. 2.1. Bivalent interaction of infliximab with its ligand cross-links soluble and membrane-bound TNF- [ (modified from Scallon B et al. 2002. J Pharmacol Exp Ther 301:418 – 426, with permission)
soluble TNF-α
membrane-bound TNF-α
2.2 Administration Infliximab is commercially formulated for intravenous infusions. It is administered to patients as an induction therapy with infusions at weeks 0, 2 and 6 followed by maintenance therapy with infusions every 8 weeks. Infusions are performed over a 2-h period.
2.3 Therapeutic Indications TNF- [ antagonists are used in inflammatory conditions that are characterized by elevated TNF- [ levels at the site of inflammation as well as systemically increased levels. For instance, increased TNF- [ expression has been detected in lesional skin of psoriatic patients (Johansen et al. 2006) or in the inflamed intestine in Crohn’s disease patients (Raddatz et al. 2005). Thus, treatment of these inflammatory conditions with TNF- [ antagonists results in the binding, neutralization and elimination of surplus TNF- [ from the blood circulation and from sites of inflammation and translates into clinical benefit for the patient. Infliximab is the only TNF- [ antagonist that is administered directly into the circulation by intravenous (i.v.) infusions; other TNF- [ antagonists like etanercept and adalimumab are administered by subcutaneous (s.c.) injections. While subcutaneous injections may be more convenient to the patient, subcutaneously administered drugs have to be absorbed from the injection site into the circulation before they can reach sites
of inflammation and can become active. Thus, based on the different routes of administration, TNF- [ antagonists present with different pharmacokinetics characterized by either a more even steady-state concentration of the subcutaneous drugs adalimumab or etanercept, or a serum profile characterized by peaks and troughs as for infliximab. The presence of peak concentrations of TNF- [ antagonist in the serum following infusions raises concern about the increased susceptibility of patients to infections by eliminating TNF- [ below a perceived safety window for an undefined time. However, accumulated data from registries that follow patients for extended period of times do not show differences in the infection rates between subjects receiving TNF- [ blockers by either s.c. or i.v. administration (Wolfe et al. 2006). Rather, increased rates of serious infections appear to be linked to elevated susceptibility of patients due to their disease (Askling et al. 2005) or concomitant medications (Wolfe et al. 2006; Westhovens et al. 2006; Lichtenstein et al. 2006). In contrast, high concentrations of TNF- [ antagonist in serum and peripheral tissue following administration might provide the opportunity for a rapid clinical response. Indeed, a clinical response to infliximab treatment was detected as early as 2 weeks following the first infusion in patients suffering from rheumatoid arthritis, Crohn’s disease and ulcerative colitis (Maini et al. 1999; Rutgeerts et al. 2005; Targan et al. 1997; Kavanaugh et al. 2000). Infliximab is currently (2006) approved for the treatment of six chronic inflammatory conditions:
2.4 Pharmacokinetics
1. For the reduction of signs and symptoms as well as improvement in physical function in patients with rheumatoid arthritis (RA) 2. For severe and active Crohn’s disease in patients who do not respond to corticosteroid or immunosuppressant therapy or those with fistulating, active Crohn’s disease 3. For ulcerative colitis in patients who do not respond to conventional therapy 4. For ankylosing spondylitis in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy 5. For active and progressive psoriatic arthritis in combination with methotrexate 6. For moderate to severe plaque psoriasis in patients who are intolerant to other systemic therapies
2.4 Pharmacokinetics The pharmacokinetics of infliximab has been determined in clinical studies in a variety of indications. In general, maximal or trough serum concentrations of infliximab are proportional to the dose of antibody administered independent of the inflammatory condition of the patient (summarized in Table 2.1). The volume of distribution is independent of the dose and indicates that infliximab is primarily distributed in the vascular space. The terminal half-life of infliximab is 8.0 – 9.5 days and the antibody is still detectable in the serum 12 weeks after the last infusion (Kavanaugh et al. 2000; Centocor 2006; Cornillie et al. 2001). 2.4.1 Pharmacokinetics in Rheumatoid Arthritis Patients The pharmacokinetics of infliximab has also been determined in patients with active RA. Patients with active rheumatoid who were on a stable dose of methotrexate received single infusions of 5, 10 or 20 mg/kg infliximab. Following infusions serum concentrations for infliximab peaked between 1- and 4- h post infusion and then declined exponentially from day 3 through week 12. The mean terminal half-life for infliximab was 9 – 12 days in doses of 5 – 20 mg/kg. Maximal serum concentrations (Cmax) as well as overall infliximab concentrations over time (area under the curve, AUC)
increased proportionally with an increase in the dose. Clearance, volume of distribution, mean residence time and terminal half-life were relatively constant for all three doses. The value of Cmax and the volume of distribution suggest that the total dose of infliximab distributes into the vascular space. Regardless of the dose, infliximab was still detectable in most patients at week 10 after the infusion. In this study, after having received only one dose of infliximab, most patients experienced a clinical response by week 1 or 2 and maintained improvement through week 10 – 12. The ACR20 response rates were similar for all three doses, with 81 % of patients responding at week 1 and 52 % maintaining the response at week 12. More patients in the higher dose groups achieved an ACR50 response at week 1 and more patients in the 20-mg/kg group achieved an ACR50 response at week 12 when response was compared across all dose groups. Of note is the rapid onset of a clinical response in this study as more than half of the patients on infliximab experienced a clinical response as early as week 1 after the first infusions (Kavanaugh et al. 2000). In the extension of this study, patients received 10 mg/kg infliximab infusions every 8 weeks. In these patients the serum infliximab concentrations stayed constant, suggesting that repeated administrations of this antibody did not substantially change its pharmacokinetics (Table 2.1). Most patients still had detectable serum inflixmab concentrations 12 weeks after the last infusion. Fifty-three percent of the patients in the extension study maintained an ACR20 response through week 40 (Kavanaugh et al. 2000). Dose and dosing frequency of infliximab and their effect on pharmacokinetics, efficacy and safety were also explored over a 30-week trial in rheumatoid arthritis patients. Patients who had active rheumatoid arthritis and remained on a stable dose of methotrexate received 3-mg/kg or 10-mg/kg infliximab infusions at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter. The trough infliximab serum concentrations at week 30 were determined [mean (SD) 1.5 (1.6) μg/ml for 3 mg/kg every 8 weeks, 9.7 (8.6) μg/ml for 3 mg/kg every 4 weeks, 8.9 (8.1) μg/ml for 10 mg/kg every 8 weeks and 35.8 (23.7) μg/ml for a 10-mg/kg dose every 4 weeks]. In all groups, over 50 % of patients experienced an ACR20 response as early as 2 weeks after the first infusion; this proportion of responders increased to 90 % at
7
8
2 Infliximab: From the Idea to the Product Table 2.1. Pharmacokinetics of infliximab Dose
Times of dosing
Trough concentration (μg/ml)
Clinical response
Ref.
Rheumatoid arthritis
3 mg/kg 3 mg/kg 10 mg/kg 10 mg/kg Placebo
3 mg/kg
Week 0, 2, 6, then every 4 weeks 8 weeks 4 weeks 8 weeks
Week 0, 2, 6, 14
Maini et al. 1999 Mean (SD) 9.7 (8.6) 15.0 (1.6) 35.8 (23.7) 8.9 (8.1)
At week 30
At week 2
22.3 μg/ml (15.3 – 29.4) 14.5 μg/ml (7.3 – 22) 2.8 μg/ml (0.6 – 6.8)
DAS 28 response at week 14 in 78 % of patients
8.5 μg/ml (2.6 – 19.6) 7.9 μg/ml (0 – 20.3) 9.9 μg/ml (0.3 – 23.5)
At week 40
At week 6 At week 14 10 mg/kg
5, 10 or 20 mg/kg At week 20 at week 0 then At week 28 10 mg/kg at week 12, 20 and At week 36 28
ACR50 29 %** 27 %** 26 %** 31 %** 5%
ACR70 11 %** 8 %** 11 %** 18 %** 0% **p e 0.002
At week 30
Wolbink et al. 2006
Non-responders had significantly lower trough than responders 0.5 (0.2 – 2.2) vs 3.6 (1.4 – 8.2) μg/ml ACR20 58 %
ACR50 37 %
Kavanaugh et al. 2000
Psoriasis At week 1 Week 0, 2, 6 5 mg/kg 10 mg/kg
Gottlieb et al. 2003
0.67 μg/ml (< 0.1*–6.09) 7.11 μg/ml (2.38 – 15.13)
*2/9 patients had levels < 0.1
5 mg/kg
Week 0, 2, 6 then every 8 weeks
Crohn’s disease 10 mg/kg Every 8 weeks
Week 10 2.8 – 3.7 μg/ml between weeks 22 IFX Placebo and 46 Week 24 IFX Placebo Week 50 IFX
Week 20 Week 28 Week 36 Week 44
7.9 μg/ml 10.0 μg/ml 8.1 μg/ml 8.0 μg/ml
week 6 or 4 weeks following the second infusion. The total response rate was maintained at week 30 between 50 % and 60 %. The ACR50 response at week 30 ranged
PASI75
PASI90
80 % 3%
57 % 1%
82 % 4%
58 % 1%
61 %
15 %
Maintenance of remission At week 44 Placebo 35 % IFX 60 %
Reich et al. 2005
Rutgeerts et al. 1999
from 26 % to 31 %, and the ACR70 response from 8 % to 18 % across all dose groups with no apparent dose response (Table 2.1) (Maini et al. 1998).
2.4 Pharmacokinetics
2.4.3 Pharmacokinetics in Psoriasis
Patients with active Crohn’s disease were originally randomized to receive placebo or a single infusion of 5, 10 or 20 mg/kg infliximab. If they did not show a response by week 4, they received an additional dose of 10 μg/ml infliximab. Eight weeks later responders were eligible to enter an extension study where they were randomized to either placebo or 10-mg/kg infusions of infliximab. Patients were retreated every 8 weeks and evaluated at week 40. In these patients the analysis of the infliximab serum concentrations before an infusion every 8 weeks showed that median trough concentrations remained stable over time at about 8 – 10 μg/ml between weeks 20 and 44 (Table 2.1). Most patients had still detectable concentrations of serum infliximab 12 weeks after the final infusion (median 2.2 μg/ml). Patients who continued infliximab treatment during the extension phase were able to maintain the initial clinical benefit (Rutgeerts et al. 1999). In another study in Crohn’s disease patients, again dose-dependent serum concentrations were observed in Crohn’s disease patients after single infusions of 5, 10 or 20 mg/kg infliximab. At the recommended 5-mg/kg dose, the maximal serum concentration was 118 μg/ml and the median half-life 9.5 days. In this study at week 12 no antibody levels were detected in the serum after the 5-mg/kg infusion (Cornillie et al. 2001).
The pharmacokinetics of infliximab was determined in psoriasis patients in a phase 2 clinical trial (Gottlieb et al. 2003). Patients received doses of 5 mg/kg or 10 mg/ kg infliximab at weeks 0, 2 and 6. The highest serum concentrations of infliximab were observed in patients at week 2 immediately after the second dose: median 158.14 and 298.89 μg/ml for the 5and 10-mg/kg dose groups, respectively. The concentrations were directly proportional to the administered dose. The lowest serum concentrations of 0.67 μg/ml were observed at week 14 for the 5-mg/kg group (range < 0.1 – 6.09 μg/ml) while at week 14 the serum levels for the 10-mg/kg group were 7.11 μg/ml (Fig. 2.3). The median half-life of infliximab was determined as 7.62 days (interquartile range 6.62 – 10.15 days) for the 5-mg/kg dose group and 9.97 days (interquartile range 6.17 – 10.14 days) for the 10-mg/kg dose group (Gottlieb et al. 2003).
1000
In pediatric Crohn’s patients (mean age 10.5 ± 3.3 years), the levels of serum infliximab were determined after infusions of 5 mg/kg at week 2 and at week 6, 4 weeks after the second infusion. The trough infliximab concentration was 16.7 + 7.3 μg/ml at week 2 and 1000
100
100
1
2
6
10
14
18
1
0.1 Week
0
2
6
10
14
Infusion
Infusion 5 mg/kg Infliximab (n = 28)
10
5421
10
0.1 Week 0
2.4.4 Pharmacokinetics in Pediatric Crohn’s Patients
Infliximab serum concentration (μg/mL)
Infliximab serum concentration (μg/mL)
2.4.2 Pharmacokinetics in Crohn’s Disease
10 mg/kg Infliximab (n = 30)
Fig. 2.2. Profile of serum infliximab concentrations vs time for fistula patients who received three infusions of 5 or 10 mg/kg infliximab at weeks 0, 2 and 6 (arrows). Serum samples were obtained before and after each infusion and at the indicated time points after the third infusion. Each point represents the median result for that time period and dose group
5 mg/kg Infliximab
10 mg/kg Infliximab
Fig. 2.3. The median half-life of infliximab was determined as 7.62 days (interquartile range 6.62 – 10.15 days) for the 5-mg/ kg dose group and 9.97 (interquartile range 6.17 – 10.14) days for the 10-mg/kg dose group (Gottlieb et al. 2003)
9
10
2 Infliximab: From the Idea to the Product
8.8 ± 7.1 μg/ml at week 6. This translates into a terminal half-life of 9.5 days and a mean residence time of 13 days. No infliximab (detection limit 1.8 μg/ml) was detected in serum of children at week 8 after sequential treatment with 5-mg/kg doses (Candon et al. 2006).
2.5 Relationship Between Infliximab Concentration and Clinical Response The relationship between serum infliximab concentrations and clinical response was tested in the ATTRACT trial for rheumatoid arthritis. Doses of 3 mg/kg or 10 mg/kg infliximab resulted in maximal maximum serum concentrations that were directly proportional to the intravenous dose; serum concentrations of 68.8 μg/ml and 219.1 μg/ml were detected 1 h post-infusion (St Clair et al. 2002). The trough concentration was also dependent on the amount and frequency of dose. Patients receiving 10 mg/kg every 4 weeks had the highest trough levels, while patients receiving 3 mg/kg every 8 weeks had the lowest trough levels. The median trough levels were comparable in patients receiving 10 mg/kg every 8 weeks and 3 mg/kg every 4 weeks (Kavanaugh et al. 2000; St Clair et al. 2002). When the trough serum levels of infliximab at week 54 were correlated with clinical response it became apparent that a higher ACR-N response was significantly associated with a higher trough serum concentration of infliximab. While no significant difference in the ACR20 response was detected for patients receiving 3 mg/kg or 10 mg/kg infliximab at either 4- or 8-week intervals, the ACR50 response rates were significantly lower in the group receiving 3 mg/kg every 8 weeks compared to the other groups. This suggested that clinical response relates to trough serum concentrations of infliximab. Indeed, when clinical responses were correlated with trough serum concentrations, most patients with a response of less than ACR20 had undetectable trough serum levels of infliximab, while the highest proportion of ACR50 and ACR70 responders had the highest trough serum levels (St Clair et al. 2002). In another open label study the relationship between infliximab levels and clinical response to infliximab treatment in RA was confirmed. Patients received 3mg/kg inflixmab infusions at weeks 0, 2, 6 and 14. At week 2 the median serum trough level for inflixi-
mab was 22.3 (15.3 – 29.4) μg/ml, at week six 14.6 (7.2 – 22) μg/ml, and at week fourteen 2.8 (0.6 – 6.8) μg/ ml. While trough serum concentrations varied considerably between patients, a better clinical response was associated with higher median trough serum concentrations (Wolbink et al. 2006). In general, in RA, a trough concentration of > 1.0 μg/ml is associated with a good therapeutic response (St Clair et al. 2002) and the clinical response declines rapidly after serum infliximab levels drop below this threshold (Markham and Lamb 2000). The relationship between trough infliximab serum concentrations and clinical response was also determined in a 1-year psoriasis study. Patients were receiving 5 mg/kg inflixmab treatment every 8 weeks after induction therapy. Between week 22 and week 46 the median pre-infusion inflixmab concentration stabilized between 2.8 μg/ml and 3.7 μg/ml. Patients who maintained their clinical response through week 50 had trough infliximab serum concentrations above 1 μg/ml, while in about 25 % of patients who lost the response the median pre-infusion infliximab concentrations dropped below 1 μg/ml (Reich et al. 2005).
2.6 Antibody Formation Against Infliximab The presence of antibodies to infliximab in patients is determined by an enzyme linked immunosorbent assay (ELISA). However, the detection of antibodies to infliximab can be hindered by the presence of infliximab in the serum. Thus, since infliximab can remain in the circulation for at least 4 – 12 weeks after infusion, serum samples are usually collected for analysis 12 weeks or later after the last infusion. When the formation of antibodies against infliximab (HACA) was determined 12 weeks after the last infusion in RA patients, HACA were detected in about 17 % of all treated patients. The rate of HACA responses was inversely proportional to the dosage; HACA formation occurred in 53 %, 21 % and 7 % of patients treated with 1, 3 and 10 mg/kg infliximab, respectively. Concomitant treatment with methotrexate decreased the rate to 15 %, 7 % and 3 % for the three respective dosages. The smaller proportion of patients on higher doses of infliximab who are developing HACA suggest that anti-TNF- [ treatment induces a phenomenon resembling tolerance (Maini et al. 1998).
2.8 Alternative Routes of Administration
A significantly higher incidence of antibodies to infliximab was detected in Crohn’s patients who received episodic treatment, i.e., they received one dose of infliximab at the beginning of the trial, but then only placebo until week 14 or later until the disease worsened. While 30 % of patients on this treatment schedule developed HACA, only 8 % of patients who received infliximab infusions every 8 weeks developed HACA. In addition, the incidence of HACA was higher in patients who did not receive immunomodulators compared to those who did (18 % vs 10 %, p = 0.02) (Hanauer et al. 2004). This suggests that higher doses of infliximab at scheduled (every 8 weeks) infusions and perhaps in combination with an immunomodulator are the best treatment paradigm to reduce the possibility of developing HACA. 2.6.1 HACA Formation and Clinical Response Administration of a chimeric human-mouse antibody can lead to the formation of antibodies against the chimeric protein and the formation of immune complexes. The presence of antibodies directed against therapeutic antibodies in patients can lead to adverse reactions upon administration or loss of efficacy due to accelerated elimination of the therapeutic antibody from the circulation. Preclinical studies in cynomolgus monkeys provided information on the formation and size of immune complexes between infliximab and anti-inflixmab antibodies, the distribution of these complexes in the whole body, and the rate and mechanism of their elimination. Cynomolgus monkeys received infusions of 1.74 mg/kg inflixmab followed by either an intravenous bolus of 0.5 mg/kg radio-labeled rhesus monkey anti-infliximab IgG (test) or radio-labeled rhesus monkey nonimmune IgG (control antibodies). In these monkeys the immune complexes between infliximab and the anti-infliximab antibodies formed quickly within 5 min of administration, while no complexes were formed between infliximab and the control antibodies. The terminal half-life of the anti-infliximab immune complex was approximately 38 h compared to 86 h for the control antibody, thus implying an about twofold accelerated clearance of infliximab in complex with an antibody (Rojas et al. 2005). In a cohort of infliximab treated Crohn’s disease patients, titers of anti-infliximab antibodies were cor-
related with clinical response. Again, anti-infliximab antibody concentrations of 8 μg/ml or greater were positively correlated with a higher risk for infusion reactions and a decreased duration of a therapeutic response to infliximab (Baert et al. 2003). These studies suggest that scheduled treatment in combination with an immunosuppressive drug carries the least risk of antibody formation against infliximab and offers the best probability to maintain the response.
2.7 Infusion Reactions/Delayed Hypersensitivity Reactions The highest frequency of adverse events in response to infliximab treatment are infusion reactions occurring within 2 h of the infusion. They typically consist of fever, shills, nausea, dyspnea, and headaches, and symptoms can be controlled with drug treatment (e.g., antihistamines). Infusion reactions led to discontinuation of treatment in approximately 3 % of patients, and were considered serious in less than 1 % of patients (St Clair et al. 2004; Sands et al. 2004; Lipsky et al. 2000; Gottlieb et al. 2004). Delayed reactions like myalgias, arthralgias, fever, rash, pruritus, facial, hand or lip edema, dysphagia, urticaria, sore throat and headache may occur within 3 – 12 days following the infusion (Lipsky et al. 2000). However, while the rate of infusion reactions positively correlated with the development of HACA, just the presence of HACA antibodies in the serum of patients proved to be poorly predictive for these events (Hanauer et al. 2004; Baert et al. 2003).
2.8 Alternative Routes of Administration For the treatment of rheumatoid arthritis, infliximab is approved in combination with methotrexate for intravenous dosing at 3 mg/kg every 8 weeks. As an alternative to the intravenous dosing route, an experimental formulation for subcutaneous and intramuscular (i.m.) dosing was evaluated in RA patients who are refractory to methotrexate therapy in a phase I clinical study. Fifteen patients were randomized to receive s.c. doses at 0.5 mg/kg, 1.5 mg/kg and 3 mg/kg. After evaluation of
11
12
2 Infliximab: From the Idea to the Product
the pharmacokinetic data from this group, a 100-mg s.c. dose was chosen to treat patients either s.c. at weeks 0, 2 and 4, or after 3-mg/kg i.v. infusions of Remicade at weeks 0 and 2 with s.c. injections at weeks 4, 6 and 8. Another group of patients received 100-mg i.m. injections at weeks 0, 2 and 4. After a single s.c. injection at doses ranging from 0.5 to 3 mg/kg, the median half-life ranged from 8.0 to 8.4 days and the Cmax and AUC increased in a roughly dose-proportional manner across these dose groups. At day 7, a 6.7-fold higher Cmax and a 6.3-fold higher AUC were determined in the 3-mg/kg dose when compared to the 0.5-mg/kg group. Subjects receiving three doses of 100 mg s.c. every 4 weeks had trough concentrations of infliximab above or equal to 1 μg/ml. Over 80 % of subjects receiving multiple doses of 100 mg infliximab s.c. achieved an ACR20 response when evaluated 2 weeks after the last dose of infliximab. In contrast, the response to i.m. infliximab administration appeared to be delayed since at 2 weeks post-treatment ~57 % of patients achieved an ACR20 response, while at 4 weeks post-treatment 83 % or five out of six patients achieved an ACR20 response. Individual patients in this study achieved higher clinical responses even after a single s.c. administration, and the majority after multiple s.c. injections achieved an ACR50 response, as did about one-third of patients in the i.m. group. Irrespective of s.c. or i.m. administration, 34 out of 43 patients experienced transient AEs of mild to moderate severity. This included ten subjects having mild to moderate infections. There were no serious injection site reactions. In addition, the humoral response to either route of administration was not suppressed. Thus this exploratory study described alternative routes of administration for infliximab that resulted in trough levels above or equal to 1 μg/ml at week 4, which is considered the serum concentration required to achieve a clinical response. However, this study is too small to draw general conclusions regarding safety or efficacy (Westhovens et al. 2006).
2.9 Summary Intravenous administration of infliximab results in serum levels that are proportional to the dose in patients suffering from a variety of inflammatory diseases. Infliximab treatment is characterized by a clini-
cal response that occurs as early as 2 weeks following the first infusion. The maintenance of the clinical response correlates with the presence of detectable infliximab concentrations of > 1 μg/ml in the serum at trough which can be maintained by infusions every 8 weeks in most patients. Formation of antibodies against infliximab has been observed in patients, and can lead to infusion reactions and faster elimination of the antibody from the circulation. While routes of administration other than infusion have been demonstrated to result in clinical benefit for patients, infliximab is commercially available only in the intravenous formulation.
References Askling J, et al. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7): 1986 – 1992 Baert F, et al. (2003) Influence of immunogenicity on the longterm efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601 – 608 Candon S, et al. (2006) Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol 118(1):11 – 19 Centocor BV, Product Information (EU) [online] (2006) Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/remicade/remicade.htm [accessed July 2006] Cornillie F, et al. (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15(4):463 – 473 Gottlieb AB, et al. (2003) Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48(1):68 – 75 Gottlieb AB, et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51(4):534 – 542 Hanauer SB, et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2(7):542 – 553 Johansen C, et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPKactivated protein kinase 2. J Immunol 176(3): 1431 – 1438 Kavanaugh A, et al. (2000) Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27(4):841 – 850 Knight DM, et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30(16):1443 – 1453
References Lichtenstein GR, et al. (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 4(5):621 – 630 Lipsky PE, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594 – 1602 Maini RN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552 – 1563 Maini R, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932 – 1939 Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59(6): 1341 – 1359 Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17(5):547 – 557 Reich K, et al. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367 – 1374 Rojas JR, et al. (2005) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313(2): 578 – 585 Rutgeerts P, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117(4): 761 – 769 Rutgeerts P, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23): 2462 – 2476
Sands BE, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350(9):876 – 885 Scallon BJ, et al. (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNFalpha and activates immune effector functions. Cytokine 7(3):251 – 259 Scallon B, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418 – 426 St Clair EW, et al. (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451 – 1459 St Clair EW, et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432 – 3443 Targan SR, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337(15):1029 – 1035 ten Hove T, et al. (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 50(2):206 – 211 Westhovens R, et al. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075 – 1086 Wolbink GJ, et al. (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711 – 715 Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54(2):628 – 634
13
Chapter 3
3 Adalimumab J. Salfeld, H. Kupper
Adalimumab (Humira, Abbott Laboratories, Abbott Park, IL, USA) is the first fully human recombinant IgG1 monoclonal antibody that acts by inhibiting tumor necrosis factor-alpha (TNF- [ or TNF) (Fig. 3.1) (Abbott Laboratories 2006). In contrast to infliximab, a chimeric antibody comprising both mouse and human domains that may elicit immune responses that potentially limit its long-term use in patients with chronic conditions such as rheumatoid arthritis, adalimumab is fully human, lowering the potential for immunogenicity (van de Putte et al. 2003). Adalimumab is composed of human-derived heavy and light chain variable regions and human IgG1:κ
Fig. 3.1. Three-dimensional structure of adalimumab
constant regions, engineered through phage display technology (Abbott Laboratories 2006). Phage display technology is designed to recapitulate the physiological antibody generation process in the laboratory. Comparable to the natural selection process for the B cell displaying the appropriate antibody, phage display allows for the selection of a fully human antibody specific for an antigen, in this case TNF, from a large repertoire of antibodies. If the desired antibody is felt to be rare in the repertoire, a variant of the technology allows for more rapid “guided selection” in a two-stage process. Therefore the first step in the generation of adalimumab was a guided selection approach using the murine anti-human TNF antibody MAK195 in order to isolate a human antibody that recognized the same neutralizing epitope as MAK195. MAK195 is a potent neutralizing monoclonal antibody, which has a high affinity and a low off-rate constant for human TNF. The MAK195 VH and VL were paired with human cognate repertoires and these phage antibody libraries underwent antigen binding selection using recombinant human TNF as the antigen. The selected human VH and VL genes were then combined to generate a fully human anti-TNF antibody. Early human anti-TNF antibodies were optimized in a second phase mirroring the natural process for antibody optimization. The final antibody, adalimumab, is a full-length immunoglobulin (IgG1) molecule with optimized heavy and light chain characterized by high specificity, affinity, and potency (van de Putte et al. 2003). It is produced in a Chinese hamster ovary host cell that is transfected with a plasmid vector containing the expression cassettes for adalimumab heavy and light chains. Adalimumab is produced by a standard, well controlled fermentation and purification process. Each batch of adalimumab is characterized rigorously in a series of biochemical and biophysical characteriza-
3.1 Pharmacology
tion assays in order to meet pre-specified release criteria. Adalimumab is indistinguishable in structure and function from naturally occurring human IgG1 and has a comparable terminal half-life (approximately 2 weeks). Adalimumab was designed as a fully human anti-TNF monoclonal antibody to have the following characteristics: ) High selectivity and affinity for TNF ) Suitability for long-term chronic administration with a low degree of immunogenicity, with or without concomitant use of methotrexate (MTX) ) A low incidence of allergic reactions ) A half-life comparable to that of human IgG1 resulting in infrequent dosing for patient convenience
shown to decrease disease activity (Cooper et al. 1992; Williams et al. 1992). Adalimumab is highly specific and does not bind to or inhibit other forms of TNF, such as lymphotoxin- [ (LT [ , previously called TNF- q ). Upon binding to TNF, adalimumab neutralizes the biologic activities of this cytokine by blocking its interaction with the TNF-RI/II cell surface receptors and modulating biologic responses that are induced or regulated by TNF (Fig. 3.2) (Salfeld et al. 1998; Lee and Kavanaugh 2005). Adalimumab also binds to and neutralizes the cell membrane-associated form of TNF, which may play a role in disease (Georgopoulos et al. 1996).
3.1 Pharmacology 3.1.1 Mode of Action TNF has been implicated in the pathogenesis of many chronic autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis, ankylosing spondylitis (AS), and Crohn’s disease. Among its diverse pathologic effects, TNF triggers the production of collagenases and other proinflammatory cytokines such as interleukin (IL)-1, IL-6, and granulocyte-macrophage colony stimulating factor (Brenner et al. 1989; Lee and Kavanaugh 2005); stimulates the expression of endothelial adhesion molecules (e.g., endothelial leukocyte adhesion molecule1, vascular cell adhesion molecule-1, and intercellular cell adhesion molecule-1), attracting leukocytes into affected joints; upregulates matrix metalloproteinase synthesis by synovial macrophages, fibroblasts, osteoclasts, and chondrocytes; and inhibits proteoglycan synthesis in cartilage (Weinblatt et al. 2003). High concentrations of TNF are found in the synovial fluid of patients with RA (Saxne et al. 1988) and PsA (Partsch et al. 1997); in psoriatic lesions of patients with psoriasis (Ritchlin et al. 1998); in the joints of patients with AS (Braun et al. 1995); and in the stool, mucosa, and blood of patients with Crohn’s disease (Braegger et al. 1992; Murch et al. 1991, 1993). In animal models of inflammatory arthritis, TNF has been shown to accelerate disease activity, and anti-TNF antibodies have been
Fig. 3.2. Tumor necrosis factor (TNF) cascade in rheumatoid arthritis. DC dendritic cells, EC endothelial cells, Fib fibroblasts, GM-CSF granulocyte-macrophage colony-stimulating factor, IL interleukin, Ly lymphocytes, Mac macrophages, MMP matrix metalloproteases, ROI reactive oxygen intermediates
15
16
3 Adalimumab
3.1.2 Pharmacodynamics In patients with RA, a rapid decrease in levels of acute phase reactants of inflammation, C-reactive protein, and fibrinogen, as well as the serum cytokines, IL-1 q and IL-6, and IL-1 receptor antagonist is observed following treatment with adalimumab (Abbott Laboratories; Barrera et al. 2001). Serum levels of matrix metalloproteinases-1 and -3 and other markers of synovial cell activation and cartilage erosion are also decreased following adalimumab administration (Abbott Laboratories 2006; Weinblatt et al. 2003). An immunology study assessing the efficacy of adalimumab plus MTX in patients with RA demonstrated that normal immune function is preserved during adalimumab therapy (Kavanaugh et al. 2002). Adalimumab treatment did not significantly alter the numbers of peripheral blood natural killer cells, monocytes/macrophages, B cells, or major T-cell subsets; moreover, in vitro lymphocyte proliferation, delayed-type hypersensitivity reactivity, and antibody responses to pneumococcal antigen vaccination were maintained during therapy (Kavanaugh et al. 2002). 3.1.3 Pharmacokinetics Adalimumab has linear pharmacokinetic properties throughout the clinical dose range. In healthy adults, the absolute bioavailability of adalimumab following a single 40-mg subcutaneous (s.c.) dose is 64 %, and maximum plasma concentrations (4.7±1.6 μg/ml) are achieved at 131±56 h. Concentrations of adalimumab in the synovial fluid from RA patients range from 31 % to 96 % of those in serum (Abbott Laboratories 2006). Adalimumab 40 mg s.c. every other week (e.o.w.) produces steady-state serum trough concentrations of 4 – 8 μg/ml, which are 3 – 7 times higher than the effective concentration (0.8 – 1.4 μg/ml) in 50 % of RA patients (Granneman et al. 2003). Concomitant MTX treatment does not significantly alter adalimumab pharmacokinetics. The presence of MTX does not adversely affect adalimumab serum concentrations. At the recommended dose of 40 mg e.o.w., mean steadystate serum concentrations are 5 μg/ml without MTX and 8 – 9 μg/ml with MTX. MTX reduced adalimumab apparent clearance after single and multiple dosing by 29 % and 44 %, respectively. Pharmacokinetic studies
have not been conducted in children or in patients with hepatic or renal impairment (Abbott Laboratories 2006). 3.1.4 Adalimumab Comparisons with Infliximab and Etanercept A number of structural and functional features of adalimumab distinguish this agent from the other registered TNF antagonists, infliximab and etanercept (Fig. 3.3). A hallmark of monoclonal antibodies is their exquisite specificity for a target antigen. Adalimumab is highly specific for TNF (in both soluble and membrane-bound forms), whereas etanercept binds and neutralizes LT [ as well as TNF. Adalimumab binds to TNF with very high affinity (Kd ~85 pM) (Kaymakcalan et al. 2002), and potently neutralizes TNF in bioassays (IC50 ~130 pM) (Salfeld 1998). The kinetic binding parameters of adalimumab and infliximab are similar, but etanercept dissociates from TNF much more rapidly than adalimumab or infliximab (Kaymakcalan 2002). These differences may relate to the fundamental structural differences between antibodies and receptors, since adalimumab and infliximab are high-affinity antibodies and etanercept is a TNF receptor fusion protein. Immunogenicity is another parameter that is directly related to the structure of protein therapeutics and can result in diminished efficacy as well as increased side effects. Adalimumab is a fully human monoclonal IgG1 antibody, indistinguishable from naturally occurring IgG1. Antibodies to adalimumab have been observed in a small proportion of patients (Abbott Laboratories 2006). This low level of immunogenicity is reflective of the natural process of anti-idiotypic antibody formation to endogenous antibodies characteristic of the natural immune network (Jerne 1974). Infliximab is a chimeric antibody, a recombinant fusion of murine and human antibody components, and is immunogenic in a high proportion of patients unless given in combination with immunosuppressive drugs (Anderson 2005; Baert 2003; Maini et al. 1998). Etanercept is comprised of human protein components, but in an artificial construct. Low levels of immunogenicity have been reported with etanercept in patients, but considerable variability was seen, depending on the assays used to detect anti-etanercept antibodies (Anderson 2005). The pharmacokinetics of the three TNF antagonists also differ significantly, and these differences may
3.1 Pharmacology
Fig. 3.3. Adalimumab structure in comparison to other TNF-antagonists. IgG1 immunoglobulin G1, TNF tumor necrosis factor. (Adapted with permission from Anderson 2005)
relate to pharmacodynamic differences underlying the differential efficacy seen across indications. Adalimumab has a significantly longer plasma half-life than etanercept (10 – 20 days vs 3 – 5.5 days, respectively), which enables less frequent dosing of adalimumab to maintain efficacious steady state drug levels. In contrast to adalimumab and etanercept, infliximab is given by intravenous injection, resulting in maximal plasma concentrations of infliximab 10- to 30-fold higher than for adalimumab or etanercept, and trough concentrations of infliximab that fall below those of adalimumab or etanercept (Granneman et al. 2003; Maini et al. 1998; Zhou et al. 2004). The impact on efficacy or safety of the large range of plasma concentrations of infliximab during treatment is not known. The comparative efficacy of the three TNF antagonists was evaluated in an animal model of rheumatoid arthritis driven by a human TNF transgene (Kaymakcalan 2002). Adalimumab was more potent than infliximab or etanercept in preventing the development of arthritis and in the suppression of histopathological
evidence of synovial inflammation, vascularity, cartilage erosion, or bone erosion. Furthermore, the clearance of human TNF from serum was significantly slower after etanercept treatment than after adalimumab or infliximab treatment, suggesting that TNF-etanercept complexes persist longer in circulation. In human clinical studies, the efficacy of adalimumab is comparable to that of infliximab or etanercept in RA, but infliximab and adalimumab appear to be significantly more efficacious than etanercept in Crohn’s disease and psoriasis. The mechanistic basis for these differences is unclear at the present time, but it is possible that antibodies have better tissue penetration and/or effector function than etanercept in these disease states. All three agents bind to membrane TNF on transfected cells, but there are conflicting in vitro data on binding and initiation of Fcmediated effector functions such as complement activation or antibody-induced cellular cytotoxicity (ADCC) by normal human cells (Scallon 1995, van den Brande 2003). Other effector mechanisms, such as the induction of apoptosis in T cells, monocytes, or other
17
18
3 Adalimumab
cells, may be mediated by TNF antagonists by “reverse signaling” following binding to membrane TNF. However, several in vitro studies, particularly with infliximab and etanercept, have yielded conflicting results regarding the induction of apoptosis in T cells and monocytes by TNF antagonists (Catrina et al. 2005; Mitoma et al. 2005; Shen et al. 2005; van den Brande et al. 2003), and the relevance of these in vitro studies to the efficacy or safety of these agents in vivo remains to be determined.
3.2 Indications Adalimumab is indicated for the treatment of moderate to severe active RA in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX has been inadequate, and for the treatment of severe, active, and progressive RA in adults not previously treated with MTX. It also is indicated for the
treatment of active and progressive PsA in adults when the response to previous DMARD therapy has been inadequate. Most recently, regulatory agencies in both the United States and European Union added an indication for AS to the adalimumab labeling (EU Humira SPC 2006; US Humira PI 2006; Abbott Laboratories 2006) (Table 3.1). Adalimumab can be used as monotherapy or in combination with MTX. Future indications currently under investigation include psoriasis (Langley et al. 2005), Crohn’s disease (Hanauer et al. 2006; Sandborn et al. 2005a), and juvenile idiopathic arthritis (Lovell et al. 2004).
3.3 Pivotal Studies in Rheumatoid Arthritis The efficacy and safety of adalimumab were assessed in five randomized, double-blind, placebo-controlled pivotal studies in patients aged 18 years or older with
Table 3.1 Approved indications and indications under investigation for adalimumab (Abbott Laboratories 2006; Hanauer et al. 2006; Langley et al. 2005; Lovell et al. 2004; Sandborn et al. 2005a; van der Heijde et al. 2006) Approved indicationa
Dose
Rheumatoid arthritis Humira (adalimumab) (Abbott Laboratories, Abbott Park, IL, USA), in combination with MTX, is indicated for: ) The treatment of moderate to severe active RA in adult patients when the response to DMARDs including MTX has been inadequate ) The treatment of severe, active and progressive RA in adults not previously treated with MTX
Adalimumab 40 mg e.o.w.; in combination with MTX or as monotherapy May increase to 40 mg weekly if not receiving MTX
Humira can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate Humira has been shown to reduce the rate of progression of joint damage as measured by radiograph and to improve physical function when given in combination with MTX
a
Psoriatic arthritis Treatment of active and progressive PsA in adults when the response to previous DMARD therapy has been inadequate
Adalimumab 40 mg e.o.w.
Ankylosing spondylitis (van der Heijde et al. 2006) Reducing signs and symptoms in patients with active AS
Adalimumab 40 mg e.o.w.
Indications under investigation
Dose
Psoriasis (Langley et al. 2005) Crohn’s disease (Hanauer et al. 2006; Sandborn et al. 2005a) Juvenile idiopathic arthritis (Lovell et al. 2004)
Under investigation (phase III) Under investigation (phase III) Under investigation (phase III)
Based on approved labeling from the European Agency for Evaluation of Medicinal Products; indications in other areas may differ AS ankylosing spondylitis, DMARDs disease-modifying antirheumatic drugs, EMEA European Agency for the Evaluation of Medicinal Products, e.o.w. every other week, FDA Food and Drug Administration, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis
3.3 Pivotal Studies in Rheumatoid Arthritis
active RA diagnosed according to American College of Rheumatology (ACR) criteria (Table 3.2). Adalimumab was administered s.c. in combination with MTX (12.5 – 25 mg), as monotherapy, or with other DMARDs (Abbott Laboratories 2006). 3.3.1 Adalimumab Plus Methotrexate The ARMADA (Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab) trial was a randomized, double-blind, placebo-controlled, multicenter trial that evaluated 271 patients with active RA who had failed therapy with one to four DMARDs and had an inadequate response to MTX. Patients received MTX plus adalimumab 20, 40, or 80 mg or MTX plus placebo e.o.w. for 24 weeks. Significant improvement in disease activity was demonstrated in patients receiving adalimumab plus MTX compared with those receiving placebo plus MTX (see Table 3.2). The addition of adalimumab to MTX substantially improved measures of functional parameters, fatigue scales, and quality of life scores in RA patients not adequately responding to MTX alone, as evidenced by the approximately 35 – 40 % reduction with the addition of adalimumab in the Disability Index of the Health Assessment Questionnaire (HAQ), clinically meaningful ( & 10 point changes) in 6 domains of the Short Form-36 (SF-36) for adalimumab plus MTX as compared with 2 domains for placebo plus MTX, and clinically important differences between adalimumab plus MTX and placebo plus MTX in Functional Assessment of Chronic Illness Therapy fatigue scores. Levels of acute-phase reactants (e.g., C-reactive protein) also were markedly reduced (Weinblatt et al. 2003). The open-label extension of this study is ongoing. Of the patients completing 5 years of treatment, clinical efficacy was sustained, with 76 %, 64 %, and 39 % of patients achieving ACR20, 50, 70 responses; 52 % achieving clinical remission; and 28 % having no physical limitations (Weinblatt et al. 2004, 2005). Furthermore, the majority of these patients were able to reduce corticosteroid and/ or MTX dosages without adversely affecting long-term efficacy (Weinblatt et al. 2005). DE019 was a randomized, double-blind, placebocontrolled, multicenter study assessing the ability of adalimumab to inhibit radiographic progression and reduce disease activity in 619 RA patients with active disease despite therapy with MTX. Patients received MTX plus either adalimumab 40 mg e.o.w., adalimu-
mab 20 mg weekly or placebo for 52 weeks. ACR20, 50, and 70 responses were significantly higher among patients treated with adalimumab plus MTX at Week 52 (see Table 3.2). Importantly, statistically significantly less radiographic progression occurred, as measured by the change in Total Sharp Score (TSS), in patients receiving 40 mg e.o.w. adalimumab plus MTX versus the placebo group, with a mean progression of 2.7 Sharp units seen in the placebo group at 1 year, and 0.1 Sharp units in the adalimumab-treated group. Additionally, at 1 year, 72 % of treated patients receiving adalimumab plus MTX had no radiographic progression from baseline. Functional improvement and QOL, as measured by the HAQ and SF-36, were also significantly improved in the combination group versus placebo, with approximately 40 % decreases in HAQ scores with the combination versus 17 % with placebo and clinically meaningful improvement in the SF-36 for the combination versus placebo (Keystone et al. 2004a). In an OLE of this study, 40 mg adalimumab was administered e.o.w. to 457 of the patients who completed DE019. At 3 years, 61 % of patients had no radiographic disease progression; moreover, significant clinical responses were sustained with 58 %, 42 %, and 23 % of patients achieving ACR20, 50, and 70 responses, respectively. Patients treated with placebo in the randomized controlled trial who had significant disease progression at 52 weeks experienced inhibition of radiographic progression and improved clinical responses when treated with adalimumab during the OLE (Keystone et al. 2004b, 2005). 3.3.2 Monotherapy The use of MTX in RA has limitations in certain patients, and many patients are unable to tolerate a high enough dose to achieve an optimal therapeutic benefit. Thus, for patients who do not tolerate MTX, monotherapy with adalimumab may be appropriate. DE011, a 26-week, randomized, double-blind, placebocontrolled, multicenter trial, evaluated the efficacy and safety of adalimumab monotherapy in 544 severely active RA patients for whom previous DMARD treatment had failed. Patients were randomized to placebo or monotherapy with 20 or 40 mg of adalimumab weekly or e.o.w. Time to clinical improvement with adalimumab was as early as 2 weeks. After 26 weeks, patients treated with adalimumab 20 or 40 mg weekly or e.o.w.
19
20
3 Adalimumab Table 3.2. Summary of primary and selected secondary endpoints from pivotal and other key trials of adalimumab in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, or Crohn’s disease Trial name
Treatmenta
Rheumatoid arthritis Adalimumab (20, 40, ARMADA 80 mg) + MTX (Weinblatt Placebo + MTX et al. 2003)
DE019 (Keystone et al. 2004a)
Study duration
69, 67, 73 24 weeks
Primary endpoint(s)
Secondary endpoints
ACR20: 48 %, 67 %, 66 % vs. 15 %
ACR50: 32 %, 55 %, 43 % vs. 8% ACR70: 10 %, 27 %, 19 % vs. 10 % 2 HAQ: –0.54, –0.62, –0.59 vs. –0.27
62
207, 212 Adalimumab (40 mg e.o.w., 20 mg weekly) + MTX Placebo + MTX 200
52 weeks
2 mTSS: 0.1, 0.8 vs. 2.7 ACR20 at Week 24: 63 %, 61 % vs. 30 % 2 HAQ: –0.59, –0.61 vs. –0.25
ACR20: 59 %, 55 % vs. 24 % ACR50: 42 %, 38 % vs. 10 % ACR70: 23 %, 21 % vs. 5 %
106, 112, 113, 103
26 weeks
ACR20: 36 %, 39 %, 46 %, 53 % vs. 19 %
ACR50: 19 %, 21 %, 22 %, 35 % vs. 8 % ACR70: 9 %, 10 %, 12 %, 18 % vs. 2 % Moderate EULAR response: 42 %, 48 %, 56 %, 63 % vs. 26 % Good EULAR response: 7 %, 10 %, 9 %, 14 % vs. 4 % 2 HAQ: –0.29, –0.39, –0.38, –0.49 vs. –0.07
24 weeks
AEs: no statistically significant ACR20: 53 % vs. 35 % differences between adalimu- ACR50: 29 % vs. 11 % ACR70: 15 % vs. 4 % mab and placebo group in serious AEs; severe or lifethreatening AEs; AEs leading to withdrawal; rates of infections or serious infections
268 274 257
2 years
ACR50 at 1 year: 62 %, 41 %, vs. 46 % 2 mTSS at 1 year: 1.3, 3.0, vs. 5.7
At year 2: ACR20: 69 %, 49 % vs. 56 % ACR50: 59 %, 37 % vs. 43 % ACR70: 47 %, 28 % vs. 28 % ACR90: 27 %, 9 % vs. 13 % 2 mTSS: 1.9, 5.5 vs. 10.4 DAS28 < 2.6: 49 %, 25 % vs. 25 % ACR70 maintained 6 months: 49 %, 25 % vs. 27 %
151 162
24 weeks
ACR20 at Week 12: 58 % vs. 14 % 2 mTSS at Week 24: –0.2 vs. 1.0
At Week 24: ACR20: 57 % vs. 15 % ACR50: 39 % vs. 6 % ACR70: 23 % vs. 1 % PASI 50: 75 % vs. 12 % PASI 75: 59 % vs. 1 % PASI 90: 42 % vs. 0 % PGA clear or almost clear: 71 % vs. 12 % 2 HAQ: –0.4 vs. –0.1
DE011 (van Adalimumab (20 mg de Putte et al. e.o.w., 20 mg weekly, 40 mg e.o.w., 40 mg 2004) weekly) Placebo
STAR (Furst et al. 2003)
N
Adalimumab + DMARDs Placebo + DMARDs
Early rheumatoid arthritis Adalimumab + MTX PREMIER (Breedveld Adalimumab et al. 2005, MTX 2006)
Psoriatic arthritis Adalimumab ADEPT (Mease et al. Placebo 2005a, 2005b, 2005c)
110
318 318
3.3 Pivotal Studies in Rheumatoid Arthritis Table 3.2. (Cont.) Trial name
Treatmenta
570 (Genove- Adalimumab Placebo se et al. 2005)
Ankylosing spondylitis ATLAS (data Adalimumab Placebo on file; van der Heijde et al. 2006) Psoriasis 528 (Langley Adalimumab (40 mg e.o.w., 40 mg weekly) et al. 2005; Wallace et al. Placebo 2005b; 2005c; 2005d)
529 (Langley et al. 2005; Wallace et al. 2005b; 2005c; 2005d)
Adalimumab (40 mg e.o.w., 40 mg weekly, placebo switched to 40 mg e.o.w.)
Crohn’s disease Adalimumab (160/ CLASSIC-I (Hanauer et 80 mg, 80/40 mg, 40/ 20 mg) al. 2006) Placebo CLASSIC-II Adalimumab (Sandborn et al. 2005a)
a
N
Study duration
Primary endpoint(s)
Secondary endpoints
51 49
12 weeks
ACR20: 39 % vs. 16 %
ACR50: 25 % vs. 2 % ACR70: 14 % vs. 0 % PGA clear or almost clear: 41 % vs. 7 % 2 TL: –47 % vs. –1.6 % 2 HAQ: –0.3 vs. –0.1
208 107
12 weeks
ASAS20: 58 % vs. 21 %
BASDAI 50: 45 % vs. 16 % ASAS40: 41 % vs. 14 % ASAS5/6: 49 % vs. 13 % Partial remission: 21 % vs. 4 %
45, 50
12 weeks
PASI 75: 53 %, 80 % vs. 4 %
PASI 50: 76 %, 88 % vs. 17 % PASI 90: 24 %, 48 % vs. 0 % PGA clear or almost clear: 49 %, 76 % vs. 2 % DLQI of 0: 33 %, 42 % vs. 2 % 2 SF-36 PCS: 3.9, 5.9 vs. 0.8 2 EuroQOL-5D: 0.25, 0.22 vs. 0.04
42, 44, 46 60 weeks
PASI 75: 67 %, 73 %, 50 %
PASI 50: 76 %, 75 %, 78 % PASI 90: 36 %, 55 %, 41 % PGA clear or almost clear: 63 %, 79 %, 66 % DLQI of 0: 34 %, 58 %, 45 % 2 SF-36 PCS: 3.4, 6.6, 2.9 2 EuroQOL-5D: 0.21, 0.22, 0.17
76, 75, 74 4 weeks
Clinical remission (CDAI <150) at Week 4: 36 %, 24 %, 18 % vs. 12 %
CDAI & 70: 59 %, 59 %, 54 % vs. 37 % CDAI & 100: 50 %, 40 %, 34 % vs. 25 %
Clinical remission (CDAI <150) at Week 56: 43 % in OL cohort
OL cohort: CDAI & 70: 69 % CDAI & 100: 61 %
52
74 221 in OL cohort; 55 in RCT arm
4-week OL segment then 52week RCT or OL arm
The dose of adalimumab is 40 mg e.o.w. unless specified otherwise ACR American College of Rheumatology, ADEPT Adalimumab Effectiveness in Psoriatic Arthritis Trial, AE adverse event, ARMADA Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis, ASAS ASessment in Ankylosing Spondylitis International Working Group Improvement Criteria, ATLAS Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CDAI Crohn’s Disease Activity Index, CLASSIC Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction Therapy in Crohn’s Disease, DAS Disease Activity Score, DLQI Dermatology Life Quality Index, DMARDs disease-modifying antirheumatic drugs, e.o.w. every other week, EULAR European League Against Rheumatism, HAQ Health Assessment Questionnaire, mTSS modified total Sharp score, MTX methotrexate, PASI Psoriasis Area and Severity Index, PGA Physician’s Global Assessment, ReAct Research in Active Rheumatoid Arthritis Trial, SF-36 PCS Short Form-36 Physical Component Summary, STAR Safety Trial of Adalimumab in Rheumatoid Arthritis, TL target lesion
21
22
3 Adalimumab
had significantly better ACR response rates than those treated with placebo (see Table 3.2). Moderate European League Against Rheumatism (EULAR) response rates were also significantly greater with adalimumab than with placebo. The 40-mg weekly dose resulted in a slightly higher ACR response than 40 mg e.o.w. Adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function in patients with severe RA refractory to DMARD treatment (van de Putte et al. 2004). The long-term efficacy and safety of adalimumab were evaluated in a rollover OLE study (DE018), enrolling 794 RA patients from DE011 and 3 other adalimumab trials in which the majority of patients received monotherapy. The clinical responses achieved at year 1 were sustained up to 5 years, with 67 %, 40 %, and 17 % of patients maintaining ACR20, 50, and 70 responses, respectively. A total of 81 % of patients had a moderate EULAR response at 5 years, and initial reductions in tender and swollen joint counts were also maintained. High retention rates were achieved, suggesting high tolerability with adalimumab therapy (Burmester et al. 2003). 3.3.3 Adalimumab Plus Traditional DMARDs The STAR (Safety Trial of Adalimumab in RA) trial assessed the safety and efficacy of adalimumab in a heterogeneous group of RA patients with persistent disease activity despite concomitant DMARD therapy. In this randomized, double-blind, placebo-controlled, multicenter study, 636 RA patients receiving 0 to & 3 DMARDs received placebo or adalimumab 40 mg e.o.w. for 24 weeks while continuing their baseline DMARDs. Patients treated with adalimumab achieved statistically superior ACR20, 50, and 70 responses at Week 24 compared with placebo-treated patients (see Table 3.2). There were no statistically significant differences between the adalimumab and placebo groups in their respective rates of adverse events (AEs), serious AEs, severe or life-threatening AEs, or AEs leading to withdrawal. In addition, rates of infections or serious infections did not vary between the groups, suggestive of a favorable safety profile of adalimumab in patients receiving standard DMARDs (Furst et al. 2003). Further assessment of adalimumab in a broad RA population was achieved through ReAct (Research in
Active Rheumatoid Arthritis Trial), a trial conducted to establish efficacy and safety in real-life clinical practice. ReAct represents the largest cohort of RA patients to be treated with a TNF antagonist in a study setting: 6,610 RA patients with active disease received adalimumab 40 mg e.o.w. for 12 weeks in addition to their current anti-rheumatic standard therapy, thus providing valuable information on the drug’s performance in patients treated with various DMARDs, including patients with previous biologic experience. Patients were offered the option of continuing adalimumab in an extension phase of the study. Enrollment criteria for ReAct mirrored national guidelines for anti-TNF treatment in participant countries (11 European countries plus Australia). At Week 12, 69 %, 40 %, and 18 % of patients achieved an ACR20, 50, and 70 response, 83 % of patients achieved a moderate EULAR response, and 33 % a good EULAR response. Response rates were maintained over time in patients who continued adalimumab treatment for 52 weeks in the extension phase (Burmester et al. 2005). Improvements in clinical and functional status, as measured by the Disease Activity Score in 28 joints (DAS28) and the disability index of the HAQ, also were clinically significant and sustained over time. In patients who had received prior TNF antagonists, the ACR20 response rate was high, at 60 %, though somewhat lower than in patients who were na¨ıve to TNF antagonists (70 %). Patients with and without previous anti-TNF treatment experienced a statistically significant reduction in disease activity and disability at Week 12. These results indicate that even after treatment failure with a TNF antagonist, a clinically important response can be achieved with a different agent of the same class (Burmester et al. 2004, 2005; data on file). 3.3.4 Early Rheumatoid Arthritis Current evidence suggests that early, aggressive combination treatment of RA achieves superior long-term outcomes (O’Dell 2002; Keystone et al. 2003a, 2003b, 2003c, 2005; Weinblatt et al. 2003). The PREMIER Study was a randomized, double-blind, active comparatorcontrolled, multicenter study designed to compare the efficacy and safety of adalimumab plus MTX versus adalimumab monotherapy or MTX monotherapy in 799 MTX-na¨ıve RA patients with early (<3 years), aggressive disease. Patients received adalimumab
3.4 Pivotal Studies in Psoriatic Arthritis
40 mg e.o.w. plus MTX, adalimumab 40 mg e.o.w. monotherapy, or MTX monotherapy (rapidly escalated to 20 mg/week after study start) for 2 years. Patients had a mean disease duration of 0.7 years. The coprimary efficacy endpoints compared combination therapy with MTX monotherapy with regard to proportion of patients who achieved an ACR50 response and the mean change from baseline in modified TSS. In all measured outcomes, combination therapy was superior to both MTX and adalimumab monotherapy (see Table 3.2). More patients receiving combination therapy (62 %) achieved an ACR50 response than patients who received adalimumab (41 %, P < 0.001) or MTX monotherapy (46 %, P < 0.001) (Fig. 3.4a). This trend also was observed for ACR20, 70, and 90 response rates 70
Patients (%)
60
*
62
*
59
50
46 41
40
43
37
Year 1 Year 2
30 20 10 0
a
Adalimumab + MTX
Adalimumab
MTX
b
Fig. 3.4. Results from the PREMIER study: a American College of Rheumatology 50 (ACR50) response at years 1 and 2. *P < 0.001 for adalimumab + MTX versus MTX alone and adalimumab + MTX versus adalimumab alone. b Mean change from baseline in total Sharp scores over time. *P < 0.001 for adalimumab + MTX versus MTX and adalimumab alone. †P < 0.001 for adalimumab + MTX versus MTX alone and P = 0.002 for adalimumab + MTX versus adalimumab alone. ‡P < 0.001 for adalimumab versus MTX alone. MTX methotrexate. (Reproduced with permission from Breedveld et al. 2006)
at 1 and 2 years. Significantly less radiographic progression occurred in the combination arm at both years 1 and 2 than in either the MTX arm or the adalimumab arm. Despite similar ACR50 response rates at 1 year in both the monotherapy arms, adalimumab-treated patients experienced significantly less radiographic progression than MTX-treated patients at 6 months, 1 year, and 2 years (Fig. 3.4b). At 2 years, 49 % of patients receiving combination therapy achieved clinical remission (DAS28 < 2.6) and 49 % achieved a major clinical response (ACR70 maintained & 6 months), a rate approximately twice that of either monotherapy arm. These results suggest that combination therapy with adalimumab plus MTX is significantly superior to MTX or adalimumab monotherapy in patients with early, aggressive RA, improving disease activity and achieving clinical remission (Breedveld et al. 2005, 2006).
3.4 Pivotal Studies in Psoriatic Arthritis Psoriatic arthritis is a chronic, inflammatory arthritis associated with psoriasis. The pathogenic mechanisms linking psoriasis and arthritis are not yet fully characterized, although TNF has been implicated in the process. TNF can be found in significantly elevated concentrations in the joints and psoriatic plaques of patients with PsA and has been validated as an appropriate therapeutic target of this disease (Mease 2002, 2005a). The management of patients with PsA requires attention to both skin and joint manifestations. ADEPT (Adalimumab Effectiveness in Psoriatic Arthritis Trial) was a randomized, double-blind, placebo-controlled, multicenter trial that evaluated the safety and efficacy of adalimumab as monotherapy or in combination with MTX compared with placebo or placebo plus MTX in the treatment of active PsA by measuring both skin and joint response. A total of 313 patients with moderately to severely active PsA who failed nonsteroidal antiinflammatory drug therapy were stratified according to MTX use (yes or no) and degree of psoriasis involvement ( & 3 % or <3 % of body surface area) at baseline, and were subsequently randomized to receive adalimumab 40 mg or placebo e.o.w. for 24 weeks. Significantly superior ACR responses were observed in patients treated with adalimumab than in those treated with placebo at all time points (Fig. 3.5a). Among the subset
23
24
3 Adalimumab
a
Fig. 3.6. Changes in modified total Sharp score (mTSS) at Weeks 24 and 48. *P < 0.001 placebo versus adalimumab using a ranked analysis of covariance (ADEPT Trial) (Mease et al. 2005a, 2005c)
b
Fig. 3.5. Results from the ADEPT study: a Percentage of patients with psoriatic arthritis who met American College of Rheumatology (ACR) ACR20, 50, 70 response criteria at Weeks 12 and 24. *P < 0.001 placebo versus adalimumab, adjusted for baseline methotrexate use and extent of psoriasis at baseline. b Percentage of patients with psoriatic arthritis and & 3 % body surface area psoriasis involvement at baseline who met Psoriasis Area and Severity Index (PASI) 50, 75, 90 response criteria at Weeks 12 and 24. *P < 0.001 placebo versus adalimumab, adjusted for baseline methotrexate use. (Reproduced with permission from Mease et al. 2005a)
of patients with 3 % body surface area affected by psoriasis, Psoriasis Area and Severity Index (PASI) response rates also were significantly improved (Fig. 3.5b). In this same subset of patients, the physician’s global assessment of psoriasis resulted in ratings of the lesions as clear or almost clear in 71 % of the 70 adalimumabtreated patients compared with only 12 % of the 70 placebo-treated patients at Week 24. Adalimumab treatment also resulted in significant inhibition of structur-
al changes on radiographs. The mean change in the modified TSS in patients who had both baseline and Week 24 radiographs was –0.2 for patients receiving adalimumab versus 1.0 for patients receiving placebo. Adalimumab treatment also significantly improved disability and QOL measures in patients with moderately to severely active PsA (Mease et al. 2005a). In an ongoing OLE phase of this trial, all patients who continued received adalimumab 40 mg e.o.w. Response rates were maintained over 48 weeks of treatment for those patients initially treated with adalimumab. The percentage of patients achieving ACR20, ACR50, and ACR70 were 61 %, 46 %, and 31 %, respectively, for adalimumab-treated patients, and 54 %, 37 %, and 21 %, respectively, for those patients originally receiving placebo who were switched to adalimumab. Of 152 placebo- and 144 adalimumab-treated patients who had radiographs at baseline and 24 weeks, 141 and 133, respectively, had radiographs taken at Week 48. Notably, the mean change in modified TSS at Week 24 was maintained to Week 48 (Fig. 3.6). At Week 48, the changes in joint space narrowing scores and in erosion scores were 0.4 and 0.5, respectively, for placebo patients and –0.1 and –0.1 for adalimumab patients (Mease et al. 2005b, 2005c).
3.6 Future Indications
3.5 Pivotal Study in Ankylosing Spondylitis Several years ago, researchers discovered increased concentrations of TNF near areas of new bone formation in sacroiliac joint biopsy specimens from patients with AS, giving way to a new therapeutic approach to this disease (Braun et al. 1995). Recent studies have demonstrated significant efficacy of anti-TNF therapy for the treatment of AS (Braun et al. 2002; van der Heijde et al. 2005). The ATLAS (Adalimumab Trial Evaluating Long-term Efficacy and Safety in Ankylosing Spondylitis) trial was a 24-week, 2:1 randomized, doubleblind, placebo-controlled, multicenter study comparing adalimumab 40 mg e.o.w. with placebo in patients with AS. After 12 weeks of therapy, 58 % of patients achieved a 20 % improvement in the ASsessment in AS (ASAS20) International Working Group Improvement response criteria with adalimumab versus placebo (21 %). Similarly, significantly more adalimumabtreated patients had at least a 50 % improvement in The Bath AS Disease Activity Index (BASDAI) score at Week 12. Patients treated with adalimumab also achieved significantly higher ASAS 5/6, ASAS 40, and partial remission responses at Weeks 12 and 24 compared with placebo-treated patients. Improvements in the signs and symptoms of active AS were sustained throughout the 24-week study period (van der Heijde et al. 2006).
3.6 Future Indications 3.6.1 Psoriasis Psoriasis is a chronic, inflammatory skin disease that requires life-long therapy. A pathophysiologic role for TNF in psoriasis is indicated by the findings of increased TNF expression in psoriatic plaques and short-term data showing that anti-TNF agents ameliorate this disease (Leonardi et al. 2003). Based on this knowledge, the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis were investigated (see Table 3.2). The initial study was a 12week, randomized, double-blind, placebo-controlled, multicenter study in which patients were randomized 1:1:1 to receive: adalimumab 80 mg at Week 0 followed by 40 mg e.o.w. beginning at Week 1; adalimumab
80 mg at Weeks 0 and 1 followed by 40 mg weekly beginning at Week 2; or placebo for 12 weeks. A significantly higher percentage of adalimumab-treated patients (53 % for 40 mg e.o.w. and 80 % for 40 mg weekly versus 4 % of placebo patients) achieved a 75 % reduction from their baseline PASI score (PASI 75) at Week 12. At Week 24, 67 % of patients treated with adalimumab 40 mg e.o.w. and 77 % of patients treated with adalimumab 40 mg weekly achieved PASI 75, and 55 % of those patients who were switched from placebo to adalimumab 40 mg e.o.w. achieved this endpoint. Quality of life also improved with adalimumab treatment as assessed by the Dermatology Life Quality Index, SF-36, and EuroQOL 5D scores. Results were maintained throughout an additional 48 weeks of treatment (Langley et al. 2005; Menter et al. 2005; Wallace et al. 2005a, 2005b, 2005c, 2005d). 3.6.2 Crohn’s Disease TNF is recognized as an important cytokine in the pathogenesis of Crohn’s disease, and is elevated in the stool, mucosa, and blood of patients with Crohn’s disease (Braegger et al. 1992; Murch et al. 1991, 1993; Papadakis et al. 2000). CLASSIC-I (Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction Therapy in Crohn’s Disease), a randomized, double-blind, placebo-controlled, multicenter dose-ranging study, evaluated the efficacy of adalimumab induction therapy in 299 patients with this disease. Patients with moderate to severe Crohn’s disease who were na¨ıve to anti-TNF therapy received induction treatment at Weeks 0 and 2 with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg or placebo and were followed for 4 weeks. Statistically significant rates of clinical remission (CDAI < 150 points) and clinical response (decrease in CDAI & 70 or 100 points from baseline, respectively) were achieved by adalimumab-treated patients at Week 4. The optimal induction dosing regimen in this study was 160 mg at Week 0 followed by 80 mg at Week 2 (Hanauer et al. 2006; Paulson et al. 2005). Patients who completed the CLASSIC-I trial were eligible to enroll in CLASSIC-II, a two-arm study (open label and randomized arms) to assess the long-term efficacy and safety of adalimumab maintenance therapy in patients with active Crohn’s disease. Fifty-five patients who were in remission at Week 0 and Week 4
25
26
3 Adalimumab Study visit (week)
0
Patients on adalimumab (N) 220 CDAI < 150a (%) 5.5 2 70 in CDAI (%) 40.5 2 100 in CDAI (%) 23.6
2
4
8
12
16
24
215 19.5 59.1 40.5
206 20.5 60.7 41.7
195 27.7 65.6 52.8
180 30.0 74.4 59.4
174 33.6 75.9 62.1
156 33.2 78.2 69.9
56 131 43 69 61
Table 3.3. Percentage of Crohn’s disease subjects in clinical remission or with clinical response (CLASSICII) (Sandborn et al. 2005a, 2005c)
a
Based on N = 220 at every time point; missing data treated as no remission CDAI Crohn’s disease activity index
were randomized to receive adalimumab 40 mg e.o.w., 40 mg weekly, or placebo for up to 1 year. The remaining subjects not in remission at both Week 0 and 4 received open-label adalimumab 40 mg e.o.w. Dose escalation to 40 mg weekly was permitted for flare or persistent nonresponse. Among patients in the randomized arm of the study, 83 % receiving adalimumab 40 mg weekly, 68 % receiving 40 mg e.o.w., and 39 % receiving placebo maintained remission at 1 year (Sandborn et al. 2005b). In the open-label arm, clinical remission was achieved in 43 %, clinical 100-point response in 61 %, and clinical 70-point response in 69 % of the patients at 1 year (Table 3.3) (Sandborn et al. 2005c).
Table 3.4. Adverse events reported by & 5 % of patients treated with adalimumab during placebo-controlled periods of rheumatoid arthritis studies (Abbott Laboratories 2006) Adverse event
Respiratory Upper respiratory infection Sinusitis Flu syndrome Gastrointestinal Nausea Abdominal pain Laboratory testsa Laboratory test abnormal Hypercholesterolemia Hyperlipidemia Hematuria Alkaline phosphatase increased
3.7 Safety The safety profile of adalimumab has been studied extensively in randomized clinical trials and in longterm OLE trials (Weinblatt et al. 2003; Keystone et al. 2004a, 2004b; Furst et al. 2003; van de Putte et al. 2004). At least 10,050 patients with moderate to severe RA have been evaluated, representing 12,506 patient-years (PYs) of adalimumab exposure (Schiff et al. 2006). Adalimumab is generally well tolerated, with less than 10 % of the patients discontinuing treatment due to AEs in RA trials (Furst et al. 2003; Keystone et al. 2004a). Additionally, data from a national registry demonstrated a high adherence rate (82 %) after 12 months of adalimumab therapy (Kristensen et al. 2004). The most common AE associated with adalimumab treatment is injection site reactions, occurring in 20.3 % of adalimumab-treated patients versus 13.8 % of placebo-treated patients across RA trials. Most injection site reactions were mild and nonrecurrent and rarely led to drug discontinuation (Wells et al. 2003). Phase IIIb studies of adalimumab in RA (Burmester et al. 2004, 2005) and in studies for other approved or potential indications (e.g., PsA, psoriasis, AS, Crohn’s
Other Injection site pain Headache Rashb Accidental injury Injection site reactionb,c Back pain Urinary tract infection Hypertension
Adalimumab 40 mg e.o.w. (n = 705) (%)
Placebo (n = 690) (%)
17 11 7
13 9 6
9 7
8 4
8 6 7 5 5
7 4 5 4 3
12 12 12 10 8 6 8 5
12 8 6 8 1 4 5 3
a
Laboratory test abnormalities were reported as adverse events in European trials b Statistically significant c Does not include erythema and/or itching, hemorrhage, pain, or swelling e.o.w. every other week
disease) have revealed no new safety signals (Langley et al. 2005; Hanauer et al. 2006; Mease et al. 2005a, 2005b; Sandborn et al. 2005a; Schiff et al. 2003, 2006; van der Heijde et al. 2006). Retrospective analysis of combined data from all clinical trials in RA patients treated with adalimumab determined that the rates of serious and nonserious
3.8 Summary
infections were similar to those reported with traditional DMARDs, and other TNF antagonists, and did not increase over time (Schiff et al. 2005, 2006). During the pivotal trials, the rate of infection was 1.0/PY in the adalimumab-treated patients and 0.9/PY in the placebotreated patients. The most frequently reported infections were upper respiratory tract infections, rhinitis, bronchitis, and urinary tract infections (Abbott Laboratories 2006). As of April 2005, the rate of serious infections among adalimumab-treated patients was 5.1/ 100 PYs, which is consistent with that of the previous assessment in August 2002 of 4.9/100 PYs. These rates are similar to those observed for the general RA population na¨ıve to TNF antagonists (Schiff et al. 2006). Cases of tuberculosis (TB) have been documented in patients treated with TNF inhibitors. Most of these cases are a result of reactivation of latent TB and occur within the first few months of therapy (Bieber and Kavanaugh 2004; Schiff et al. 2003). During the first 534 PYs of adalimumab exposure in clinical trials, screening for TB was not required and 7 TB cases were reported, all in Europe (1.3/100 PYs); however, the rate of TB decreased by 75 % (0.33/100 PYs) after the introduction of routine TB screening in European clinical trials (Schiff et al. 2006). In North American clinical RA trials, 4 cases had been reported after 4,914 PYs of exposures (0.08/100 PYs). In the postmarketing period from 31 December 2002 through 30 June 2005, there were 17 cases of TB (0.02/100 PYs) reported in the United States, of which 5 had extrapulmonary involvement (Schiff et al. 2006). These data are consistent with those for other TNF inhibitors and the decrease in cases seen after screening was introduced prior to beginning TNF antagonist therapy highlights the importance of screening for latent TB prior to commencing therapy with adalimumab or other TNF antagonists (Lee and Kavanaugh 2005). Reports in the literature suggest that RA patients have an approximately twofold increased risk of lymphoma than the general population, which may be further increased in patients with highly active disease (Gridley et al. 1993; Isomaki et al. 1978; Mellemkjaer et al. 1996). After 12,506 PYs of adalimumab exposure, 15 cases of lymphoma were observed (0.12/100 PYs). Most patients in adalimumab clinical trials had moderately to severely active RA at study entry, increasing their risk for lymphoma. The Standardized Incidence Ratio of 3.19 for lymphoma in adalimumab-treated patients is consistent with that expected in RA patients na¨ıve to TNF antagonists (Schiff et al. 2006).
Ten cases of demyelinating conditions were observed among RA patients who had received adalimumab after 12,506 PYs of exposure (0.08/100 PYs). Six of these were cases of multiple sclerosis (MS) (Schiff et al. 2006). This rate is consistent with the background rate of MS in society as a whole and with that of other TNF inhibitors. The literature suggests that patients with MS have a statistically significantly higher coexistence of RA, psoriasis, and goiter than matched controls (Heinzlef et al. 2000). Patients with RA and Crohn’s disease who develop neurologic signs after exposure to TNF inhibitors may innately be at increased risk of developing MS as compared with the general population (Magnano et al. 2004). The true impact of TNF inhibitors on the development of this disorder is unknown (Lee and Kavanaugh 2005; Magnano et al. 2004). Approximately 3 – 12 % of patients treated with adalimumab develop autoantibodies to antinuclear antigen and double-stranded DNA. The clinical implications of these antibodies remain to be defined, because progression to lupuslike illness appears to be uncommon. After 12,506 PYs of adalimumab exposure, 13 cases of systemic lupus erythematosus and lupuslike syndromes have been reported. None of these cases had significant internal organ involvement. Other rare reports include aggravation of congestive heart failure (CHF) (Kavanaugh et al. 2003). During adalimumab trials, 44 patients reported a medical history of CHF, and 3 (7 %) of these patients reported CHF events during the trials. Thirty-two cases of CHF were observed among 10,006 (0.3 %) patients who did not report a medical history of CHF. Over the 2.5 years in which the rate of CHF was evaluated, the frequency of these conditions appears to have remained stable (Schiff et al. 2006).
3.8 Summary TNF plays a key role in a number of chronic inflammatory and autoimmune disease states, including RA, PsA, psoriasis, AS, and Crohn’s disease. The introduction of TNF antagonists has significantly improved the clinical status of many patients with these conditions (Lovell et al. 2000; Breedveld et al. 2005, 2006; Burmester et al. 2004, 2005; Furst et al. 2003; Genovese et al. 2005; Hanauer et al. 2006; Keystone et al. 2004a; Lang-
27
28
3 Adalimumab
ley et al. 2005; Mease et al. 2005a; Sandborn et al. 2005a; van der Heijde et al. 2006; van de Putte et al. 2004; Weinblatt et al. 2003). Adalimumab, the first fully human TNF antagonist, is currently indicated for the treatment of moderate to severe active RA and progressive PsA in patients who have had an inadequate response to DMARDs as well as for use in adults with severe, active, and progressive RA who are na¨ıve to MTX therapy. Randomized, placebo-controlled trials evaluating the efficacy and safety of adalimumab treatment in a broad spectrum of RA patients have demonstrated substantial improvements in disease symptoms, as well as improvements in QOL and functional status, and arrest of disease progression; moreover, adalimumab had a rapid onset of action and sustained efficacy with longterm treatment. In adalimumab OLE studies, patient retention is high, supporting the tolerability data from pivotal trials. Recent evaluations of adalimumab for the treatment of PsA have demonstrated significant efficacy in both skin and joint components of the disease. Results from the PREMIER trial demonstrate that combination therapy with adalimumab plus MTX provided significant inhibition of disease progression as well as significant clinical remission outcomes superior to MTX monotherapy in patients with early, aggressive RA. Treatment of early RA patients not previously treated with MTX and treatment of patients with AS has now been included in the adalimumab label in the United States and European Union following the PREMIER and ATLAS studies, respectively. The therapeutic potential of adalimumab in JIA, psoriasis, and Crohn’s disease is currently under investigation; results of studies evaluating adalimumab in these conditions appear promising.
References Abbott Laboratories (2006) Adalimumab [prescribing information]. Abbott Laboratories, North Chicago, IL Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl1):19 – 22 Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601 – 608 Barrera P, Joosten LA, Den Broeder AA, et al. (2001) Effects of treatment with a fully human anti-tumour necrosis factor [ monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF [ in patients with rheumatoid arthritis. Ann Rheum Dis 60:660 – 669
Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of TB in patients with rheumatoid arthritis receiving biologic treatments. Rheum Dis Clin North Am 30: 257 – 270 Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89 – 91 Braun J, Bollow M, Neure L, et al. (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499 – 505 Braun J, Brandt J, Listing J, et al. (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187 – 1193 Breedveld FC, Weisman MH, Kavanaugh AF, et al. (2005) The efficacy and safety of adalimumab (Humira®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis: 1- and 2-year results of the PREMIER study [abstract]. Ann Rheum Dis 64 (Suppl III):60 (OP013) Breedveld FC, Weisman MH, Kavanaugh AF, et al., for the PREMIER investigators (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26 – 37 Brenner DA, O’Hara M, Angel P, Chojkier M, Karin M (1989) Prolonged activation of jun and collagenases genes by tumour necrosis factor-alpha. Nature 337:661 – 663 Burmester GR, van de Putte LBA, Rau R, Schattenkirchner M, Hartz D, Kupper H (2003) Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refractory RA [abstract]. Ann Rheum Dis 62(Suppl 1):192 – 193 (Poster THU0275) Burmester GR, Saez IM, Malaise M, et al. (2004) Efficacy and safety of adalimumab in European clinical practice: the ReAct Trial [abstract]. Ann Rheum Dis 63(Suppl 1):90 (OP0105) Burmester GR, Monteagudo S´aez I, Malaise MG, Kary S, Kupper H (2005) Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year results of the ReAct study [abstract]. Arthritis Rheum 52(Suppl):S541–S542 (poster 1436) Catrina AI, Trollmo C, af Klint E, et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61 – 72 Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS (1992) Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 89:244 – 250 Furst DE, Schiff MH, Fleischmann RM, et al. (2003) Efficacy and safety of the fully human anti-tumour necrosis factor- [ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563 – 2571
References Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA (2005) Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract]. Ann Rheum Dis 64 (Suppl III [3]):313 (poster FRI0187) Georgopoulos S, Plows D, Kollias G (1996) Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46:86 – 97 Granneman RG, Zhang Y, Noetersheuser PA, et al. (2003) Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humira™, Abbott) in rheumatoid arthritis patients during Phase II/III clinical trials [abstract]. Arthritis Rheum 48(Suppl):S140 (poster 256) Gridley G, McLaughlin JK, Ekbom A, et al. (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307 – 311 Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology (in press) Heinzlef O, Alamowitch S, Sazdovitch V, et al. (2000) Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 101:36 – 40 Isomaki HA, Hakulinen T, Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691 – 696 Jerne NK (1974) Towards a network theory of the immune system. Ann d’Immunologie 125C:373 – 389 Kavanaugh A, Grenwald M, Zizic T, et al. (2002) Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract]. Arthritis Rheum 45(Suppl 9):S132 Kavanaugh A, Cush JJ, Matteson E, ACR Hotline (2003) FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II. CHF, infection, and other safety issues. Available at: http://www.rheumatology.org/publications/hotline/0803chf.asp?aud=mem. Accessed September 11, 2006 Kaymakcalan Z, Beam C, Kamen R, Salfeld J (2002) Comparison of adalimumab (D2E7), infliximab, and etanercept in the prevention of polyarthritis in a transgenic murine model of rheumatoid arthritis. Arthritis Rheum 46(Suppl):S304 Keystone E, Furst DE, Kavanaugh AF, Chartash E, Fischkoff S (2003a) Subgroup analysis of radiographic progression in RA patients treated with adalimumab [abstract]. Ann Rheum Dis 62(Suppl 1):169 (poster THU0198) Keystone E, Kavanaugh AF, Fischkoff S, et al. (2003b) Response to adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 62(Suppl 1):170 (poster THU0201) Keystone E, Haraoui B, Bykerk VP (2003c) Role of adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Clin Exp Rheumatol 21(5 Suppl 31):S198–S199 Keystone ED, Kavanaugh AF, Sharp JT, et al. (2004a) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 50:1400 – 1411
Keystone ED, Kavanaugh AF, Sharp JT, et al. (2004b) Inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA) plus methotrexate [abstract]. Arthritis Rheum 50(Suppl):S189 (poster 370) Keystone EC, Kavanaugh AF, Sharp JT, et al. (2005) Inhibition of radiographic disease progression in patients with longstanding rheumatoid arthritis following 3 years of treatment with adalimumab (Humira®) plus methotrexate. Ann Rheum Dis (Suppl III):419 (poster SAT0034) Kristensen L, Saxne T, Geborek P (2004) Adherence to therapy of infliximab, etanercept, adalimumab, and anakinra in chronic arthritis patients treated in clinical practice in southern Sweden [abstract]. Ann Rheum Dis 64(Suppl 1):263 (poster FRI0049) Langley R, Leonardi C, Toth D, et al. (2005) Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl)203 (poster P2825) Lee SJ, Kavanaugh A (2005) Adalimumab for the treatment of rheumatoid arthritis. Therapy 2:13 – 21 Leonardi CL, Powers JL, Matheson RT, et al., for the Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014 – 2022 Lovell D, Giannini, E, Reiff A, et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763 – 769 Lovell DJ, Ruperto N, Goodman S, et al. (2004) Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA). Arthritis Rheum 50(Suppl):S436– S437 Magnano M, Robinson WH, Genovese MC (2004) Demyelination and the use of TNF inhibition. Clin Exp Rheumatol 22(5 Suppl 35):S134–S140 Maini RN, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552 – 1563 Mease P (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298 – 304 Mease P (2005) TNF- [ inhibitors in psoriatic arthritis. In: Gordon KB, Ruderman EM (eds) Psoriasis and psoriatic arthritis: an integrated approach. Springer-Verlag, Heidelberg, pp 223 – 234 Mease PJ, Gladman DD, Ritchlin CT, et al., for the ADEPT Study Group (2005a) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. ADEPT. Arthritis Rheum 52:3279 – 3289 Mease PJ, Gladman DD, Ritchlin CT, et al. (2005b) Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48week results of ADEPT [abstract]. Arthritis Rheum 52(Suppl):S215 (Poster 500) Mease P, Sharp J, Ory P, et al. (2005c) Inhibition of joint destruction in PsA with adalimumab: 48-week results of ADEPT [abstract]. Arthritis Rheum 52(Suppl):S631 (poster 1699)
29
30
3 Adalimumab Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753 – 1757 Menter MA, Gordon K, Leonardi C, Chen D (2005) Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis [abstract]. J Am Acad Dermatol 52(3 Suppl):174 (poster P2713) Mitoma H, Horiuchi T, Hatta N, et al. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[945]. Gastroenterology 128:376 – 392 Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT (1991) Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32:913 – 917 Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705 – 1709 O’Dell J (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283 – 285 Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148 – 1157 Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor- [ and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518 – 523 Paulson SK, Noertersheuser P, Pollack P, Hoffman R (2005) Pharmacokinetics of adalimumab from CLASSIC, a randomized phase 3 trial for the induction of clinical remission in patients with Crohn’s disease [abstract]. Gastroenterology 128(4 Suppl 2):A-585 (poster W1057) Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544 – 1552 Salfeld J, Kaymakcalan Z, Tracey D, Robert A, Kamen R (1998) Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 41(Suppl):S57 Sandborn W, Hanauer S, Lukas M, et al. (2005a) Induction and maintenance of clinical remission and response in subjects with Crohn’s disease treated during a 6-month open-label period with fully human anti-TNF- [ monoclonal antibody adalimumab (Humira®). Gastroenterology 128(4 Suppl 2):A111 (presentation 723) Sandborn WJ, Hanauer S, Enns R, et al. (2005b) Maintenance of remission over 1 year in patients with active Crohn’s disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study. Gut 54(Suppl VII):A81 – 2 (oral presentation OP-G-353) Sandborn WJ, Hanauer S, Lukas M, et al. (2005c) Clinical remission and response in patients with Crohn’s disease treated with open-label for 1 year with fully human antiTNF- [ monoclonal antibody adalimumab. Gut 54(Suppl VII):A18 (oral presentation OP-G-78) Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041 – 1045
Scallon BJ, Moore MA, Trinh H, Knigh DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251 – 259 Schiff M, van de Putte LB, Breedveld FC, et al. (2003) Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis 62(Suppl I):184 (poster THU0246) Schiff MH, Burmester GR, Kent J, et al. (2005) Safety of adalimumab in long-term treatment of patients with rheumatoid arthritis [abstract]. J Am Acad Dermatol 52(3 Suppl):203 (poster P2826) Schiff MH, Burmester GR, Kent J, et al. (2006) Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889 – 894 Shen C, Assche GV, Colpaert S, et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21(3):251 – 258 van den Brande JM, Braat H, van den Brink GR, et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774 – 1785 van der Heijde D, Dijkmans B, Geusens P, et al., for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582 – 591 van der Heijde D, Kivitz A, Schiff MH, et al. (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum 54:2136 – 2146 van de Putte LBA, Salfeld J, Kaymakcalan Z (2003) Adalimumab. In: Moreland LW, Emery P (eds) TNF inhibition in the treatment of rheumatoid arthritis. Martin Dunitz, London, 71 – 93 van de Putte LB, Atkins C, Malaise M, et al. (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508 – 516 Wallace KL, Langley R, Bissonnette R, Melluli L, Hoffman R (2005a) Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl):192 (poster P2783) Wallace KL, Gordon KB, Langley M, et al. (2005b) Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl):180 (poster P2734) Wallace KL, Bissonnette R, Leonardi C, et al. (2005c) Effects of adalimumab on health status as measured by EQ-5D in patients with moderate to severe plaque psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl):181 (poster P2741) Wallace KL, Leonardi C, Kempers S, et al. (2005d) General physical and mental health status in patients with moderate
References to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl):185 (poster P2757) Weinblatt ME, Keystone EC, Furst DE, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor [ monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48:35 – 45 Weinblatt ME, Keystone EC, Furst DE, et al. (2004) The ARMADA trial: sustained efficacy and long-term safety of adalimumab (Humira) plus methotrexate over 3 years in patients with long-standing rheumatoid arthritis [abstract]. Ann Rheum Dis 64(Suppl 1):295 (poster FRI0152) Weinblatt ME, Keystone EC, Furst DE, et al. (2005) Long-term efficacy, remission, and safety of adalimumab (HUMIRA®) plus methotrexate in patients with rheumatoid arthritis in
the ARMADA trial [abstract]. Arthritis Rheum 52(Suppl): S563 (poster 1497) Wells AF, Kupper H, Fischkoff S, Chartash E (2003) Injection site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann Rheum Dis 62(Suppl I): 411 (abstract AB0166) Williams RO, Feldmann M, Miani RN (1992) Anti-tumour necrosis factor ameliorates joint disease in murine collageninduced arthritis. Proc Natl Acad Sci USA 89:974 – 978 Zhou H, Buckwalter M, Boni J, et al. (2004) Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:267 – 276
31
Chapter 4
4 Etanercept Ch.T. Molta
4.1 Structure Etanercept is a tumor necrosis factor- [ (TNF- [ ) antagonist used in the treatment of adult and juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a recombinant, fully human, soluble, dimeric fusion protein that consists of two copies of the extracellular ligand-binding domain of the human 75-kDa TNF- [ receptor linked to the Fc portion of human immunoglobulin (Ig) G1 (European Medicines Agency 2005). It is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006). A simplified structure of etanercept is provided in Fig. 4.1. The CH2 and CH3 domains and the hinge region of the Fc portion of IgG1 are included but not the CH1 domain. It consists of 934 amino acids (fully human amino acid sequences) with an apparent molecular weight of 150 kDa (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006).
The structure of etanercept makes it a 50- to 100fold more potent binder of TNF- [ than the endogenous unconjugated soluble TNF- [ receptor (Goffe and Cather 2003; Strober 2005). Given its dimeric structure, each etanercept molecule can bind up to two TNF- [ molecules (Goffe and Cather 2003), compared with the monomeric endogenous TNF- [ receptor, which can only bind one TNF- [ molecule. Linkage of the receptor to the Fc portion of IgG1 also substantially prolongs the half-life of etanercept relative to the endogenous soluble forms (Strober 2005).
4.2 Pharmacokinetics The pharmacokinetic parameters for etanercept (Table 4.1) are similar regardless of adult age, sex, or disease state of the patient. Etanercept is administered by subcutaneous injection once or twice weekly. Given its route of administration, its rate of absorption is slower than that observed with agents administered intravenously. 4.2.1 Absorption
Fig. 4.1. Chemical structure of etanercept. IgG1 immunoglobin G1, TNF tumor necrosis factor
Etanercept is slowly absorbed after subcutaneous injection, with peak serum concentrations being achieved about 50 – 70 h after single-dose administration (Zhou 2005). Studies have consistently indicated that the mean percentage of etanercept available to the target tissues (the absolute bioavailability) after subcutaneous administration is 58 – 63 % (Zhou 2005). Administering a single 25-mg dose subcutaneously to healthy individuals resulted in a mean peak concentration of 1.5 mg/l at 51 h. A similar dosage administered
4.2 Pharmacokinetics Table 4.1. Summarizing table Structure Mechanism of action Pharmacodynamics
Receptor fusion protein (ligand-binding portion of TNF p75 receptor linked to the Fc region of IgG1) Binds to soluble or membrane-bound TNF- [ Modulates biological responses mediated by TNF- [ , including expression of adhesion molecules important for leukocyte migration, and serum levels of other cytokines and matrix metalloproteinase
Pharmacokinetics
Healthy individuals
Patients with rheumatoid arthritis
1.5 ± 0.72 mg/l 51 ± 14 h
1.1 ± 0.6 mg/l 69 ± 34 h
Single dose (25 mg) Cmax (mean ± SD) tmax (mean ± SD) Multiple dosing (25 mg twice weekly) Cmax (mean ± SD) tmax (mean ± SD) Multiple dosing (50 mg once weekly) Cmax (mean ± SD) Mean absolute bioavailability Half-life Indications (dosage)a
2.6 ± 1.2 mg/l 62 ± 29 h
2.4 ± 1.5 mg/l 58.0 %
62.6 %
2.8 ± 0.8 days (single 25-mg dose) 4.3 ± 1.3 days (25 mg BIW) Active rheumatoid arthritis (alone or with MTX) in adults with an inadequate response to DMARDs, including MTX, and for severe, active, and progressive rheumatoid arthritis in adults not previously treated with MTX (25 mg twice weekly or 50 mg once weekly) Active polyarticular-course juvenile chronic arthritis in children aged 4 – 17 years with an inadequate response to, or intolerance of, MTX (0.4 mg/kg, up to 25 mg per dose, twice weekly) Active and progressive psoriatic arthritis in adults with an inadequate response to DMARD therapy (25 mg twice weekly) Severe active ankylosing spondylitis in adults with an inadequate response to conventional therapy (25 mg twice weekly) Moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant of, other systemic therapy, including methotrexate, cyclosporine, or psoralen plus ultraviolet A phototherapy (25 mg twice weekly for up to 24 weeks; 50 mg twice weekly may be used for up to 12 weeks followed, if necessary, by 25 mg twice weekly, for up to 24 total)
a
Indications approved by the European Medicines Agency, valid as of date of publication BIW twice weekly, Cmax peak concentration, DMARD disease-modifying antirheumatic drug, IgG1 immunoglobulin G1, MTX methotrexate, SD standard deviation, tmax time to peak concentration, TNF tumor necrosis factor
to patients with rheumatoid arthritis achieved a mean peak concentration of 1.1 mg/l at 69 h. With multiple weekly dosing, etanercept achieves a smooth and uniform steady-state concentration-time profile that is linearly proportional to the weekly dosage administered (Nestorov 2005). The absorption profile of etanercept is similar in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriasis (Nestorov et al. 2004; Zhou et al. 2004b). At the end of 24 weeks’ treatment with etanercept 25 mg subcutaneously twice weekly, patients with rheumatoid arthritis achieved a mean peak concentration of 2.4 mg/l at 32 h after the last dose (Zhou 2005). In patients with rheumatoid arthritis, the steady-state pharmacokinetic profiles of etanercept 50 mg once weekly and etanercept
25 mg twice weekly are similar in terms of peak concentration (2.4 vs 2.6 mg/l), trough concentration (1.2 vs 1.4 mg/l), and partial area under the concentrationtime curve (297 vs 316 mg h/l) (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006). Pharmacokinetic modeling of steady-state trough concentrations of etanercept 25 mg twice weekly was similar for rheumatoid arthritis and ankylosing spondylitis patients (2.1 vs 2.0 mg/l, respectively) (Zhou et al. 2004b). In addition, steady-state pharmacokinetic parameters for etanercept 25 mg twice weekly were similar in rheumatoid arthritis and psoriasis patients, respectively, in terms of peak concentration (2.6 vs 2.5 mg/l), trough concentration (1.4 vs 1.5 mg/l), time to peak concentration (62 vs 61 h), and area under
33
34
4 Etanercept
the concentration-time curve (316 vs 321 mg h/l) (Nestorov et al. 2004). 4.2.2 Distribution The apparent volume of distribution of etanercept is about 12 l after single-dose administration. This is larger than the plasma volume (about 3.75 l in a 75-kg person) but less than that of extracellular water (about 16 l) (Zhou 2005). Based on its macromolecular size, extravascular distribution would likely be limited for etanercept (a 150-kDa macromolecule). Despite its molecular size, however, data suggest that etanercept penetrates into synovial fluid at levels similar to those seen in serum (Zhou 2005). Although no formal studies have been done in lactating women, the estimated amount of etanercept excreted in breast milk was reported in a case study (Ostensen and Eigenmann 2004; Zhou 2005). The patient was a 30-year-old woman with rheumatoid arthritis who received 25 mg etanercept twice weekly for 4 weeks. The concentration of etanercept found in the breast milk ranged from 0.025 to 0.075 mg/l. Considering the small amount of drug excreted into breast milk, and the lack of oral bioavailability of etanercept, the risk of attaining pharmacologic concentrations of etanercept in a nursing infant remains speculative but is not likely (Zhou 2005). Nonetheless, in the absence of formal data, the drug label recommends that a decision should be made to discontinue nursing or discontinue etanercept while nursing. 4.2.3 Metabolism and Elimination A single subcutaneous administration of 25 mg etanercept in patients with rheumatoid arthritis resulted in a mean half-life of 102 h (about 4 days) and a clearance rate of 160 ml/h, with no significant change in these pharmacokinetic parameters observed with repeated dosing (Enbrel: US Full Prescribing Information 2005; Zhou 2005). Although not confirmed, it is thought that the elimination of etanercept occurs after it binds to TNF, and metabolism of the complex could occur through either peptide or amino acid degradation pathways. Amino acids could then be recycled or eliminated through the bile or urine (Culy and Keating 2002; Zhou 2005). The metabolites of etanercept are not bioactive.
4.2.4 Age 4.2.4.1 Pediatric Patients The pharmacokinetic profile of etanercept is similar in pediatric and adult patients. Mean steady-state peak serum concentrations of etanercept were similar in patients aged 4 – 17 years who received etanercept 0.4 mg/kg twice weekly for up to 18 weeks (2.1 mg/l) and in adults who received etanercept 25 mg twice weekly (2.4 mg/l) (Culy and Keating 2002). Pharmacokinetic modeling performed in patients aged 4 – 17 years showed that there were overlapping steadystate pharmacokinetic profiles for the 0.8-mg/kg onceweekly and the 0.4-mg/kg twice-weekly dosing regimens of etanercept. The respective peak concentrations were 2.9 and 2.6 mg/l, and the respective trough concentrations were 1.6 and 1.9 mg/l (Yim et al. 2005). In younger children (4 – 8 years), etanercept clearance may be slightly reduced (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006), and a weight-based dosing schedule is warranted for pediatric patients (see “Indications” for more detailed prescribing information). 4.2.4.2 Elderly Patients Estimates of clearance and volume of distribution were similar in patients aged < 65 years and in those aged 65 – 87 years (Culy and Keating 2002); therefore, no dosage adjustment is required in the elderly. 4.2.5 Gender Women have a slightly lower clearance rate than men (0.117 vs 0.138 l/h), which results in a slightly longer half-life in women than in men (95.4 vs 80.9 h) (Lee et al. 2003). No dosage adjustment, however, is required in women. 4.2.6 Patients with Renal or Hepatic Insufficiency The presence of renal or hepatic impairment should not require a change in dosage of etanercept, as suggested by limited data in patients with acute renal fail-
4.3 Pharmacodynamics
ure or acute hepatic failure (European Medicines Agency 2005). The steady-state pharmacokinetics of etanercept (25 mg twice weekly) in patients with chronic renal failure receiving hemodialysis were similar to those in patients with psoriasis with normal renal function (Don et al. 2005). Hemodialysis had no significant effect on etanercept levels and the elimination rate constant, suggesting that no dose modification for etanercept is necessary in patients receiving hemodialysis. 4.2.7 Drug Interactions Limited studies have evaluated drug-drug interactions for etanercept. Concomitant treatment with methotrexate, warfarin, or digoxin does not significantly affect the pharmacokinetic profile of etanercept (Zhou 2005). This is particularly important in the case of methotrexate, which is often given concomitantly with etanercept in patients with rheumatoid arthritis. A pharmacokinetic modeling study reported that etanercept absorption, bioavailability, volume of distribution, and clearance were similar in patients receiving etanercept monotherapy and in those receiving combination therapy with etanercept and methotrexate (Zhou et al. 2004a). Digoxin reduced the mean peak concentration of etanercept by 4.2 % and the area under the curve by 12.5 %. This attenuation was not considered to be clinically relevant (Zhou 2005). Likewise, etanercept does not significantly affect the pharmacokinetics of any of these agents (methotrexate, warfarin, or digoxin); therefore, no dosage adjustment must be made for the coadministration of these agents with etanercept. Etanercept should not be coadministered with anakinra. Concomitant administration has been associated with an increased risk of serious infections and neutropenia (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006). In a clinical study of patients who were receiving established doses of sulfasalazine, those patients who were receiving a combination of etanercept and sulfasalazine experienced statistically significant reductions in mean white blood cell counts relative to patients receiving sulfasalazine alone. No interactions have been observed in clinical trials with the concurrent administration of etanercept with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs, analgesics, or methotrexate.
4.3 Pharmacodynamics The proinflammatory cytokine TNF- [ plays an important role in the pathogenesis of a number of chronic inflammatory disorders, such as rheumatoid arthritis, juvenile rheumatoid arthritis, Crohn’s disease, Beh¸cet’s disease, psoriatic arthritis, psoriasis, sarcoidosis, systemic lupus erythematosus, and ankylosing spondylitis (Goffe and Cather 2003; Nickoloff and Stevens 2006). Overproduction of TNF- [ can lead to chronic inflammation and tissue damage, and a number of other adverse effects on various cell types (Table 4.2) (Goffe and Cather 2003). Etanercept modulates biological responses that are initiated or controlled by TNF- [ (Table 4.3) (Goffe and Cather 2003; Kavanaugh 2005). This section will review the pharmacodynamics of etanercept, the mechanisms of action, and the resulting biochemical and physiologic effects of the drug. 4.3.1 Mode of Action Etanercept inhibits the action of TNF by competitively binding to either TNF- [ and/or TNF- q (also known as lymphotoxin- [ ), thus preventing TNF from binding to endogenous receptors located on the cell surface (Fig. 4.2) (European Medicines Agency 2005; Enbrel: US Full Prescribing Information 2006; Jarvis and Faulds 1999). Etanercept also binds to TNF expressed on cell surface membranes (cell-bound TNF) (Enbrel: US Full Prescribing Information 2006; Jarvis and Faulds 1999). Tumor necrosis factor- [ , which circulates in its soluble form, is primarily produced by macrophages and to a lesser extent by T cells (Choy and Panayi 2001; Jarvis and Faulds 1999). There are two types of TNF- [ cellsurface receptors, a 55-kDa protein (p55) and a 75-kDa protein (p75), and interaction with these receptors triggers the effects of TNF- [ (Choy and Panayi 2001). The etanercept TNF- [ p75 receptor binds to and inactivates TNF- [ . Unlike TNF- [ monoclonal antibodies, when the soluble fusion protein etanercept binds to TNF- [ expressed on the membrane surface of cells, it does not induce complement-mediated cell lysis (Goffe and Cather 2003; Enbrel: US Full Prescribing Information 2006; Jarvis and Faulds 1999).
35
36
4 Etanercept Cell type
Action of TNF
Effect
Macrophage
↑ Proinflammatory cytokine production ↑ Chemokine production
↑ Inflammation ↑ Joint swelling
T lymphocyte
↑ Proinflammatory cytokine production ↑ Nuclear transcription factor activation
↑ Inflammation
Dendritic cell
↑ Proinflammatory cytokine production
↑ Inflammation
Table 4.2. Action and effects of TNF- [ on different cells. (Adapted with permission from Goffe B, Cather JC. 2003. Etanercept: An overview. J Am Acad Dermatol 49:S105 – 111)
Dendritic cell maturation ↑ Dendritic cell migration from skin to lymph nodes T-cell activation and differentiation Keratinocyte
↑ Proliferation
Scale and thickness
Endothelial
↑ Expression of adhesion molecules
↑ Leukocyte infiltration into
↑ Production of vascular endothelial
↑ Angiogenesis and erythema
skin and joints growth factor
Auspitz sign
Hepatocyte
↑ Acute phase response
↑ C-reactive protein
Synoviocyte (fibroblast-like)
↑ Metalloproteinase synthesis
Articular cartilage degradation
Table 4.3. Known and proposed mechanisms of action of etanercept. (Adapted with permission from Kavanaugh AF. 2005. Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol 32:2285 – 2287) TNF-␣ and TNF- (LT-␣) inhibition/binding Down-regulation of other inflammatory mediators Other cytokines (IL-1, IL-6, GM-CSF) Chemokines (IL-8, RANTES) Other mediators and signaling pathways (metalloproteinases, PGE2, NF-κB) Alteration of vascular function/leukocyte traffic/cellular activation Adhesion molecule expression/function Angiogenesis Down-regulation of innate immune system interactions (e.g., decreased TLR2/4 expression) Effects on T cells Increase regulatory T-cell number/function Normalize the activation threshold for CD3/TCR signaling Alter Th1/Th2 phenotype/cytokine secretion Effects on monocytes/macrophages Increase MHC Class II expression/stimulation of T cells GM-CSF granulocyte-macrophage colony-stimulating factor, IL interleukin, LT lymphotoxin, MHC major histocompatibility complex, NF-κB nuclear factor kappa B, PGE2 prostaglandin E2, RANTES regulated on activation, normal T cell expressed and secreted, TCR T-cell receptor, Th1 type 1 helper T cell, Th2 type 2 helper T cell, TLR toll-like receptor, TNF tumor necrosis factor
TNF- [ tumor necrosis factor-alpha
Overall, etanercept results in little impairment of general immune function in patients with rheumatoid arthritis, as shown by the lack of a significant effect on delayed-type hypersensitivity reactions, serum Ig levels, T-cell proliferative response, neutrophil function, and incidence of infection (Enbrel: US Full Prescribing Information 2006; Moreland et al. 2002). Infection rates in adult patients treated with etanercept were not significantly different from that of placebo in several randomized controlled trials, and did not increase with long-term exposure (Keystone et al. 2004; Krueger et al. 2006; Moreland et al. 2006; Tyring et al. 2006). Nonetheless, some cases of serious infection have been reported in patients receiving etanercept and, similar to treatment with any drug that modulates immune function, clinicians need to monitor patients appropriately. 4.3.2 Pharmacodynamics in Disease States The pharmacodynamics of etanercept as it relates to the pathophysiology of a number of inflammatory disease states (i.e., rheumatoid arthritis, spondyloarthropathies [ankylosing spondylitis and psoriatic arthritis], and psoriasis) are described in the following sections.
4.3 Pharmacodynamics
Fig. 4.2. Mechanism of action of etanercept. TNF tumor necrosis factor. (Reprinted with permission from Amgen, Thousand Oaks, CA, USA)
4.3.2.1 Rheumatoid Arthritis An important component of the inflammatory process in rheumatoid arthritis is the synovial infiltration of CD4+ T cells. Antigen-activated CD4+ T cells stimulate the production of inflammatory cytokines TNF- [ , interleukin-1 (IL-1), and IL-6, which help drive ongoing inflammation in rheumatoid arthritis (Olsen and Stein 2004). As a result, these activated CD4+ cells are thought to stimulate B cells to produce immunoglobulins such as rheumatoid factor, which in turn may activate complement via immune complex formation. In an animal model of rheumatoid arthritis, activated CD4+ cells were thought to produce joint damage via direct stimulation of osteoclastogenesis (Choy and Panayi 2001). Elevated TNF- [ levels can be found in blood and synovial fluid in patients with rheumatoid arthritis (Jarvis and Faulds 1999; Saxne et al. 1988). Long-term treatment (9 months) with etanercept (25 mg twice weekly) in patients with rheumatoid arthritis reduced the elevated numbers of TNF- [ – and IL-1 q –secreting peripheral blood mononuclear cells to normal levels (Schotte et al. 2004). Etanercept 25 mg twice weekly for 6 months significantly reduced elevated levels of IL-6 in patients with active rheumatoid arthritis, and these reductions were accompanied by reductions in disease activity, C-reactive protein (CRP), and erythrocyte
sedimentation rate (ESR) but not transforming growth factor- q levels, suggesting a potential unknown mechanism for overexpression of transforming growth factor- q in rheumatoid arthritis (Drynda et al. 2002). TNF- [ also stimulates production of matrix metalloproteinases (MMPs), which are thought to induce bone resorption and cartilage destruction. The MMPs stromelysin 1 (MMP-1) and fibroblast collagenase (MMP-3) are present in higher levels in the serum and synovial fluid of rheumatoid arthritis patients than in controls (Keyszer et al. 1999). Treatment with etanercept 25 mg twice weekly for 2 – 3 months down-regulated serum levels of MMP-1 and MMP-3, which may be an important means for the prevention of joint damage progression. This was accompanied by concurrent reductions in CRP and ESR (Catrina et al. 2002). 4.3.2.2 Spondyloarthropathies Ankylosing Spondylitis T cells are also thought to play an important role in the pathogenesis of the spondyloarthropathies, a group of seronegative inflammatory conditions that mainly affect the axial skeleton. Ankylosing spondylitis is the prototype spondyloarthropathy characterized by spinal inflammation, radiologic evidence of sacroiliitis and spondylitis, arthritis, and soft tissue inflammation,
37
38
4 Etanercept
including enthesopathy (van der Linden et al. 2005). A number of findings implicate TNF- [ in the pathogenesis of ankylosing spondylitis, including the development of an ankylosing spondylitis-like syndrome in mice expressing a truncated form of the TNF gene, higher serum levels of TNF in patients with ankylosing spondylitis relative to patients with noninflammatory back pain, and the detection of TNF- [ mRNA in sacroiliac joint specimens from patients with ankylosing spondylitis (Braun et al. 1995; Davis 2005). Studies conducted in patients with ankylosing spondylitis have generally evaluated the effects of etanercept on clinical end points, and therefore pharmacodynamic data in this condition are somewhat limited. Etanercept has been shown to modify markers of cartilage turnover in patients with ankylosing spondylitis via reduced type II collagen degradation and increased aggrecan turnover (Maksymowych et al. 2005). Sixteen weeks’ treatment with etanercept (25 mg twice weekly) significantly reduced levels of C2C epitope, a biomarker of cartilage turnover (marker of type II collagen degradation by collagenase), in patients with ankylosing spondylitis. This change correlated with reductions in CRP and ESR (Maksymowych et al. 2005). Psoriatic Arthritis Psoriatic arthritis is a seronegative spondyloarthropathy consisting of inflammatory arthritis associated with psoriasis. The understanding of the immunologic mechanisms that contribute to psoriatic arthritis is evolving, but the importance of TNF- [ has been demonstrated. As in rheumatoid arthritis, blood mononuclear cells from patients with psoriatic arthritis secrete significantly larger amounts of biologically active TNF[ than cells from healthy controls (Ritchlin et al. 2003). TNF- [ is also found at elevated levels in synovial fluid in patients with psoriatic arthritis and is expressed by psoriatic synovial explants and lining cells, especially in patients with the erosive form of arthritis (Partsch et al. 1997; Ritchlin et al. 1998). Osteoclast precursors are markedly elevated in psoriatic arthritis and are thought to be important factors in the unique bone erosions observed in this condition (Mease 2004). These precursors arise from TNF- [ – activated peripheral mononuclear cells and migrate to inflamed synovium and subchondral bone, where they become mature osteoclasts causing bone erosion. Twelve weeks’ treatment with etanercept (25 mg twice
weekly) significantly reduced osteoclast precursors by 79 – 96 %, and these decreases were accompanied by a clinical response as measured by the number of tender and swollen joints (Ritchlin et al. 2003). In addition to its effects on the arthritis components of psoriatic arthritis, TNF- [ antagonism produces improvements in the psoriatic manifestations of the disease, discussed in the following section. 4.3.2.3 Psoriasis The epidermal hyperplasia associated with psoriasis is mediated by CD8+ and CD4+ T lymphocytes that proliferate and accumulate in diseased skin (Krueger 2002; Schön and Boehncke 2005). Activated T cells in the skin reenter the circulation and preferentially extravasate at sites of cutaneous inflammation. Upon encountering the respective antigen, T cells in the skin exert their inflammatory effect via secretion of proinflammatory cytokines such as TNF- [ , IL-1, granulocyte-macrophage colony-stimulating factor, IL-6, and transforming growth factor- [ (Schön and Boehncke 2005). High levels of TNF- [ are found in psoriatic skin lesions, in blister fluid of psoriatic skin, and in the serum of patients with psoriasis (Goffe and Cather 2003). Etanercept competitively binds to TNF- [ and prevents interactions with its cell surface receptors on keratinocytes and endothelial and inflammatory cells (Goldsmith and Wagstaff 2005). In patients with psoriasis, etanercept (25 mg twice weekly) given for 3 months significantly reduced keratinocyte adhesion molecule expression, epidermal T-cell infiltration, and markers of keratinocyte activation and proliferation, with resulting reduced epidermal thickness (Goldsmith and Wagstaff 2005). These important actions on psoriasis skin lesions are thought to be the result of down-regulation of proinflammatory and proproliferative gene expression induced in keratinocytes as a result of local TNF- [ synthesis (Gottlieb et al. 2005).
4.4 Indications In adult patients with rheumatoid arthritis, the European Medicines Agency (2005) has approved etanercept 25 mg twice weekly (alternatively, 50 mg once weekly, as two 25-mg injections or a single 50-mg injection, has
4.4 Indications
been shown to be safe and effective) as monotherapy or in combination with methotrexate in those who have had an inadequate response to previous treatment with other disease-modifying antirheumatic drugs (DMARDs), including methotrexate. It is also approved for patients with severe, active, and progressive rheumatoid arthritis in those not previously treated with methotrexate. The drug has been shown to reduce the signs and symptoms of rheumatoid arthritis (at a dose of 25 mg twice weekly or 50 mg weekly), inhibit the progression of structural damage, and improve physical function in patients with rheumatoid arthritis. Etanercept 0.4 mg/kg (up to 25 mg per dose maximum) twice weekly is also indicated for the treatment of active polyarticular-course juvenile chronic arthritis in children aged 4 – 17 years with an inadequate response or intolerability to methotrexate. Etanercept 50 mg once weekly (or 25 mg twice weekly) is indicated for the treatment of severe active ankylosing spondylitis in patients with an inadequate response to conventional therapy and for the treatment of active and progressive psoriatic arthritis in patients with an inadequate response to previous DMARD therapy. Etanercept has been shown to improve the clinical signs and symptoms of ankylosing spondylitis in affected patients. In patients with psoriatic arthritis, etanercept (50 mg once weekly or 25 mg twice weekly) can reduce the signs and symptoms of the disease, inhibit progression of structural damage of active arthritis, and improve physical function. Etanercept is also indicated for the treatment of moderate to severe plaque psoriasis in those who have failed to respond to, or who have a contraindication to, or are intolerant of, other systemic therapy including methotrexate, cyclosporine, or psoralen plus ultraviolet A phototherapy. The recommended dose in plaque psoriasis patients is 25 mg twice weekly until remission is achieved, for up to 24 weeks. Alternatively, 50 mg twice weekly may be used for up to 12 weeks, and if needed, followed by a dose of 25 mg twice weekly until remission is achieved, for up to 24 weeks. In patients with psoriasis, etanercept has been shown to reduce the signs and symptoms of the disease, including the proportion of body surface area affected and measures of plaque severity (induration, erythema, and scaling). A summary of adverse events associated with etanercept treatment based on clinical trial and postmarketing experience is presented in Table 4.4. The most
Table 4.4. Frequency of adverse events associated with etanercept based on clinical trials and postmarketing experience
a
Frequencya
Adverse event
Very common (> 1/10)
Injection site reactions Infections
Common (> 1/100, e 1/10)
Fever Pruritus Allergic reactions Autoantibody formation
Common (> 1/1,000, e 1/100)
Serious infections Rash Angioedema Urticaria Thrombocytopenia
Number of adult patients expected to experience the reaction
common adverse events associated with etanercept therapy are injection site reactions, including bleeding, bruising, erythema, itching, pain, and swelling. Serious adverse events have been reported in patients receiving etanercept, some fatal, including infections, lymphoma (observed rates and incidence are similar to those expected for the population studied), as well as neurologic and hematologic disorders. Etanercept is contraindicated in patients with sepsis or risk of sepsis and should not be initiated in patients with active infections, including chronic or localized infections. Clinicians should refer to the product label for a comprehensive list of patient warnings and precautions. Outside of Europe, some countries may follow the US Food and Drug Administration indications. In the United States, etanercept is approved for moderate to severe active rheumatoid arthritis (as monotherapy or as combination therapy with methotrexate, DMARD failure not required), moderate to severe active polyarticular juvenile arthritis in those with an inadequate response to at least one DMARD, active ankylosing spondylitis, active psoriatic arthritis, and chronic moderate to severe plaque psoriasis (in candidates for systemic therapy or phototherapy). The recommended dose for etanercept in the United States is 50 mg once weekly in adults with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In psoriasis patients, the dose is 50 mg twice weekly for 3 months followed by 50 mg once weekly. The recommended dose for pediatric patients with rheumatoid arthritis is 0.8 mg/kg per week (maximum 50 mg/week).
39
40
4 Etanercept
Etanercept is available in Europe as single-use 25-mg and 50-mg vials and a 25-mg multiple-dose vial of lyophilized powder for reconstitution. It is also available as a prefilled syringe containing 50-mg etanercept for single use or 25-mg etanercept for single use. In the United States, etanercept is available as 25-mg multipledose vials of lyophilized powder for reconstitution, as well as a 1-ml prefilled syringe containing 50-mg etanercept for single use, and an autoinjector containing 50-mg etanercept for single use.
4.5 Summary Etanercept is a recombinant, fully human, soluble, TNF- [ fusion protein. It modulates the activity of the proinflammatory cytokine TNF- [ by competitively binding to both cell-surface and soluble TNF- [ , preventing the interaction of TNF- [ with endogenous receptors located on the cell surface. Unlike TNF- [ monoclonal antibodies, when this soluble fusion protein binds to cell-bound TNF- [ , it does not induce complement-mediated cell lysis. The pharmacokinetics of etanercept is similar across different adult populations, including women and the elderly, and across several inflammatory disease states. In addition, pharmacokinetic parameters in children receiving a weight-based dose are similar to those in adults. Etanercept has shown clinical efficacy in the treatment of rheumatoid arthritis, active polyarticular-course juvenile chronic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Moreover, etanercept has demonstrated a similarly favorable safety profile across all indications. Acknowledgement. The author would like to thank Rick Davis, MS, RPh, for his significant contribution to the writing of this chapter.
Key References Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907 – 916 Goffe B, Cather JC (2003) Etanercept: An overview. J Am Acad Dermatol 49:S105 – 111 Goldsmith DR, Wagstaff AJ (2005) Etanercept: a review of its
use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 6:121 – 136 Kavanaugh AF (2005) Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol 32:2285 – 2287 Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167 – 2179 Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899 – 1912 Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490 – 497
References Braun J, Bollow M, Neure L, et al. (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499 – 505 Catrina AI, Lampa J, Ernestam S, et al. (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP1 in rheumatoid arthritis. Rheumatology (Oxford) 41:484 – 489 Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907 – 916 Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493 – 2537 Davis JC, Jr (2005) Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 34:668 – 677 Don BR, Spin G, Nestorov I, et al. (2005) The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 57:1407 – 1413 Drynda S, Kuhne C, Kekow J (2002) Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 61:254 – 256 Enbrel® (etanercept) (2005) US Full Prescribing Information. Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals, Thousand Oaks, CA, 2005 European Medicines Agency (2006) Enbrel product information. Available at: http://www.emea.eu.int/humandocs/ Humans/EPAR/enbrel/enbrel.htm. Accessed March, 2006 Goffe B, Cather JC (2003) Etanercept: An overview. J Am Acad Dermatol 49:S105 – 111 Goldsmith DR, Wagstaff AJ (2005) Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 6:121 – 136 Gottlieb AB, Chamian F, Masud S, et al. (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175:2721 – 2729 Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945 – 966 Kavanaugh AF (2005) Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol 32:2285 – 2287
References Keystone EC, Schiff MH, Kremer JM, et al. (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353 – 363 Keyszer G, Lambiri I, Nagel R, et al. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26:251 – 258 Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1 – 23 Krueger GG, Elewski B, Papp K, et al. (2006) Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 54:S112 – 119 Lee H, Kimko HC, Rogge M, et al. (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348 – 365 Maksymowych WP, Poole AR, Hiebert L, et al. (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32:1911 – 1917 Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63:755 – 758 Moreland LW, Bucy RP, Weinblatt ME, et al. (2002) Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 103:13 – 21 Moreland LW, Weinblatt ME, Keystone EC, et al. (2006) Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33:854 – 61 Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13 – 18 Nestorov I, Zitnik R, Ludden T (2004) Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31:463 – 490 Nickoloff BJ, Stevens SR (2006) What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 54:S143 – 151 Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167 – 2179 Ostensen M, Eigenmann GO (2004) Etanercept in breast milk. J Rheumatol 31:1017 – 1018 Partsch G, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518 – 523
Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544 – 1552 Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821 – 831 Saxne T, Palladino MA, Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041 – 1045 Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899 – 1912 Schotte H, Schluter B, Willeke P, et al. (2004) Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:960 – 964 Strober BE (2005) The treatment of psoriasis with etanercept. Semin Cutan Med Surg 24:28 – 36 Tyring S, Gottlieb A, Papp K, et al. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: doubleblind placebo-controlled randomised phase III trial. Lancet 367:29 – 35 van der Linden S, van der Heijde D, Braun J (2005) Ankylosing spondylitis. In: Harris EJ, Budd R, Firestein GS, et al. (eds) Kelly’s textbook of rheumatology. Elsevier Saunders, Philadelphia, pp 1125 – 1141 Yim DS, Zhou H, Buckwalter M, et al. (2005) Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45:246 – 256 Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490 – 497 Zhou H, Mayer PR, Wajdula J, Fatenejad S (2004a) Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44:1235 – 1243 Zhou H, Buckwalter M, Boni J, et al. (2004b) Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:267 – 276
41
Chapter 5
5 Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development S. Jahn, K. Schmitt-Rau
5.1 Introduction Efalizumab is a humanized monoclonal antibody binding to the lymphocyte function-associated antigen (LFA-1). LFA-1 belongs to the family of q 2 integrins and is expressed on the surface of T cells (CD4+ cells, Thelper cells; CD8+ cells, cytotoxic T cells). LFA-1 is essential for every step in the process of immune surveillance and mounting an immune response (Dustin et al. 2004): (1) firm adherence to the wall of blood vessels under blood flow, (2) scanning by T cells of other cells within tissues, and (3) formation of the immunological synapse between T cells and antigen-presenting cells (APCs). LFA-1, Mac-1 and p159,95, members of the q 2 integrin family, are heterodimeric molecules consisting of a q -subunit (CD18), common to all three molecules, which is non-covalently linked to the respective [ chain CD11a (LFA-1), CD11b (Mac-1), and CD11c (p159,95). T cells mainly express LFA-1 (CD11a/CD18). LFA-1 expression is regulated by activation of T cells which may induce a conformation change in the molecule resulting in a switch of the LFA-1 affinity from a low- to a high-affinity state as the T cell moves on from a resting to an activated state. The LFA-1 affinity maturation is influenced by a whole complex of so called “inside-out” signals, like activation of specific G-protein-coupled receptors, cytokine stimulation of motility, and T-cell-receptor-mediated signals following antigen binding by the respective T-cell receptor (TCR). The ligands for LFA-1 are intercellular adhesion molecules (ICAMs). They include ICAM-1, expressed on leucocytes, vascular endothelium cells and epithelial cells, including keratinocytes, ICAM-2 expressed on resting endothelium and lymphocytes and ICAM-3, expressed on monocytes and resting lymphocytes.
ICAM expression can be triggered by pro-inflammatory mediators, such as tumour necrosis factor- [ (TNF- [ ) and interferon- * (IFN- * ). LFA-1 antagonism has the potential to differentially affect functions of distinct T-cell populations as LFA-1 is expressed at higher levels on memory than on na¨ıve T-cell populations. Monoclonal antibodies (mAbs) to LFA-1 or its ligands have been found to inhibit T-cell activation in vitro, to inhibit T-cell-dependent T-cell responses, to inhibit lymphocyte proliferation responses, to reduce lymphocyte trafficking and homing, and to reduce adhesion of T cells to endothelial cells in vitro. Therefore, it may be proposed that the inhibition of LFA-1/ICAM interaction leads to a suppression of several T-cell-dependent immune functions, which are crucial for the pathogenesis of inflammatory autoimmune diseases, namely (auto)-antigen presentation (Fig. 5.1a) and immune cell migration from blood flow to the target tissue (Fig. 5.1b). Results derived from animal models imply that inhibiting LFA1/ICAM interaction by anti-CD11a antibodies may have a clinical benefit in certain T-cell-dependent diseases. CD11a blockade is predicted to produce less global immune suppression compared with CD18 blockade because T cells are relatively dependent on CD11a/CD18 (LFA-1) in contrast to other types of leucocytes. A humanized monoclonal anti-CD11a IgG1 antibody, efalizumab, therefore showed clinical efficacy in psoriasis and other T-cell-mediated autoimmune diseases and is actually registered for the indication plaque psoriasis.
5.2 Development and Characterization of the Antibody a
b
Fig. 5.2. Humanized monoclonal antibody efalizumab. CDR complementarity determining regions, FR framework regions, VH variable part of the heavy chain, VL variable part of the light chain
Fig. 5.1. a Scheme of antigen presentation by an antigen-presenting cell (APC) to T cells. Open circle indicates the participation of LFA-1/ICAM-1 interaction in the formation of the immunological synapse. b Scheme of adhesion molecule interaction between leucocytes and endothelial cells. Asterisk indicates LFA-1/ICAM-1 interaction
5.2 Development and Characterization of the Antibody Efalizumab (rhuMAb CD11a, hu1124) is a full-length, IgG1 kappa isotype antibody composed of two identical kappa light chains consisting of 214 amino acid residues, and two gamma heavy chains consisting of 451 residues. Each light chain is covalently coupled through a disulphide link to a heavy chain. The two heavy chains are covalently coupled to each other via inter-chain disulphide bonds consistent with the structure of human
IgG1. The molecular weight of intact efalizumab is 148,841 daltons. Originally developed as a murine anti-CD11a monoclonal antibody (MHM24; Hildreth and August 1985), efalizumab has been prepared by substituting human DNA sequences using genetic engineering methods to reduce immunogenicity. In detail, complementarity determining regions (CDRs) from the murine antibody MHM24 were grafted into consensus human IgG1 V heavy and light chain sequences. This results in a “humanized” mAb (HuIgG1) in which the CDRs of the murine antibody – important for specific antigen recognition – are preserved. Previous studies on murine MHM24 have shown that, similar to other anti-CD11a antibodies, it is able to inhibit T-cell function. The consensus sequences for the human heavy chain subgroup III (VH-CH1) and the light chain subgroup k 1 were used as the framework for the humanization (Fig. 5.2). Several humanized variants were made and screened for binding as Fabs. To construct the first Fab variant of humanized MHM24, all six CDR residues were transferred from the murine antibody to the human framework. Further variants were constructed by targeted exchange of either framework residues, or residues within CDRs using the first variant (Fab-1), as a tem-
43
44
5 Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development
plate. For that purpose, both light and heavy chains were completely sequenced for each variant. Plasmids containing the sequences were then transformed to Escherichia coli for protein expression. All variants were tested for CD11a binding in the Jurkat cell assay. VL and VH domains of the variant with optimal binding characteristics were then transferred to human IgG1 constant domains, giving the fulllength intact humanized antibody (Werther et al. 1996). Several in vitro assays were performed to compare efalizumab with its parent murine antibody MHM24, including the keratinocyte cell-adhesion assay and the mixed lymphocyte response assay (MLR). The results showed that, in these assays, efalizumab worked as well as MHM24. In addition, the apparent Kd values, as determined by saturation binding using peripheral blood mononuclear cells (PBMCs) of two human donors, were similar for both MHM24 and efalizumab (0.16 ± 0.01 nM and 0.13 ± 0.02 nM vs 0.11 ± 0.08 nM and 0.18 ± 0.03 nM, respectively).
5.3 Efalizumab: From Mode of Action to the Treatment of Psoriasis 5.3.1 Psoriasis: Prevalence, Characteristics and Therapeutic Options Psoriasis is one of the most common dermatological diseases. Although there is a great variation in the prevalence of psoriasis in different countries due to environmental and genetic factors, it can be said that it affects roughly 2 – 3 % of the world’s Caucasian population. About 20 – 25 % of these people suffer from moderate-to-severe forms of the disease. The majority of patients with plaque psoriasis (75 %) show first signs of disease manifestation before the age of 40 years, with a peak in the second decade of life. These patients usually have a family history of psoriasis, their disease is more severe, and it is characterized by frequent relapses. The most common form of psoriasis, with a prevalence of about 70 %, is plaque psoriasis or “psoriasis vulgaris”. Plaque psoriasis is characterized by hyperkeratosis, parakeratosis and the presence of inflammatory lesions in the skin. There is a predilection for symmetrical involvement of the scalp, elbows, knees and lower back. It can occur, however,
anywhere on the body. Other, less frequent, morphologies of psoriasis include guttate, inverse, pustular, and erythrodermic forms. They may occur individually, concomitantly or sequentially. There is agreement today that immunological mechanisms play an important role in the pathogenesis of many chronic relapsing inflammatory skin diseases, such as psoriasis (Krueger 2002; Schoen and Boehncke 2005). Evidence of the pivotal role played by T cells in the pathology of psoriasis is accumulating. ) Activated T cells are found in psoriatic lesions. ) T cells have the ability to induce the altered keratinocyte growth and differentiation pattern typical of psoriasis. This has been demonstrated in a SCID mouse model by injecting autologous immunocytes into the dermis of mice that have received grafts of human skin. Plaques typical of those seen in psoriasis are observed when immunocytes from a patient with psoriasis are injected into a mouse possessing a graft of symptom-free skin from the same patient. ) T-cell-targeted immune suppressive drugs, such as cyclosporine, and antibodies against the CD25 receptor and CD4, have been shown to improve psoriasis. ) In bone marrow transplantation, psoriasis can be transferred from a donor suffering from the disease to a healthy recipient. Also, psoriasis can be “cured” when bone marrow is transplanted from a healthy donor to a person with psoriasis. ) When symptomless skin from psoriasis patients was engrafted onto AGR129 mice, deficient in type I and type II interferon receptors and for the recombination activating gene 2, resident human T cells in the skin grafts underwent local proliferation, demonstrating the importance of resident immune cells in the development of psoriasis. There is a whole battery of treatment options available today. The mild forms of psoriasis are usually treated with topical preparations, including vitamin D3 analogues, corticosteroids and retinoids. When the disease becomes severe, phototherapeutic regimens are applied. Finally, there is the option to use an oral immune suppressive drug, such as methotrexate, cyclosporin, oral retinoids, or fumaric acid esters, as monotherapy or in combination. As the majority of patients develop their disease before the age of 40 years, many of those with moderate-to-severe psoriasis will require
5.3 Efalizumab: From Mode of Action to the Treatment of Psoriasis
Fig. 5.3. Scheme of the immune pathogenesis of psoriasis and the proposed mechanisms of LFA-1 blockade by the CD11a antibody efalizumab. Points of action for efalizumab are indicated
decades of continuous systemic or phototherapy. Unfortunately, none of the available therapies can be used chronically, because of long-term safety and toxicity problems. Recent advances in the understanding of T-cell interactions in the pathogenesis of psoriasis have led to the development of several biological substances, such as the targeted T-cell modulator efalizumab, for continuous immune therapy of this disease, without the safety problems of the traditional systemic preparations (Fig. 5.3). 5.3.2 Pathogenesis of Psoriasis: Targets for Efalizumab 5.3.2.1 T-Cell Activation The first step in the immune pathogenic cascade of psoriasis is the capture and processing of auto-antigen by Langerhans cells or dendritic cells (”antigen-presenting cells” [APCs]) in the epidermis or dermis, respectively. The nature of the antigen is still unknown. There is, however, some evidence that in genetically predispo-
sed subjects, keratinocyte-derived peptides may be involved. The APC–antigen complex migrates to a skin-draining lymph node, where the antigen is presented via major histocompatibility complex II (MHC II) on the surface of the APC to the T-cell receptor (TCR) of the specific na¨ıve CD4+ cell, or via MHCI to the TCR of CD8+ T cells respectively. Interaction of the APC-MHCII/antigen–TCR complex is, however, not sufficient for T-cell activation. The initial binding of T cells and APCs, as well as stabilization of the cell pair, is mediated by LFA-1 on T cell and ICAM-1 on the APC. This stabilized structure has been referred to as the “immunological synapse” (Fig. 5.1a), formation of which is followed by delivery of the antigen-specific signal (signal 1) and a costimulatory signal (signal 2), which are also mediated by LFA-1 and ICAM-1. Delivery of signal 1 and signal 2 is followed by binding of cytokines that induce T cells to proliferate (i.e. undergo clonal expansion) and differentiate. Proliferation is thought to be largely mediated by the cytokine interleukin-2 (IL-2).
45
46
5 Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development
5.3.2.2 T-Cell Migration and Extravasation Following activation, T cells leave the lymph node and start trafficking via the bloodstream to the dermal vessels (Fig. 5.1b). Stimulation by keratinocyte-derived cytokines (IL-8, CCL27) leads to increased expression of adhesion molecules, including E-selectin and ICAM1, in the post-capillary venules of inflamed skin. Eselectin is the target for cutaneous lymphocyte antigen (CLA) on the T-cell surface. Binding of CLA to E-selectin, as well as the interaction of the lymphocyte chemokine receptor (CCR10) with its ligand CCL27, slows circulating lymphocytes and causes their “rolling” along the endothelial wall. As a result of increased exposure to chemokines, the affinity of LFA-1 for ICAM-1 is increased, probably mediated by a conformational change in the LFA-1 molecule. Bound T cells flatten and pass through the epithelium into the surrounding tissue – a process known as diapedesis. Once they have left the venule, T cells respond to chemokines; drawing them towards the site of inflammation in the dermis, and from there into the epidermis. 5.3.2.3 T-Cell Reactivation Following transmigration from the circulation into dermal and epidermal tissue, memory T cells are brought into contact with antigen-presenting dendritic and Langerhans cells, as well as with keratinocytes, which, probably due to genetic alterations, are also able to act as APCs. This interaction leads to the re-activation of T cells and is followed by increased production and secretion of cytokines, including IL-2, IFN- * and TNF- [ , which show the TH-1 cytokine pattern typically observed in psoriasis. ) IFN- * leads to induction of ICAM-1 in keratinocytes and endothelium, and consequently supports binding of lymphocytes to keratinocytes. ) TNF- [ induces keratinocyte proliferation and stimulates keratinocyte-induced interleukin-8 (IL-8) production. This leads to chemotaxis of lymphocytes and neutrophils into the epidermis. TNF- [ is also able to induce activation and proliferation of endothelial cells. However, the exact mechanism by which (re-)activated T cells cause psoriatic lesions is not known. Direct lym-
phocyte/keratinocyte interactions could be involved, or cytokines produced during T-cell re-activation may be responsible for the most prominent alteration in psoriatic skin: hyperproliferation. In summary, a combination of different mechanisms may be responsible for the changes observed histologically and clinically in psoriatic skin. These include: ) Increased proliferation of keratinocytes (hyperkeratosis) ) Neutrophil and mast-cell migration into epidermis and dermis, respectively ) Increased production of defensins by activated keratinocytes ) Increased angiogenesis 5.3.3 Efalizumab: Mechanism of Action As already described, efalizumab is a humanized monoclonal antibody against CD11a, the [ -subunit of LFA-1. Binding of efalizumab to CD11a leads to blockade of the interaction between LFA-1 and ICAM-1. The blockade of this interaction has several consequences (Jullien et al. 2004) (Fig. 5.1), including activation of T lymphocytes in lymph nodes ) Inhibition of extravasation of circulating lymphocytes in inflammatory skin ) Blockade of T-lymphocyte re-activation in skin by APCs ) Reduction of the keratinocyte interaction with activated T lymphocytes Therapeutic administration of efalizumab induces an increase of both na¨ıve and memory populations of CD4+ and CD8+ lymphocytes in peripheral blood. The largest increase was detected for memory CD8+ cells. This CD8+ memory T-cell subpopulation represents the most prominent T-cell subset found in psoriatic skin lesions. Furthermore, an increase in Type I (IFN * producing) T cells during treatment was described. Results of histological analysis of lesional tissue indicated a significant decrease of memory T-cell counts in the epidermis and dermis, correlating with a decrease in mean epidermal thickness in the majority of efalizumab-treated patients. It can be concluded therefore that highly pathogenesis-relevant T-cell subsets are blocked from cutaneous entry by efalizumab. By interacting with the CD11a subunit of LFA-1, efalizumab
5.4 Pharmacology and Toxicology of Efalizumab
inhibits the formation of the immunological synapse of T cells, once in the skin, with APCs and therefore their antigen-specific activation. By inhibiting these processes, efalizumab may be able to prevent abnormal cytokine production, keratinocyte hyperproliferation and abnormal keratinocyte differentiation, which are characteristic of the psoriatic phenotype.
5.4 Pharmacology and Toxicology of Efalizumab 5.4.1 Preclinical Studies A number of preclinical studies have been conducted with efalizumab to evaluate its pharmacodynamic and pharmacokinetic properties, as well as its toxicity. In vitro studies performed with efalizumab have shown that it is able to bind to human and chimpanzee leucocytes, inhibit lymphocyte binding to ICAM-1 on keratinocytes and inhibit T-cell proliferation. In murine and chimpanzee in vivo models, efalizumab was able to down-regulate LFA-1 expression on lymphocytes, while efalizumab has been shown to have two-compartment kinetics with non-linear elimination in monkeys. Anti-mouse CD11a antibodies have been used to study developmental toxicity in mice. In these studies, doses were administered at up to 30 times the equivalent recommended clinical dose of 1 mg/kg. No adverse effects were observed on mating, fertility or reproductive parameters. There was also no evidence of maternal toxicity, embryotoxicity or teratogenicity. Similarly to other immunoglobulins, anti-mouse CD11a antibody is secreted in the milk of lactating mice that are exposed to the antibody during gestation and lactation. Furthermore, a significant reduction was observed in the ability of their offspring to generate an antibody response at 11 weeks of age, which was – at least partially – reversible at week 25. There were, however, no adverse effects on behaviour, growth and reproductive function of the offspring. Immunization of chimpanzees exposed to high doses of efalizumab (> 10 times the clinical dose) with tetanus toxoid produced an impaired antibody response compared with control animals. However, there have been no animal reproduction studies and long-term carcinogenicity studies conducted with efalizumab.
5.4.2 Pharmacodynamics The pharmacodynamic properties of efalizumab were investigated in several Phase I and Phase II studies following intravenous and subcutaneous administration, either as a single dose or repeated weekly administration. In the single-dose intravenous study, doses of 0.03 – 10 mg/kg were given. Within 24 h, treatment with efalizumab reduced the level of CD11a expression on T cells to 25 % of pretreatment levels. This suppression persisted as long as efalizumab was present in the circulation. In the above mentioned study (i.v., single dose), CD11a expression returned to baseline within 7 – 10 days following clearance of efalizumab, without showing any signs of lymphocyte depletion. Total white blood cell (WBC) count was slightly increased within about 8 h of efalizumab administration; circulating lymphocyte counts were increased by day 7. Following multiple weekly dosing, lymphocytes remained elevated but returned to baseline after efalizumab clearance. This elevation of lymphocyte count is probably due to demargination – blocked entry of efalizumab-bound cells to tissues. To achieve the full pharmacodynamic effect, intravenous doses of above 0.3 mg/kg were necessary. Complete saturation and maintenance of CD11a binding site down-regulation on lymphocytes required weekly intravenous doses of 0.6 mg/kg, which corresponds to an efalizumab plasma concentration of 5 μg/ml. Several histological changes were observed in psoriatic plaques following efalizumab administration. A marked reduction of keratin-16, corresponding to decreased disease activity, was noted. Keratinocyte ICAM-1 levels were also reduced, indicating reduced cytokine-mediated inflammation. Furthermore, a significant thinning of the epidermis and restoration of normal skin was observed after 28 days of treatment, in concordance with reductions of over 50 % in cutaneous T-cell infiltration and reduced CD11a availability. These data demonstrate that by reducing CD11a on the surface of circulating and cutaneous T cells, efalizumab is able to reverse both the histological signs of inflammation and the pathological hyperplasia characteristic of plaque psoriasis. In general, the effects of subcutaneous efalizumab on lymphocytes were comparable to those observed after intravenous dosing. Subcutaneous doses of
47
48
5 Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development
1 mg/kg/week or above produced the required efalizumab plasma concentrations of 5 μg/ml for binding site down-regulation and saturation. No additional clinical benefits of higher doses (e.g. doses of 2 mg/kg/week and 4 mg/kg/week) were observed. In addition to reduced CD11a expression on the surface of CD3+ T cells, binding of efalizumab also causes a reduced expression of other adhesion molecules, such as CD11b, L-selectin or q 7 integrin. The down-modulation of these adhesion molecules likely contributes to the anti-adhesive effects of efalizumab. There is also a decrease of [ q + T-cell receptors and of TCR-associated co-receptors, such as CD4, CD8 or CD2. Inhibition of TCR-mediated activation therefore seems to also play a role in efalizumab’s mode of action. 5.4.3 Pharmacokinetics The pharmacokinetic properties of subcutaneous efalizumab were determined in an open, multicentre, Phase I study of 70 patients suffering from moderate-tosevere plaque psoriasis. Patients received weekly doses of either 1 mg/kg (n = 33) or 2 mg/kg (n = 37) efalizumab for 12 weeks subcutaneously. 5.4.3.1 Absorption After subcutaneous administration of efalizumab, peak plasma concentrations are reached after 2 – 3 days. The average estimated bioavailability was about 50 % at the recommended dose level of subcutaneous efalizumab, 1.0 mg/kg/week. 5.4.3.2 Distribution Steady-state serum concentrations of efalizumab were achieved after four doses of weekly efalizumab, 1 mg/ kg, and after 8 weeks in patients receiving 2 mg/kg. At this dose level (with an initial dose of 0.7 mg/kg in the first week), the mean efalizumab plasma trough values were 9.1 ± 6.7 μg/ml in the 1 mg/kg group and 23.5 ± 12.2 μg/ml in the 2 mg/kg group. Volumes of distribution of the central compartment after single intravenous doses were 110 ml/kg at dose 0.03 mg/kg and 58 ml/kg at dose 10 mg/kg.
5.4.3.3 Biotransformation The metabolism of efalizumab is through internalization followed by intracellular degradation as a consequence of either binding to cell surface CD11a or through endocytosis. The expected degradation products are small peptides and individual amino acids which are eliminated by glomerular filtration. Cytochrome P450 enzymes, as well as conjugation reactions, are not involved in the metabolism of efalizumab. 5.4.3.4 Elimination Efalizumab is cleared by dose-dependent non-linear saturable elimination. Mean steady-state clearance is 24.3 ± 18.5 and 15.7 ± 12.6 ml/kg/day for the 1 mg/kg/ week and 2 mg/kg/week groups, respectively. The elimination half-life was about 6.21 ± 3.11 days for the 1 mg/ kg/week group and 7.4 ± 2.5 days in the 2 mg/kg/week group. Tend at steady state is 25.5 ± 1.6 days at 1 mg/kg/ week and 44 ± 10 days at 2 mg/kg/week. Efalizumab shows dose-dependent non-linear pharmacokinetics, which can be explained by its saturable specific binding to cell surface receptors CD11a. Clearance was more rapid at lower doses, suggesting a receptor-mediated mechanism at drug levels below 10 μg/ml. In a population pharmacokinetic analysis of 1,088 patients, body weight was found to be the most significant covariate affecting efalizumab clearance. Other covariates such as baseline Psoriasis Area and Severity Index (PASI), baseline lymphocyte count and age had modest effects on clearance; gender and ethnic origin had no effect. Additional pharmacokinetic data are available from an open-label extended treatment trial in which patients who responded to an initial treatment of efalizumab, 2 mg/kg, for 12 weeks, received the drug in a maintenance phase for up to 33 months at a dose of 1 mg/kg. Pharmacokinetic analysis of each 12-week treatment period for up to 15 months showed that steady-state trough levels remained constant during continuous efalizumab dosing. There was no evidence of efalizumab accumulation or alteration of the pharmacokinetic profile of efalizumab during long-term continuous dosing.
References
5.5 Indication(s) The European Medicines Agency (EMEA) approved efalizumab (Raptiva) for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to, other systemic therapies including cyclosporine, methotrexate and PUVA. The Food and Drug Administration (FDA) approved efalizumab for the treatment of adult patients ( & 18 years old) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Efalizumab was tested in a phase II study to treat psoriasis arthritis. However, there was no significant clinical improvement detected in treated patients in comparison with the placebo group. Case reports were published about the use of efalizumab in patients with dermatomyositis, palmo-plantar pustulosis or atopic dermatitis.
5.6 Summary Efalizumab is a humanized monoclonal antibody binding to lymphocyte function-associated antigen (LFA-1). LFA-1 belongs to the family of the q 2 integrins and is expressed on the surface of T cells (CD4+ cells, T-helper cells). It is involved in several T-cell activities, such as T-cell activation and migration, as well as T-cell adhe-
sion during cellular interactions that are important for induction and maintenance of immune-mediated inflammatory processes. Efalizumab (Raptiva) is indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to, other systemic therapies including cyclosporine, methotrexate and PUVA.
References Dustin ML, Bivona TG, Philips MR (2004) Membranes as messengers in T cell adhesion signaling. Nature Immunol 5: 363 – 372 Hildreth JEK, August JT (1985) The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): functional effects of subunit-specific monoclonal antibodies. J Immunol 134:3272 – 3280 Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, Dedrick R, Natta P (2004) T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 208:297 – 306 Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1 – 23 Schön MP, Boehncke W-H (2005) Medical progress: psoriasis. N Engl J Med 352:1899 – 1912 Werther WA, Gonzalez TN, O’Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Prestal LC (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986 – 4995
49
Chapter 6
6 Monoclonal Antibody Targeted Radiation Cancer Therapy L.M.M. Keller, C.A. Boswell, D.E. Milenic, E.D. Brady, M.W. Brechbiel
6.1 Overview Rituximab (Rituxan), a monoclonal antibody (mAb) against CD-20, and trastuzumab (Herceptin), a mAb against HER2, have shown efficacy in clinical trials and have gained approval for therapeutic use from the Food and Drug Administration (FDA). Mylotarg, an antiCD33 mAb conjugated with the exceedingly cytotoxic antibiotic calicheamicin, has also proven effective for treating patients with acute myeloid leukemia (AML) and it has also received FDA approval. A major area of development in mAb therapeutics involves the use of radionuclides to augment the inherent mAb activity and to exploit specific targeting properties. Zevalin, an antiCD20 mAb armed with 90Y, and Bexxar, an anti-CD20 mAb armed with 131I, are two radionuclide-bearing mAbs that have recently been approved by the FDA. This chapter presents the background and strategies pertaining to radiolabeled monoclonal antibody therapy.
6.2 Introduction and Background The advent of the hybridoma, described by Kohler and Milstein, resurrected the concept put forth by Ehrlich a century ago: antibodies might serve as “magic bullets” (Ehrlich et al. 1904). Their seminal publication described the fusion of a plasmacytoma with spleen cells and the subsequent isolation of hybrids that secreted monoclonal antibodies of a pre-defined specificity. Such work was a clear step towards the development of targeted antibody therapy (Kohler and Milstein 1975). In the 1980s much interest was focused on the generation of murine mAbs against tumor-associated antigens (TAAs). Multitudes of pre-clinical studies followed,
which provided proof-of-concept for the potential application of mAbs in chemotherapeutics. However, inherent limitations of these models also demonstrated discordance in predictability of therapeutic efficacy. Preclinical and clinical investigations with murine mAbs illustrated several constraints that required attention before any degree of success could be achieved in cancer therapy. Foremost of these was the seemingly inevitable production of human anti-murine immunoglobulin antibodies (HAMAs) after one to three treatments (Schlom 1990). Other factors limiting treatment included: (1) insufficient tumor penetration with resulting inadequate therapeutic dose delivered to tumor lesions; (2) insufficient activation of effector function(s); (3) slow blood compartment clearance; (4) low mAb affinity and avidity; and (5) trafficking to or targeting of normal organs (Schlom 1990). Some of these limitations were addressed by chemical modification of the mAb, but most of these challenges have been addressed with genetic engineering techniques (Milenic 2000). This effort has primarily been applied to eliminating HAMAs by the production of chimeric mAbs, complementaritydetermining region (CDR) grafting, or complete humanization of the protein (Milenic 2000). Current advances have reached the stage where investigators are finally able to fully explore the real therapeutic potential of radiolabeled mAbs (Fig. 6.1). With the elimination of many obstacles and a better understanding of the inherent limitations of mAbs, coupled with interest and support from industry, several radiolabeled mAbs have been and are currently being evaluated in Phase III clinical trials (Table 6.1). With the groundbreaking FDA approval of two radiolabeled mAbs, Zevalin and Bexxar, for the treatment of nonHodgkin’s lymphoma (NHL), additional targeted radiation therapy products seem very probable (Srivastava and Dadachova 2001).
6.3 The Radioisotope
Fig. 6.1. Monoclonal antibodies are linked to radionuclides through methods based on the chemical characteristics of that element. Halogens, such as 131I, are routinely introduced by direct halogenation of tyrosine residues of the protein. Metallic radionuclides, such as 111In or 90Y, require chelation of the metal through a suitable ligand. This chelating agent frequently targets N-terminal and 5 -amines of lysine residues. Linking moieties include isothiocyanates, bromoacetamides, maleimides (post-thiolation of the protein), and active esters. Variations of these moieties are also employed for the indirect introduction of radio-halogens (Milenic et al. 2004) Table 6.1. Selection of monoclonal antibodies in advanced radioimmunotherapy clinical trials (Milenic et al. 2004)
CLL chronic lymphocytic leukemia, NHL non-Hodgkin’s lymphoma, PEM polymorphic epithelial mucin, CEA carcinogenic embryonic antigen, HLA human leukocyte antigen, mu murine, hu humanized
Antibody
Antibody form
Radio- Antigen Disease nuclide
Clinical trial
Bexxar
mu IgG2a
131I
CD20
NHL
Lymphocide hu IgG1 (LL2) CEA-cide hu IgG1
90
CD22
NHL
FDA approved Phase III
90Y
CEA
Cotara
hu IgG
90Y
DNA
Oncolym
hu IgG1
131I
Theragyn Zevalin
mu IgG1 mu IgG1
90
HLADR10 PEM CD20
Colorectal, breast, lung, pancreatic, stomach carcinoma Glioblastoma multiforme, anaplastic astrocytoma NHL, CLL
Y
Y
90Y
6.3 The Radioisotope The size and presentation of the disease are both critical considerations when evaluating the most appropriate radionuclide for potential treatment. As disease does not present in an exclusive form, fractionation of
Ovarian, gastric carcinoma NHL
Phase III Phase II/III Phase II/III Phase II/III FDA approved
both chemotherapeutics and external beam radiation are routine regimens. It logically follows that no single radionuclide is likely to address every therapeutic need. Unfortunately, isotope selection is also often driven by economic rather than biomedical considerations, which could negatively impact both pre-clinical and clinical trials. Ultimately, the limitations of the tar-
51
52
6 Monoclonal Antibody Targeted Radiation Cancer Therapy Radionuclide 90
Y
131I 177Lu 153Sm 186
Re Re 67Cu 225Ac 213 Bi 212Bi 211At 212Pb 125 I 123I 67 Ga 195m Pt 188
Type
Half-life
Emax (MeV)
q
2.7 days 8.0 days 6.7 days 2.0 days 3.8 days 17.0 h 2.6 days 10 days 45.7 min 1.0 h 7.2 h 10.6 h 60.1 days 13.2 h 3.3 days 4.0 days
2.3 0.81 0.50 0.80 1.1 2.1 0.57 5.83 5.87 6.09 5.87 0.57 0.35 0.16 0.18 0.13
q, * q, * q, * q, * q, * q, * [, q [ [ [ q Auger Auger Auger, q , * Auger
Mean range (mm) 2.76 0.40 0.28 0.53 0.92 2.43 0.6 0.04 – 0.1 0.04 – 0.1 0.04 – 0.1 0.04 – 0.1 0.6 0.001 – 0.02 0.001 – 0.02 0.001 – 0.02 0.001 – 0.02
Imageable
Table 6.2. Therapeutic radionuclides (Milenic et al. 2004)
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No
Fig. 6.2. A periodic table highlighting elements of interest for nuclear medicine and radiation oncology applications color coded by emission type. With the exception of the halogens, the majority of the medically relevant radionuclides require chelating chemistry for attachment to proteins or other targeting vehicles. Specific radionuclides from cyclotrons or reactors may be obtained in pure form for longer-lived isotopes, or as the products of generator elutions for short-lived isotopes (Milenic et al. 2004)
geting vehicles and radionuclides will be more clearly defined and a rational plan for future clinical trials will follow. Some of the critical considerations for successful targeted radiation are those variables pertaining to the radiation including emission type, energy and range of emission, and the radionuclide half-life. A sampling of available isotopes (Table 6.2) results in several options comprising (Fig. 6.2) three types of emission: [ - or q -particles, or Auger electrons (Srivastava and Dadachova 2001). Historically, q -emitters have received the greatest attention. The emission path lengths of q -emitters are relatively long, yet sparse, with an average range of 275 nm and
a maximum range of 500 – 600 nm (for 90Y). q -emitters have a relatively low linear energy transfer (LET) and thus energy deposition takes place some distance from the actual decay event (Humm 1986). Therapeutic benefit results from “crossfire” where the targeted cell is not necessarily the effective target of the decay event as there is a substantial amount of irradiation of neighboring receptor-negative tumor cells as well as potentially normal cells. As such, some of the limitations of q -emitters are clearly illustrated: q -emitters cannot adequately address the treatment of small tumor burdens including single cell metastatic disease (Humm 1986). However, one great advantage of q -emitters includes the ability to bypass tumor antigen heteroge-
6.3 The Radioisotope
neity through the differential penetration of the labeled mAb. The ability to uniformly target an entire lesion becomes possible when the particle emission range exceeds the radius of the targeted lesion (O’Donoghue et al. 1995). Convenience, availability, and familiarity with radiolabeling chemistry have traditionally supported the use of the iodine isotopes such as 131I. Other clinically relevant q -emitters include 90Y, 67Cu, 186Re, and more recently 177Lu, with others having either been investigated or proposed (vide infra). Discussion of these will be limited here except to state that emission energy and half-life requirements can be met with a small cross-section of isotopes that are already available (Humm 1986). Direct radio-iodination of tyrosine moieties of the mAb has dominated this field. However, the convenience of this method is overshadowed by the rapid deiodination of the protein post-cellular internalization – a characteristic bypassed when radio-metals are used (Mattes et al. 1997; Zhang et al. 2001). 90Y has a pure q -emission which delivers ~4.5 times more radiation per mCi to a tumor than does 131I. The greater emission range (typically 1 – 10 mm) of 90Y means that the majority of the decay energy is deposited in tumors with a diameter of at least 1 cm. Unlike 131I, 90Y lacks an imageable * emission, thereby requiring dosimetry with 111In for * -scintigraphy and single photon emission computed tomography (SPECT). However, 90Y and 111 In have different chemistries and as such this approach may not prove sufficiently accurate. Furthermore, the longer emission range associated with 90Y may result in a significant degree of irradiation of normal surrounding tissue. Notably myelosuppression, with a nadir at approximately 2 weeks post-radioimmunotherapy (RIT), due to longer range q -emissions that occur during circulation, is a consistent dose limiting toxicity (Knox and Meredith 2000). 177Lu and 67Cu, lower-energy q -emitters with much shorter ranges, may offer distinct advantages for treating smaller lesions and micrometastases. 177Lu and 67Cu have both been evaluated in clinical trials for therapeutic efficacy (Mulligan et al. 1995; Alvarez et al. 1997; O’Donnell et al. 1999). Both possess imageable * -emissions permitting determination of disease extent, calculation and prediction of dosimetry, and monitoring of therapeutic efficacy. It should be noted that this same * -emission contributes to normal tissue toxicity, illustrating the desires and compromises that must be balanced in radionuclide selection. Scientists are also
beginning to consider the fact that different q -particle combinations may work synergistically. Notably, a successful 177Lu/90Y combination radionuclide therapy has been reported (de Jong et al. 2005). Despite these concerns and limitations, use of q -emitters continues to dominate pre-clinical and clinical trials. Therefore, it is of no surprise that Zevalin and Bexxar, the first radiolabeled monoclonal antibodies to receive FDA approval, are both armed with q -emitters. The list of [ -emitting radionuclides qualified for targeted radiation therapy is short owing largely to half-life constraints. Presently 212Bi, 213Bi, and 211At are actively being studied (McDevitt et al. 1998; Hassfjell and Brechbiel 2001). Additionally, 225Ac (Table 6.2) has shown promise despite concerns about the lengthy half-life and trafficking of free decay products in vivo (McDevitt et al. 2001). The bismuth radioisotopes, 212Bi and 213Bi, are available from generators based on 224Ra and 225Ac, respectively, and decay via branched pathways that results in both [ - and q -emissions. Thirtytwo percent of 212Bi decay includes a high energy * emission which 213Bi lacks. As such 213Bi is generally considered a more attractive candidate for RIT (Geerlings 1993). Protocols analogous to radio-iodination chemistry were initially applied for 211At. However, this has been supplanted with linking reagents that address the inherent instability of direct tyrosine protein labeling with this isotope (Vaidyanathan and Zalutsky 1996). As a group, the [ -emitters have high-energy particles (4 – 9 MeV), which travel relatively short distances (40 – 100 μm). They are characterized by dense emission path lengths of high LET which is approximately 400 times greater than that of q -emitters (80 vs 0.2 keV/μm), with energy deposition taking place immediately at the decay site (Fig. 6.2) (Humm 1986). Alpha-particle radiation is exquisitely cytotoxic at a dose rate of 1 cGy/h (Kurtzman et al. 1988). The short emission range limits their use to a complementary scale of disease. Most, if not all, of the therapy results from the direct emission of the [ -particle, which makes the targeted cell and immediate neighboring cells the effective targets. In contrast to q -emitters, a very low number of nuclear traversals (approximately 1 – 3) are all that is required to kill a cell with an [ -emitter, as seen in Fig. 6.3 (Humm 1986). The inherent physical limitation of [ -emitters is their relatively short physical half-life. This, coupled with a short emission path length, has generally been thought to limit their use to
53
54
6 Monoclonal Antibody Targeted Radiation Cancer Therapy
Fig. 6.3. A comparison of the path lengths and density of emission tracks of [ - vs q –-particle emissions is depicted. The q –-particle emissions occur in a spectrum of path lengths. The sparse energy track from these emissions is deposited over many cell diameters some distance from the decay event. The [ -particle emissions occur at a discrete energy and path length resulting in high linear energy transfer. The dense energy track from these emissions is deposited directly from the decay event over only a few cell diameters, 50 – 80 μm in tissues (Milenic et al. 2004)
leukemias, highly vascularized tumors, and micrometastatic disease in which optimal access, targeting time, and appropriate disease size converge. Avenues for future work include bone marrow purging for transplant conditioning and selective vasculature tumor targeting with the ultimate goal of total tumor eradication (Bethge et al. 2003; Thorpe and Derbyshire 1997). Adjuvant therapies and combination with q -emitters may ultimately prove viable (Hassfjell and Brechbiel 2001; Hartmann et al. 1994). Auger emitters such as 67Ga, 195mPt, 123I, and 125I (Table 6.2) have received the least attention due to the accepted premise that their extreme cytoxicity is limited by the prerequisite for the emissions to occur within the cell nucleus (Kassis et al. 1999). Auger electrons are extremely low-energy atomic orbital electrons that are emitted as an alternative to X-ray emission following electron capture, a form of q – decay (Kassis et al. 1987; Kassis 2004). Auger-electron therapy is a useful strategy for specific tumor cell killing originating from subcellular (nm) ranges and highly localized energy deposition (106 – 109 cGy) in an extremely small volume (several nm3) around the decay site (Goddu et al. 1994). Auger electron emitters produce an array of reactive radicals (e.g., OH, H, e–aq,) similar to [ -emitters. The estimated absorbed dose rate at the center of a cell delivered by 99mTc, 123I, 111In, 67Ga, and 201Tl is respectively 94, 21, 18, 74, and 76 times higher if the radioactivity is localized within the nucleus versus being on the cell membrane (Faraggi et al. 1994). In a revealing study, the therapeutic effects of an internalizing monoclonal antibody labeled with 125I, 131I, 111In, or 90Y were directly compared (Behr et al. 2000). Both Auger emitters (125I and 111In) showed
better therapeutic results than the q –-emitters. In addition, a trend towards better therapeutic results with the radiometals compared to radioiodine was demonstrated. The latter finding rationalized by the fact that radiometals attached to antibodies are residualized intracellularly while radioiodinated antibodies undergo lysosomal degradation to mono- or di-iodotyrosine that is rapidly released from cells. Despite the apparent limitation posed by a nuclear localization requirement, future studies may demonstrate that Auger emitters have a significant role in chemotherapeutics (Makrigiorgos et al. 1990; Michel et al. 2003).
6.4 Linking the Radionuclide to Protein Research has sought to balance the conditions required to achieve a radiolabeled product with adequate stability of the resulting complex. However, such scales must be balanced within the constraints imposed by isotope chemistry and half-life. As such, the options of realistic isotopes and chelating agents have become narrowed and focused as this field has matured. However, refinement of bifunctional chelating agents (BCAs) remains an active area of endeavor (Packard et al. 1999). All metallic radionuclides require chelation chemistry for attachment to a mAb (Fig. 6.4). BCAs are chelates possessing specific functional groups that permit the conjugation of proteins to stable metallic radionuclide complexes. Since suitable radio-metals are diverse in their properties and coordination chemistry, no single BCA is
6.4 Linking the Radionuclide to Protein Fig. 6.4. A general view of the conjugation of a bifunctional chelating agent to a monoclonal antibody. Specifically, a bifunctional chelating agent possesses two functionalities. One portion binds (crab = chelos = chelate) metallic radionuclides while the other portion bearing a reactive functional group reacts and covalently binds to N-terminal and 5 -amines from lysine on the protein. Generally, the metallic radionuclide is added last in this sequence prior to purification of the final product; however, a pre-formed radio-metal complex can also be conjugated to protein (Milenic et al. 2004)
suitable for all (Packard et al. 1999). A selection of examples is provided in Fig. 6.5. The laudable goal of “instant” radionuclide complex formation with infinite stability has proven non-trivial. Numerous chemical criteria must be considered in the choice of chelating agent including its design and actual use. Characteristics of the metal, such as coordination number, ionic radius, binding character (hard vs soft), and reactivity (hydrolysis vs complexation) must also be considered with respect to chelate design (Packard et al. 1999). A BCA may form and maintain an adequately stable metal complex, but the formation kinetics may render a BCA impractical for an intended radionuclide. For example, DOTA (1, 4, 7, 10-tetra-azacylcododecane-N, N’, N’’, N’’’-tetraacetic acid) forms highly stable and kinetically inert complexes with 212Bi and 213Bi (Michel et al. 2003). However, Bi(III) complexation kinetics with DOTA require 15 – 45 min for reaction completion. The half-lives of the radionuclides are 60 or 46 min, respectively, making this particular combination wasteful and highly impractical (Ruegg et al. 1990). Higher temperatures traverse this in part, but are limited by denaturation of the protein vehicle. In contrast to macrocyclic BCAs, acyclic BCAs tend to possess far faster complex formation rates (Fig. 6.5). However, these are not quite as stable, representing another forced compromise. The acyclic CHX-A’’, a cyclohexylDTPA (diethylenetriamine pentaacetic acid) (Fig. 6.5), has been shown to be a viable alternative to DOTA for labeling of mAbs with Bi(III) isotopes (Brechbiel and Gansow 1992; Milenic et al. 2001). This BCA complexes bismuth “instantaneously” (t1/2 = 0.27 s) and is sufficiently stable for clinical trials (Jurcic et al. 2002). In addition, it was reported to have similar stability with the q -emitter 177Lu versus DOTA and PA-DOTA, the lat-
ter of which has been employed in clinical trials in combination with 177Lu (Mulligan et al. 1995; Alvarez et al. 1997; Schott et al. 1994). In summary, this ligand not only provides considerable versatility for radiolabeling mAbs with the [ -emitters 213Bi and 212Bi, but also with q -emitters, such as 90Y and 177Lu, permitting a wide range of clinical applications (Milenic et al. 2001; Roselli et al. 1999; Milenic et al. 2002). Although 67Cu copper isotopes have been investigated, the choice of BCA remains an open and unresolved topic (Novak-Hofer and Schubiger 2002). Several different macrocyclic chelating agents have been reported as stable and inert with 67Cu, despite reports of its transchelation to superoxide dismutase and detection in patients’ ceruloplasmin and liver (DeNardo et al. 1998; Bass et al. 2000; Rogers et al. 1996). 67Cu remains an interesting candidate for therapy with regards to emission energy, half-life, and imageable emissions (Novak-Hofer and Schubiger 2002). Production and availability may limit 67Cu and as such 64Cu may eventually be deemed more viable (Wu et al. 2000). The chemistry for linking 211At to proteins has been dominated by aryl active ester reagents that have advanced to clinical trials (Vaidyanathan and Zalutsky 1996; Zalutsky et al. 2002). Issues of inadequate in vivo stability for general application in clinical settings are as yet unresolved. Such concerns may be addressed with a better understanding of the chemistry of 211At itself.
55
56
6 Monoclonal Antibody Targeted Radiation Cancer Therapy
Fig. 6.5. Selected examples of acyclic and macrocyclic bifunctional chelating agents that have been or are in use in antibody targeted radiation therapy clinical trials (Milenic et al. 2004)
6.5 The Protein Vehicle Despite the fact that the protein vehicle is present in low concentrations in most targeted radiation therapies, its contribution to therapeutic efficacy must not be overlooked or discounted. Direct tumor cell killing via the protein vehicle may be achieved by two separate pathways: antibody-dependent cell cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). ADCC is triggered when the Fc * receptor on effector cells engages the Fc region of an engaged antibody and tumor cell death proceeds through an effector cell-dependent mechanism. CDC is induced when complement component C1q binds to the Fc region of an engaged antibody with resultant activation of the complement cascade and tumor cell death via an effector cell-independent mechanism. Cellular receptors are integral in all aspects of cellular function including proliferation, migration, and communications. Binding of cellular membrane receptors with a mAb can induce either cell growth or death (Clynes et al. 2000; Johnson and Glennie 2003). Preclinical experiments have demonstrated a reduced therapeutic effect against breast cancer and lymphoma, by rituximab and trastuzumab, respectively, when the Fc portion of the antibody is absent (Trauth et al. 1989; Baselga and Mendelsohn 1984). The chimeric antiCD20 mAb, rituximab, approved for therapy of NHL appears to invoke a series of signaling events including
increased phosphorylation, phospholipase C * activation, c-myc up-regulation and induction of apoptosis in B lymphocytes (Cragg et al. 1999; Deans et al. 1993; Maloney et al. 1998). Trastuzumab (Herceptin), which binds HER2 and has efficacy against adenocarcinomas which overexpress HER2 as determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), has been postulated to have a direct antiproliferative signaling effect by blocking receptorligand interactions and by causing down-regulation of the HER2 receptor (Sarup et al. 1991; Uchiyama et al. 1981). In addition, anti-Tac (daclizumab), which recognizes the 55-kDa [ -chain of the interleukin (IL)-2 receptor (also known as CD25), achieves therapy through interference of cellular signaling by blocking IL-2 binding and thereby inhibiting lymphoid lineage tumor cell proliferation (Goldenberg 1999). A mAb that modifies cell signaling may result in synergistic effects when used in conjunction with chemo- or conventional radiotherapy. Studies in animal models have served to confirm this, as anti-HER2 mAbs in combination with external beam radiation have resulted in therapeutic efficacy in model systems where radiation or mAb alone had minimal effect on tumor xenografts (Pietras et al. 1999). Also notable is that trastuzumab combined with paclitaxel or doxorubicin enhanced both rates of response and duration of response in patients with metastatic breast cancer (Hortobagyi and Perez 2001).
References
6.6 Conclusions An overview of radiolabeled mAb directed approaches with an emphasis on the components (protein, radionuclide, chemistry) has been presented. After greater than two decades, mAb targeted therapies are generally recognized as making a significant impact in chemotherapeutics. The FDA approvals of Zevalin and Bexxar have fueled renewed enthusiasm for developing mAb directed therapies. As such, their full potential is only beginning to be appreciated and understood. However, despite the wealth of knowledge and capability in antibody engineering, the first two approved radiolabeled mAbs are murine in nature and subject to all of the limitations therein including immunogenicity and short biological half-lives. In many aspects actual clinical knowledge pertaining to the use of radiolabeled mAbs remains in its infancy. This is particularly true in regards to therapies beyond hematological diseases, including fractionated dosing schema and the rational construction of drug combination cocktail therapies in efforts to functionally integrate targeted radiation therapy with established chemotherapies and external beam therapies. Clear evidence exists that valuable results may be achieved by execution of these strategies. Dominance of mAb therapies for the lymphohematopoietic malignancies and their success therein reflects inherent accessibility and radiosensitivity of these cancers. Literature consensus appears to support mAb-based therapies of solid tumor applied in the treatment of minimal residual micrometastatic disease and as an adjuvant component of a multi-modality treatment regimen. However, limitations were recognized through the investigations with less than optimal targeting agents, suboptimal chemistry, incorrect radionuclide choice, and a less than rational experimental design. As such there remains a continuing effort to refine and optimize all of the components to improve efficacy and minimize toxicity. The future will prove exciting due to the rational exploration and application of the cumulative knowledge towards making targeted radiation therapy a reality and mainstream component for the treatment and management of cancer. Acknowledgements. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, and Center for Cancer Research.
References Alvarez RD, et al. (1997) Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A Phase I/II study. Gynecol Oncol 65:94 – 101 Baselga J, Mendelsohn J (1984) Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64:127 – 154 Bass LA, et al. (2000) In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjugate Chem 11:527 – 532 Behr TM, et al. (2000) Therapeutic advantages of auger electron- over q -emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 27(7): 753 – 765 Bethge WA, et al. (2003) Selective T-cell ablation with bismuth213 labeled anti-TCR [ q as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101: 5068 – 5075 Brechbiel MW, Gansow OA (1992) Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 [ -particle emitter. J Chem Soc Perkin Trans 11173 – 11178 Clynes RA, et al. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med 6:443 – 446 Cragg MS, et al. (1999) Signaling antibodies in cancer therapy. Curr Opin Immunol 11:541 – 547 Deans JP, et al. (1993) Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 151:4494 – 4504 DeNardo GL, et al. (1998) Maximum tolerated dose of 67Cu2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma: A pilot study. Anticancer Res 18:2779 – 2788 Ehrlich P, et al. (1904) Ueber einige Verwendungen der Naphtochinonsulfos/iure. Z Physiol Chem 61:379 – 392 Faraggi M, et al. (1994) The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J Nucl Med 35(1):113 – 119 Geerlings MW (1993) Radionuclides for radioimmunotherapy: criteria for selection. Int J Biol Markers 8:180 – 186 Goddu SM, et al. (1994) Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 35(3):521 – 530 Goldenberg MM (1999) Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309 – 318 Hartmann F, et al. (1994) Radioimmunotherapy of nude mice bearing a human IL2R-expressing lymphoma utilizing the [ -emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 54:4362 – 4370 Hassfjell S, Brechbiel MW (2001) The development of the [ particle emitting radionuclides 212Bi and 213Bi for therapeutic applications. Chem Rev 101:2019 – 2036
57
58
6 Monoclonal Antibody Targeted Radiation Cancer Therapy Hortobagyi GN, Perez EA (2001) Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 28:41 – 46 Humm JL (1986) Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490 – 1497 Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30:3 – 8 Jurcic JG, et al. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100:1233 – 1239 Kassis AI (2004) The amazing world of auger electrons. Int J Radiat Biol 80(11 – 12):789 – 803 Kassis AI, et al. (1987) Kinetics of uptake, retention, and radiotoxicity of I-125 UDR in mammalian cells – implications of localized energy deposition by auger processes. Radiat Res 109(1):78 – 89 Kassis AI, et al. (1999) Comparison of strand breaks in plasmid DNA after positional changes of auger electron-emitting iodine-125. Rad Res 151:167 – 176 Knox SJ, Meredith RF (2000) Clinical radioimmunotherapy. Semin Radiat Oncol 10:73 – 93 Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495 – 497 Kurtzman SH, et al. (1988) 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 80:449 – 452 Makrigiorgos G, et al. (1990) Auger electron emitters: insights gained from in vitro experiments. Rad Environ Biophys 29: 75 – 91 Maloney DG, et al. (1998) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin’s lymphoma. Blood 90:2188 – 2195 Mattes MJ, et al. (1997) The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD-22 monoclonal antibody. Int J Cancer 71:429 – 435 McDevitt MR, et al. (1998) Radioimmunotherapy with alphaemitting nuclides. Eur J Nucl Med 25:1341 – 1351 McDevitt MR, et al. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294:1537 – 1540 Michel RB, et al. (2003) A comparison of radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 44:632 – 640 Milenic DE (2000) Radioimmunotherapy: designer molecules to potentiate effective therapy. Semin Radiat Oncol 10:139 – 155 Milenic DE (2002) Monoclonal antibody-based therapy strategies: Providing options for the cancer patient. Curr Pharm Design 8:1749 – 1764 Milenic DE, et al. (2001) In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biotherap Radiopharm 16:133 – 146 Milenic DE, et al. (2002) In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29:431 – 442 Milenic DE, et al. (2004) Antibody targeted radiation cancer therapy. Nat Rev Drug Discov 6:488 – 499 Mulligan T, et al. (1995) Phase I study of intravenous Lulabeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1:1447 – 1454
Novak-Hofer I, Schubiger PA (2002) Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med 29: 821 – 830 O’Donnell RT, et al. (1999) A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin’s lymphoma. J Nucl Med 40:2014 – 2020 O’Donoghue JA, et al. (1995) Relationships between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med 36:1902 – 1909 Packard AB, et al. (1999) Metalloradiopharmaceuticals. In: Clarke MJ, Sadler PJ (eds) Metalloradiopharmaceuticals II: diagnosis and therapy. Springer-Verlag, New York, pp 45 – 116 Pietras RJ, et al. (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347 – 1355 Rogers BE, et al. (1996) Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjugate Chem 7:511 – 522 Roselli M, et al. (1999) In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother Radiopharm 14:209 – 220 Ruegg CL, et al. (1990) Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 50:4221 – 4226 Sarup JC, et al. (1991) Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regulat 1:72 – 82 Schlom J (1990) Monoclonal antibodies: They’re more and less than you think. In: Broder S (ed) Molecular foundations of oncology. Williams and Wilkins, Baltimore, MD, pp 95 – 134 Schott ME, et al. (1994) Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 73:993 – 998 Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31:330 – 341 Thorpe PE, Derbyshire EJ (1997) Targeting of vasculature of solid tumors. J Control Release 48:277 – 288 Trauth B, et al. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301 – 305 Uchiyama T, et al. (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 126:1398 – 1340 Vaidyanathan G, Zalutsky MR (1996) Targeted therapy using alpha emitters. Phys Med Biol 41:1915 – 1931 Wu AM, et al. (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment Proc Natl Acad Sci USA 97:8495 – 8500 Zhang Y, et al. (2001) Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 42:1538 – 1544 Zalutsky M, et al. (2002) Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study. Neuro-oncol 4:S103
Chapter 7
The Production of Biopharmaceuticals B. Hughes, L.E. Hann
7.1 Introduction The term biologics refers to a broad class of medicinal products that share a number of common features. Unlike traditional medicines that are made by chemical synthesis, biologics are made by biosynthesis in living cells. Biologics are generally much larger than traditional synthetic medicinal products and range from highly complex inactivated vaccines and plasmaderived factors to highly purified, well characterised recombinant therapeutic proteins. As new biological therapies come to market, the term biologics may encompass a diverse portfolio and include therapeutic options such as gene and cellular therapies, therapeutic vaccines, and nucleic acid preparations. The scope of this chapter focuses primarily on therapeutic proteins produced in mammalian cell culture processes. The use of therapeutic proteins as the treatment of choice for certain unmet medical needs was enabled by the convergence of two emerging technologies in the 1970s: genetic engineering and the science of cell culture. These technologies provided researchers with the ability to create specific recombinant DNA molecules encoding specific proteins and the methodology to introduce these recombinant DNA molecules into bacterial or animal cells that synthesised the protein. Further advances in cell culture technology permitted the development of high-viability, high-density cell cultures and the ability to scale cultures to larger volumes. Cell cultures, maintained in large, computer-controlled, stainless steel bioreactors enabled large-scale protein production. An interesting illustrative case history in the development of a biologic can be seen with the medicinal product alpha-interferon. In the early 1970s, interferons were heralded as promising therapeutics for a vari-
ety of disease conditions from viral infections to cancer. Initially, alpha-interferon was produced by purification of the active protein from human white blood cells. As cell culture technology advanced, a number of groups were successful in producing alpha-interferon in vitro, from cultures of transformed human lymphoblastoid cells that spontaneously produced a range of endogenous interferons. The advent of recombinant DNA technology enabled the creation of DNA vectors containing the alpha-interferon gene and the successful expression of the gene in bacterial cells. In 1986, both nonrecombinant and recombinant alpha-interferons gained regulatory approval. The introduction of recombinant expression systems cleared the way for several major protein products to be launched as therapeutics. Peptide hormones (erythropoietin, growth hormone, beta-interferon, reproductive hormones) (Chu and Robinson 2001; Lubiniecki and Lupker 1994; Simson 2002; Walsh 2003a) and enzymes (tissue plasminogen activator) (Walsh 2003a, 2003b) were produced. These molecules were used as “replacement therapies” to treat patients with diseases caused by the deficiency of specific molecules; supplementation of endogenous protein levels with the recombinant product provided a therapeutic benefit. Frozen cell banks, containing recombinant cells producing these replacement proteins, provided a readily available supply of the required factor that was not dependent on rare and potentially hazardous raw materials such as human blood and tissue. The next generation of protein therapeutics moved beyond the established strategies of managing disease states by restoring or supplementing endogenous proteins. Recombinant proteins emerged in the 1990s that included antibodies designed to bind to specific antigens or the cells they were attached to, permitting the removal or destruction of the antibody-bound moiety
7
60
7 The Production of Biopharmaceuticals
by the immune system or via toxic molecules attached to the antibodies. Antibodies targeting tumor markers [alemtuzumab (CamPath 2005), gemtuzumab ozogamicin (Mylotarg 2006) and trastuzumab (Herceptin 2005)] and markers of inflammatory disease [antitumour necrosis factor (TNF) antibodies for rheumatoid arthritis (Humira 2005, Remicade 2005) and antiIgE for asthma (Xolair 2005)] were successfully developed and deployed in the clinic, having a profound impact on a range of diseases. Additionally, the ability to screen patients and identify those who would respond to a particular therapy added a further refinement in treatment of various diseases. The trastuzumab molecule (Herceptin 2005), targeted toward the human epidermal growth factor receptor 2 (HER2) antigen present on certain tumor cells, has been described as an early example of “patient-directedmedicine”. In this model, the patient is first assessed for the presence and level of a specific cancer antigen, allowing for treatment with an antibody that binds to that specific antigen and recruits the immune system to attack the tumor cells. Additional mechanisms are suspected in the case of trastuzumab. Fusion proteins such as etanercept (Enbrel 2005), an anti–TNF-targeted therapy, joined the arsenal of therapeutic proteins in the late 1990s. Etanercept contains a portion of the human endogenous TNF receptor fused to the constant region (Fc) of an immunoglobulin molecule; the therapeutic effect of the molecule is to bind and sequester the proinflammatory cytokine, TNF. The development of biologics for therapeutic purposes has shown a rapid series of advances over the past 25 years from the extraction of endogenous human proteins to the development and manufacture Products (company) Erypo/Procrit (Johnson & Johnson) Epogen (Amgen) Enbrel (Amgen/Wyeth) Aranesp (Amgen) Remicade (Johnson & Johnson/ Schering-Plough) Mabthera/Rituxan (Roche) Neulasta (Amgen) Avonex (Biogen Idec) Neupogen (Amgen/Roche) Lantus (Aventis) Total top 10 Global biotech market
2004 sales Percent ($US millions) change
of specifically designed molecules targeting specific mediators of disease processes. “Designer” antibodies, containing significant modifications and specialization, add an even further level of complexity: some antibodies that target tumor cells contain a covalently bound toxin or radionuclide to replace or supplement the potency of the immune system. Additionally, advances in formulation science have allowed the development of liquid formulations that have improved patient convenience, compliance, and persistence with treatment.
7.2 The Success of Modern Biotechnology The contribution of biotechnology to medical practice and the pharmaceutical industry can be evaluated by reviewing medical advances and product revenues, as well as looking at pipeline compositions and recent approvals. Biopharmaceuticals are a growing part of research and development pipelines across the pharmaceutical industry, with an ever increasing percentage of discovery stage candidates being described as large molecules. Biologics that have gained regulatory approval over the past 10 years include molecules that offered new approaches to treating a range of diseases, allowing physicians to intervene close to the root cause of the disease rather than alleviating symptoms. Antibodies have been developed for the treatment of infectious disease (Synagis 2004), anemia (Epogen 2005), and allergenic asthma (Xolair 2005), and a number of anticancer antibodies have been added to the options available to oncologists (Walsh 2003a). Additionally, Annual 2004 market growth (%)a share (%)
3,989 2,897 2,578 2,569 2,506
–4.2 –3.8 58.8 77.9 19.8
23.0 14.1 42.1 N/A 130.8
2,192 1,873 1,383 1,344 1,014 22,346 44,353
24.4 52.1 16.4 –6.8 80.9 20.7 17.0
62.7 N/A 18.1 2.5 N/A 31.3 21.6
9.0 6.5 5.8 5.8 5.6 4.9 4.2 3.1 3.0 2.3 50.4 100.0
Table 7.1. Top ten biopharmaceuticals by global sales [from IMS Health reproduced in Lawrence S (2005) Biotech drug market steadily expands. Nat Biotechnol 23:1466]
a
Compound annual growth 1999 – 2003 N/A not available
7.3 The Science and Technology Behind Modern Biopharmaceuticals
specific anti-TNF therapies have made major contributions to the treatment of inflammatory disease. Data published in December 2005, based on 2004 sales of biotechnology drugs (excluding vaccines), showed that the global market for the top ten recombinant protein therapeutics was in excess of $44 billion (Table 7.1) (Lawrence 2005). In these reports, biopharmaceuticals constituted 5 of the top 20 best-selling drugs, and monoclonal antibody sales grew by 52 %. Moreover, biotech molecules comprised 12 of 64 FDA new molecular entity approvals in 2003 and 2004 (F-D-C Reports 2005).
7.3 The Science and Technology Behind Modern Biopharmaceuticals Heterologous gene expression is possible in a variety of systems including bacteria, yeast and animal cells, as well as in transgenic animals and plants. However, to date, every commercial therapeutic protein produced utilises either a mammalian or a microbial cell culture expression platform (Walsh 2005). The first licensed human biotechnology product, recombinant human insulin (Humulin), was produced using the bacterium Escherichia coli (Johnson 1983). Today, 30 – 40 % of all approved biopharmaceuticals are made in E. coli (Walsh 2005). The small size and relatively simple structure of insulin permitted successful manufacture in E. coli. However, insolubility issues necessitating expensive refolding steps, often associated with a reduction in bioactivity, have hampered the widespread use of bacterial manufacturing platforms. Many of today’s biopharmaceuticals are more complex recombinant replacement proteins (e.g. factor VIII for haemophilia A) or monoclonal antibodies that require post-translational modifications, such as glycosylation, for biological activity and stability. While proteins expressed in yeast and transgenic systems are glycosylated, N-glycans produced by yeast and plants are different than those present in humans, thus creating immunogenicity concerns (Wurm 2004). Recent advances in yeast glycoengineering, utilizing humanised Pichia pastoris, have demonstrated the ability to produce therapeutic glycoproteins containing nearly homogeneous human glycoforms (Gerngross 2004), paving the way for the future production of glycosylated biopharmaceuticals in nonmammalian
expression systems. As of this writing, transgenic animal systems remain commercially unproven; currently, mammalian expression systems remain the platform of choice for the manufacture of high-fidelity, soluble glycoproteins. At present, about 60 – 70 % of all licensed biopharmaceuticals are produced using mammalian cell processes. For an excellent review on protein production in mammalian systems see Wurm (2004). The majority of mammalian cell culture processes utilise Chinese hamster ovary (CHO) cells, although alternative cell lines have been used successfully including mouse myeloma (NSO), baby hamster kidney (BHK), human embryonic kidney (HEK-293), or human retina derived (PER-C6) (Butler 2005). CHO cells are the dominant platform due to their ability to grow rapidly in single-cell suspension cultures. CHO cells produce glycan structures similar, but not identical, to those found in humans due to the absence of several enzymes present in the human glycosylation pathway (Jenkins and Curling 1994). However, unlike mouse cells that generate glycan structures that are highly immunogenic in humans (Jenkins et al. 1996), nonhuman glycoforms produced by CHO cells are generally not immunogenic (Butler 2005). Suspension cultures offer advantages in terms of scale-up. Currently, stainless steel bioreactors as large as 20,000 litres are used for the manufacture of biopharmaceuticals (Thiel 2004). In 2001, 70 % of licensed processes for the production of recombinant proteins utilised stirred-tank bioreactors. While animal sera were required to support the growth of high-density cell cultures in the past, approximately 50 % of current manufacturing processes employ serum-free cell culture medium. The most common production processes for the manufacture of biopharmaceuticals are perfusion and fed-batch cultures (Hu and Aunins 1997). Perfusion culture systems allow for the continuous or semicontinuous removal of medium containing accumulated inhibitory metabolic waste products such as ammonia and lactate and add an equal volume of fresh nutrients (Griffiths 2001). Fed-batch processes utilise slow feeding of key nutrients to maintain a low concentration and steady level of primary carbon sources. This results in a more efficient primary metabolism that generates lower ammonia and lactate levels (Butler 2005). Fed-batch processes are cost-effective and have greatly increased yields. With the ability to control gas and nutrient levels as well as inhibitory waste products, cell densities of greater than 107 cells per millilitre can
61
62
7 The Production of Biopharmaceuticals
be achieved (Butler 2005). Currently, high producing processes are in the range of 3 – 6 grams per litre (Winder 2005; Wurm 2004). Cell culture conditions can affect product quality. Therefore, identification and control of critical process parameters are essential to ensure performance consistency from batch to batch. For example, the glycosylation profile of a particular recombinant protein can vary depending upon the culture duration, nutrient level, growth state of the cells, pH, temperature, and dissolved gas. Thus, process control and accurate analytical methods to monitor process controls can greatly affect manufacturing process robustness and product quality. Future technological advances will significantly influence the biopharmaceutical industry’s approach to manufacturing. Presently, mammalian cell culture processes remain competitive relative to other seemingly less expensive platforms due to the proven ability of mammalian processes to deliver high-fidelity, soluble, efficacious proteins. It is expected that further improvements, such as increases in overall productivity through increased volumetric productivity and increased yields via streamlined chromatographic purification trains, will enable mammalian expression systems to remain economically competitive with other expression platforms. However, as alternative manufacturing platforms demonstrate production and economic advantages through higher yields and shorter production times, while maintaining product safety and efficacy, these new production platforms may offer a competitive advantage. The development and application of new technologies to current manufacturing paradigms will be key in determining operational flexibility of manufacturing facilities, influencing future capital investments, overall manufacturing costs, and ultimately patient access to important new therapeutic proteins.
7.4 Process Development The delivery of a new biopharmaceutical to the marketplace requires an extensive and extended period of process development involving the application of advanced techniques in molecular biology, cell culture, separation technology, and formulation science, taking several years to complete. Prior to regulatory approval,
development of the manufacturing process consumes considerable resources in terms of equipment and material as well as the people that are needed to prepare and characterise the clinical trial material. Once the manufacturing process is finalised, the process details are transferred to the manufacturing facility where the material is to be made. Details of the manufacturing process and the characterisation of the material produced are provided to the regulatory agencies to provide evidence of a stable and reproducible process, molecule, and product. Process changes after regulatory approval require additional process and molecular analyses as well as additional filings in many cases. The creation of the Master Cell Bank (MCB) is a critical milestone in biopharmaceutical process development. The MCB is a cryopreserved, long-term store of recombinant cells, either bacterial or mammalian, containing the gene that encodes the desired protein. Following transfection of host cells with a DNA plasmid containing the desired gene, the cells are subjected to a cloning procedure to ensure genetic uniformity and then are screened to identify clones that have a stable, high-level expression of the desired protein. Once identified, the desired clone is expanded and cryopreserved in vials, creating the MCB. The MCB is the source of all cells used to manufacture the medicinal product, either directly by thawing MCB vials or via an intermediate working cell bank (WCB) derived from the MCB. Cell banks are usually laid down as hundreds of vials and stored at multiple redundant locations to ensure security of supply. These cell banks are extensively tested and characterised to ensure that they are fit for purpose, stably express the desired protein over the manufacturing period, and do not contain microbiological contaminants. Another major component of process development is defining the cell culture process that expands the small number of cells in the MCB or WCB vials into the large volumes of cells required to produce economically viable amounts of proteins in a production facility. For example, the process may require expanding 3 million cells in a 1-millilitre vial to a 20,000-litre volume in a stainless steel bioreactor to achieve 10 million cells per millilitre. The cell culture development process establishes the appropriate nutrient media and specific physiological conditions for cell growth including O2 and CO2 levels and the pH of the medium, as well as any specific manipulations required to achieve high levels of protein production. Processes may be separated into
7.5 Biopharmaceutical Manufacturing
Fig. 7.1. Overview of the production process for a biopharmaceutical product. [Reprinted with permission from Walsh, G (ed) (2003) Biopharmaceuticals: Biochemistry and biotechnology, 2nd edn. John Wiley & Sons, Chichester]
two phases including an early rapid cell growth phase to maximise the number of cells available to make protein and a second production phase to maximise protein output. The phase transition can be triggered by changes in bioreactor conditions or by the addition of certain induction molecules to the cell culture medium. The cell culture process (”upstream process”) presents the expressed protein to the “downstream process” for further processing to a pure active ingredient (Fig. 7.1). This downstream processing is usually composed of a harvest step that separates the cells from the protein product as well as a number of further separation steps that purify the protein product from the remaining cell culture-derived impurities. The process development team evaluates a wide range of separation technologies and experimental conditions to determine the optimal conditions for separating the protein product from the process impurities to ensure that all products made using the process will meet predetermined quality specifications. An important activity in most process development projects is the definition of the formulation in which the protein is delivered to the clinic or marketplace. Chemical solutions are assessed for their ability to maintain stable, intact, and biologically active protein for the desired shelf life of the biopharmaceutical. Biopharmaceuticals generally are relatively fragile at room temperature and require cold chain transport and storage. Long-term stability studies (several years in duration) are carried out on the protein using a range of temperatures followed by detailed characterisation to detect any changes in chemical structure or biological activity.
7.5 Biopharmaceutical Manufacturing Over the past 2 decades, the manufacture of biopharmaceuticals has progressed dramatically to the highly complex, state-of-the-art operations that epitomise the industry today. Modern biopharmaceutical production facilities comprise multiple departments that function together to produce, test, and assure the quality of the biological drug (usually called the drug substance) before release to a fill/finish facility for drug product manufacture. Drug product manufacturing involves the preparation of the final, sterile presentation of the biological drug substance and can include lyophilised or liquid products in vials or syringes. The drug product is packaged before ultimate delivery to the patient. Biopharmaceutical manufacturing is carried out under the philosophy and approach of good manufacturing practice (GMP). GMP is an aspect of quality assurance that ensures that the biological drug is consistently produced and controlled to a standard appropriate for its intended use. The tight controls present in modern biopharmaceutical manufacturing plants ensure consistency in the manufacture of the biological drug. Raw materials such as media, water, and gases are tested against multiple specifications before being released for use in the process. Cleaning procedures are validated to ensure that process residues or by-products are removed from equipment between successive batches. Sterilisation procedures are verified for all equipment, such as bioreactors and automated process equipment, governed by a central or distributed con-
63
64
7 The Production of Biopharmaceuticals
trol system, which helps to remove human error in the process step execution. Air quality is regulated by environmental control systems to maintain pressure differentials and high-quality, low-particulate air in processing zones that require clean operations such as latestage purification operations. Taken together, these steps assure that all aspects of manufacture are tightly controlled to deliver a biological drug that meets a predefined series of pharmaceutical biochemical and functional specifications. No aspect of the manufacturing process may be changed without proper technical assessment of its impact by authorised groups within the manufacturing organisation, and where relevant, regulatory authorities. This process, known as change control, is overseen by the quality organisation. During its manufacture, the biological drug is transferred between stages of the manufacturing process (e.g., drug substance to drug product manufacturing) only after all quality control test criteria are met and a quality assurance-led batch release process is executed.
7.6 Quality Assurance and Quality Control Quality systems, including Quality Control (QC) and Quality Assurance (QA), ensure that patients receive a safe, pure, potent, and stable product. While there are considerable similarities between biopharmaceuticals and chemically synthesised drug products, the QA/QC issues and challenges are very different in some respects. Raw materials of biological origin are carefully selected and extensively tested to minimise the risk of microbial contamination of the cell culture systems. Although biopharmaceuticals can be characterised chemically to varying degrees, it is generally accepted that the structure-function relationships and key determinants of activity for biologics are not fully determined. For these reasons, most biopharmaceuticals require some element of biological testing in addition to chemical testing, as part of routine quality control processes. Immunological, biochemical, or bioassay techniques are often used to determine the concentration and activity of the active ingredient. There is heavy reliance on in-process sampling and testing as well as testing of the final drug substance and drug product due to the complexity of the molecules. As most biopharmaceuticals are provided as injectable solutions
and are administered parenterally, careful attention is paid to the maintenance of sterility of the final product.
7.7 Facility Considerations The continued development of the biopharmaceutical industry has resulted in a significant increase in demand for manufacturing capacity. The construction of a biopharmaceutical manufacturing facility is a major undertaking, even for large, established pharmaceutical companies. Wyeth’s Grange Castle facility in Dublin, Ireland, is an example of a modern integrated biopharmaceutical campus. For smaller start-up companies, the risk level and levels of human and financial capital investment required to build a manufacturing facility can be prohibitive. A large biopharmaceutical plant with the ability to generate bulk drug substance and manufacture final drug product can take up to 5 years to build and can cost up to $1 billion. Due to timeline considerations, the construction of these expensive facilities is often underway before the efficacy of the medicine or the marketplace demand is known. Because of the inherent risk and high cost associated with building a manufacturing facility, many companies decide to partner with another company with existing capacity or use a contract manufacturer. There is a complex interplay between facility design, process development, and market assessment. It is not unusual for market volume predictions to vary by 50 – 100 % or more during the development of an innovative new biopharmaceutical. For new facilities, where emerging market data exceed the initial design capacity, a difficult series of decisions must be made. A change to the facility design during the detailed planning phase will usually incur cost and time penalties. A similar change once construction has commenced can involve major increases in project cost and timelines. In this environment, the value of an effective process development unit and a sophisticated approach to project management are invaluable. An innovative process development group can help mitigate extra expense by increasing process output or recovery, in the bioreactor or downstream process respectively, increasing plant output without additional capital spending.
Key References
7.8 Biosimilar Products (or Follow-on Biologics) The era of follow-on biopharmaceuticals has arrived. A number of early biopharmaceuticals that lost patent protection in 2006 are already in production by noninnovator companies (Walsh 2003a). Some of the follow-on biologics currently on the market include human growth hormone and alpha-interferon in eastern Europe, and colony stimulating factor in China (Walsh 2003a). The terminology used for generic biopharmaceuticals is complex, with different terms having different regulatory implications. The terms “generic biopharmaceuticals”, “biogenerics”, or “generic biologics” are very similar to the small-molecule generic paradigm and suggest no requirement for clinical trials. Regulatory agencies in the United States (Food & Drug Administration, FDA) and Europe (European Medicines Agency, EMEA) have adopted the terms “followon biologic” and “biosimilar” respectively. Implied in this terminology is the understanding that clinical trials would be required to assess safety and efficacy prior to approval. The EMEA has already issued guidelines for regulatory approval of biosimilars where limited clinical trials would be required for simple, less complex products, and more extensive clinical trials required for more complex products. While numerous stakeholders have asked that the FDA develop guidance paving the way for approval of certain “generic” biologics, as of this writing, the agency has yet to offer guidelines for generic biopharmaceutical production. Many believe that the paradigm for chemical identity between biopharmaceuticals and their generic counterparts is different from small molecule drugs. For small-molecule generics, pharmaceutical and bioequivalence predict an equal therapeutic equivalence. This certainly may not be the case for many generically manufactured biopharmaceuticals. Hurdles will be high for a generic biopharmaceuical to be approved as interchangeable with an innovator’s product, especially in terms of safety and efficacy profiles: the use of a different cell line for the manufacture of a generic biopharmaceutical may result in a different product profile with respect to heterogeneity, impurities, and glycosylation, raising potential immunogenicity and other concerns. The increased immunogenicity observed with reformulated erythropoietin (Eprex) is a cautionary example illustrating how changes in stabilisers, storage, and route of administration can influence
human clinical immunogenetic responses, experiences, and safety (Casadevall and Rossert 2005). The probability that follow-on biologics or biosimilars will require limited clinical trials to prove “comparability” will make the cost of these molecules higher than their small-molecule generic counterparts. While the targets for biosimilars are known and proven, the development of generic versions of biopharmaceuticals will take longer and cost more than small-molecule generics. Sales and marketing costs are likely to be incurred, as most biosimilars will not be approved as interchangeable with the innovators’ product. However, even with these costs, it is likely that the price of biosimilars may be lower than innovators’ biopharmaceuticals and the savings may be significant enough for healthcare payers to exert pressure or offer incentives to switch to the lower cost alternative. Safety issues such as immunogenicity, which are difficult to predict from animal models, remain a concern and may potentially affect the widespread use of biosimilars.
7.9 Conclusion Biopharmaceuticals have become well established in the treatment of serious diseases. Hundreds of molecules, targeting a range of diseases, are being evaluated in the academic research community and in the pipelines of the pharmaceutical industry. In parallel, the technology for manufacturing these molecules is advancing. Higher capacity processes with better yields and reliability are beginning to make an impact on the high cost of producing these medicines, allowing more efficient use of costly manufacturing plants. Further progress in the technologies of biopharmaceutical discovery, development, and manufacturing is likely to increase the supply of important medicines to the patients who need them.
Key References Chu L, Robinson DK (2001) Industrial choices for protein production by large scale cell culture. Curr Opin Biotechnol 12:180 – 187 Thiel KA (2004) Biomanufacturing, from bust to boom...to bubble? Nature Biotechnol 22:1365 – 1372 Walsh G (2003a) Biopharmaceutical benchmarks – 2003. Nature Biotechnol 21:865 – 880
65
66
7 The Production of Biopharmaceuticals Walsh G (ed) (2003b) Biopharmaceuticals: Biochemistry and biotechnology, 2nd edn. John Wiley & Sons, Chichester Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393 – 1398
Full Reference List Butler M (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 68:283 – 291 CamPath® (alemtuzumab) (2005) Full prescribing information. Genzyme, Cambridge, MA Casadevall N, Rossert J (2005) Importance of biologic followons: experience with EPO. Best Pract Res Clin Haematol 18:381 – 387 Chu L, Robinson DK (2001) Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 12:180 – 187 Enbrel® (etanercept) (2005) Full prescribing information. Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals, Thousand Oaks, CA Epogen® (epoetin alfa) (2005) Full prescribing information. Amgen, Thousand Oaks, CA F-D-C Reports (2005) FDA clears 31 new molecular entities in 2004, up 10 from previous year. Pharmaceuticals Approvals Monthly 10 (January 15):3 – 5 Gerngross TU (2004) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22:1409 – 1414 Griffiths B (2001) Scale-up of suspension and anchoragedependent animal cells. Mol Biotechnol 17:225 – 238 Herceptin® (trastuzumab) (2005) Full prescribing information. Genentech, South San Francisco, CA Hu WS, Aunins JG (1997) Large-scale mammalian cell culture. Curr Opin Biotechnol 8:148 – 153 Humira® (adalimumab) (2005) Full prescribing information. Abbott Laboratories, North Chicago, IL
Jenkins N, Curling EM (1994) Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb Technol 16:354 – 364 Jenkins N, Parekh RB, James DC (1996) Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol 14:975 – 981 Johnson IS (1983) Human insulin from recombinant DNA technology. Science 219:632 – 637 Lawrence S (2005) Biotech drug market steadily expands. Nat Biotechnol 23:1466 Lubiniecki AS, Lupker JH (1994) Purified protein products of rDNA technology expressed in animal cell culture. Biologicals 22:161 – 169 Mylotarg® (gemtuzumab ozogamicin) (2006) Full Prescribing Information. Wyeth Pharmaceuticals, Philadelphia, PA Remicade® (infliximab) (2005) Full prescribing information. Centocor, Inc., Malvern, PA Simson H (2002) Growth hormone replacement therapy for adults: into the new millennium. Growth Hormone IGF Res 12:1 – 33 Synagis® (palivizumab) (2004) Full prescribing information. MedImmune, Inc., Gathersburg, MD Thiel KA (2004) Biomanufacturing, from bust to boom...to bubble? Nat Biotechnol 22:1365 – 1372 Walsh G (2003a) Biopharmaceutical benchmarks – 2003. Nat Biotechnol 21:865 – 870 Walsh G (ed) (2003b) Biopharmaceuticals: Biochemistry and biotechnology, 2nd edn. John Wiley & Sons, Chichester Walsh G (2005) Current status of biopharmaceuticals: approved product and trends in approvals. In: Knablein J (ed) Modern biopharmaceuticals. John Wiley & Sons, Chichester, pp 1 – 34 Winder R (2005) Biomanufacturing. Cell culture changes gear. Chemistry Industry 20:18 – 20 Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393 – 1398 Xolair® (omalizumab) (2005) Full prescribing information. Genentech, South San Francisco, CA
Part II
Disease-Specific Applications and Clinical Trials
II
Chapter 8
Treating Autoimmune Bullous Skin Disorders with Biologics R. Eming, A. Niedermeier, M. Pfütze, A. Jacobi, M. Hertl
8.1 Introduction
the specificity of the targeted antigens, several clinically and immune serologically distinct bullous disorders have been defined (Fig. 8.2).
8.1.1 Autoimmune Bullous Skin Disorders Autoimmune bullous skin disorders represent a group of severe, chronic skin diseases which are characterized by the presence of autoantibodies targeting distinct adhesion molecules of the epidermis and dermoepidermal basement membrane zone leading to a loss of adhesive function of the target antigen(s) (Fig. 8.1). The appearance of blisters and erosions of the skin and/ or mucous membranes is the leading clinical sign of autoimmune bullous skin disorders (Fig. 8.2). While histopathology reveals the location of the blister formation, the detection of tissue bound autoantibodies by immunofluorescent staining of uninvolved perilesional skin biopsies is mandatory for diagnosing autoimmune bullous skin disorders. Circulating autoantibodies can be visualized by indirect immunofluorescence using tissue substrates such as monkey esophagus and sodium chloride-split human skin. Based on
a
Fig. 8.1. Schematic overview of desmosomal and hemidesmosomal autoantigens in autoimmune bullous skin disorders. Shown are the major components of desmosomes which have been identified as autoantigens in the different clinical variants of pemphigus (a)
8.1.1.1 Pemphigus Desmogleins (Dsg) are transmembranous components of desmosomes, adhesion units specialized in conferring epidermal keratinocyte adhesion, and are linked to intercellular molecules of the desmosomal plaque which in turn interact with components of the cytoskeleton (Fig. 8.1a). Among several forms of pemphigus, pemphigus vulgaris (PV) and pemphigus foliaceus (PF) represent the major subtypes. IgG autoantibodies against Dsg3 in PV and Dsg1 in PF lead to loss of desmosomal adhesion of epidermal keratinocytes and intraepidermal blister formation (Fig. 8.2A – C). In PV patients suffer from flaccid blister/erosions of the mucous membranes, primarily the oral mucosa and the skin. PF is characterized by crusted painful erosions typically of the seborrheic areas such as scalp, face,
8
70
8 Treating Autoimmune Bullous Skin Disorders with Biologics Fig. 8.1. (cont.) The integrity of epidermal cohesion is largely dependent on desmosomes, plaque-like intercellular adhesion structures that connect transmembranous adhesion molecules such as the desmogleins and desmocollins with keratins of the cytoskeleton through interaction with intracellular components of the desmosomal plaque, such as desmoplakin, plakoglobin, plakophilin, envoplakin and periplakin. In addition to desmoglein 3 and 1, which are autoantigens in pemphigus, all the other aforementioned components of desmosomes have been identified as autoantigens of different clinical variants of pemphigus (b). Components of hemidesmosomes and the basement membrane are autoantigens of the pemphigoids and epidermolysis bullosa b acquisita. Basal keratinocytes adhere to the basement membrane zone by the interaction of cytoplasmic and transmembranous components of hemidesmosomes, such as BP180, BP230 and q 4 integrin, respectively, with ligands such as laminin 5 located in the dermoepidermal basement membrane zone. The intracellular hemidesmosomal components BP230 and plectin are linked to keratins of the cytoskeleton and interact with the cytoplasmic domains of BP180 and [ 6 q 4 integrin which in turn interact with laminin 5 via their ectodomains. Type VII collagen is the major component of anchoring fibrils which link the basement membrane to the dermis by direct interaction with laminin 5 in the lamina densa of the basement membrane (modified from Hertl et al. 2006) Fig. 8.2. Diagnostic and clinical characteristics of autoimmune bullous skin disorders. Pemphigus is characterized by the presence of IgG (and occasionally IgA) specific for desmosomal target antigens (as shown here by direct immunofluorescence, (A) resulting in a loss of intraepidermal adhesion (as shown by histopathology, (B) and blisters/erosions of the mucous membranes and skin (C). In the pemphigoids, including linear IgA bullous dermatosis, IgG (or IgA) autoantibodies bind to antigens of hemidesmosomes and the dermoepidermal junction (D), resulting in a loss of subepidermal adhesion (E) and tense blisters (F). Epidermolysis bullosa acquisita is associated with IgG (and sometimes IgA) binding to the anchoring fibrils underneath the dermoepidermal junction (G), resulting in a subepidermal loss of adhesion (H) and tense blisters with a tendency to scarring and milia formation (I). Dermatitis herpetiformis is associated with IgA deposits in the papillary dermis (the dotted line indicates the dermoepidermal junction) reactive with epidermal transglutaminase (K), a subepidermal loss of adhesion (L), and herpetiform blisters or pruritic papules (M)
8.1 Introduction
chest and upper back whereas mucosal lesions are absent in PF. In general, the treatment of pemphigus is based on immunosuppressive treatment regiments consisting of high dose glucocorticoids and immunosuppressive “steroid-sparing” adjuvants, including azathioprine or mycophenolate mofetil. 8.1.1.2 Bullous Pemphigoid In the pemphigoids, IgG autoantibodies against components of the dermoepidermal basement membrane, such as bullous antigen 180 (BP180/BP antigen 2/type XVII collagen), BP antigen 230 (BP230/BP antigen 1), and laminin 5 interfere with the adhesion of basal epidermal keratinocytes to the dermoepidermal basement membrane zone (Fig. 8.1b). BP180 and BP230 are transmembranous and intracellular components, respectively, of hemidesmosomes of basal epidermal keratinocytes while laminin 5 is a ligand of BP180 located in the lamina lucida of the basement membrane zone (Fig. 8.1b). Bullous pemphigoid (BP) is the most common autoimmune blistering disease in adults. Prodromal, non-bullous periods of BP may occur in which patients demonstrate pruritic eczematiform papules or urticarial plaques. The bullous manifestations of BP present as tense, fluid-filled vesicles and bullae on normal or erythematous skin in combination with urticated plaques (Fig. 8.2D – F). Involvement of the oral mucosa is rarely observed in about 10 – 30 % of patients. In contrast to pemphigus, the use of potent topical corticosteroids such as clobetasol propionate has been shown to be effective even in the treatment of generalized BP. Nevertheless, BP patients with extensive disease are usually treated with systemic prednisone at doses of 0.5 – 1.0 mg/kg/day, which is then progressively tapered. 8.1.1.3 Epidermolysis Bullosa Acquisita Epidermolysis bullosa acquisita (EBA) is a rare chronic subepidermal bullous disease of the skin and mucous membranes characterized by the presence of autoantibodies against type VII collagen, a major component of anchoring fibrils. There is a great diversity in the clinical presentation of the disease. Generally, it can be differentiated into the mechanobullous or classic form of EBA and inflammatory variants, resembling BP, Brun-
sting-Perry pemphigoid, mucous membrane pemphigoid or linear IgA bullous dermatosis. Mechanobullous EBA presents as a non-inflammatory disease with an acral distribution and skin fragility over trauma prone surfaces. The blisters and erosions heal with scarring and milia formation (Fig. 8.2G – I). Especially the mechanobullous form of EBA often reveals itself refractory to high doses of systemic glucocorticoids combined with immunosuppressive adjuvants. Other treatment options include the use of colchicines, high dose immunoglobulins or immunoadsorption. 8.1.1.4 Dermatitis Herpetiformis Duhring Dermatitis herpetiformis (DH) represents a bullous or pruritic autoimmune disorder with subepidermal blister formation which is considered to be a specific cutaneous manifestation of celiac disease, although most DH patients do not present gastrointestinal symptoms. The autoantigen of dermatitis herpetiformis, epidermal transglutaminase, is targeted by autoantibodies of the IgA class. Immunofluorescent staining of uninvolved perilesional skin biopsies reveals granular IgA deposition in the papillary dermis (Fig. 8.2K – M). DH patients show an intense pruritus with eruption of erythematous papules and herpetiform vesicles distributed symmetrically on the extensor surfaces. In addition to a gluten-free diet, the sulphonamide diamino-diphenyl sulfone (dapsone) is most commonly used in the treatment of DH. 8.1.2 Immune Pathogenesis of Bullous Autoimmune Disorders Pemphigus and pemphigoid are considered to be prototypic bullous disorders based on their well-characterized immune pathogenesis. Apart from pemphigus and BP, there is only circumstantial evidence that autoreactive T cells are present and involved in the pathogenesis of the autoimmune bullous disorders epidermolysis bullosa acquisita and dermatitis herpetiformis. In PV and BP, autoreactive CD4+ T lymphocytes that are presumably crucial in initiating the autoimmune response recognize distinct epitopes of the extracellular portions of Dsg3 and BP180, components of desmosomal and hemidesmosomal adhesion complexes of human skin, respectively. Dsg3- and BP180-reactive T cells produce T-helper 2 (Th2) cytokines, such as IL-4,
71
72
8 Treating Autoimmune Bullous Skin Disorders with Biologics Fig. 8.3. Schematic overview of the immune pathogenesis of pemphigus vulgaris. Pemphigus vulgaris (PV) is the prototype of an autoantibody-mediated immunobullous skin disorder and is characterized by a loss of intraepidermal adhesion primarily caused by IgG autoantibodies specific for desmoglein (Dsg)3 and Dsg1, components of the desmosomal adhesion complex of epidermal keratinocytes that are connected to the keratin cytoskeleton through interaction with the intracellular plaque proteins plakoglobin (PG) and desmoplakin (DP) (inset). IgG production by the autoreactive B cells is presumably regulated by Dsg3- and Dsg1-reactive Th1 and Th2 cells
IL-5 and IL-13, and presumably foster the production of autoantibodies of the Th2-dependent IgG4 subtype which are preferentially seen in active stages of these disorders (Fig. 8.3).
8.2 Rituximab (Anti-CD20 Monoclonal Antibody) in the Treatment of Autoimmune Bullous Skin Disorders 8.2.1 Biological Activity of Rituximab Rituximab is a chimeric human/mouse IgG1 monoclonal antibody with human constant regions and variable murine regions derived from a murine anti-CD20 antibody (IDEC 2B8). Rituximab is directed toward CD20, a pan B-cell glycoprotein which is expressed on B lymphocytes from the pre-B-cell stage to the pre-plasmacell stage. CD20 is a four-transmembrane glycoprotein that is involved in B-cell differentiation and activation, although its exact physiological function is not yet fully understood. Several characteristics make the CD20 antigen attractive for immunotherapy; since CD20 does not circulate in the plasma, it is neither internalized nor downregulated and there is no evidence that antibody binding leads to shedding from the cell sur-
face of the CD20+ target B cells. Among several mechanisms involved in B-cell killing by rituximab, its B-cell cytolytic activity mainly depends on antibody-dependent cell-mediated cytotoxicity (ADCC). Polymorphisms of the Fc * RIII receptor which mediates ADCC seem to influence the response to rituximab. Other mechanisms such as complement-mediated lysis and induction of apoptosis may also contribute to the Bcell-depleting activity of rituximab. Interestingly, there is recent evidence suggesting that the mechanism of Bcell killing by rituximab depends on the tissue microenvironment (Fig. 8.4). In vivo studies using hCD20 BAC (bacterial artificial chromosome) transgenic mice demonstrate that depletion of B lymphocytes varies among different B-cell compartments. In these mice, over 90 % of the circulating B cells in the peripheral blood are depleted within minutes. In lymph nodes and the spleen, B-cell depletion occurs within 24 h after application of rituximab and within 7 days in the peritoneal cavity where significant B-cell depletion is delayed. Even though more than 90 % of follicular B cells in the spleen are depleted within 2 days after rituximab application, germinal center B cells, particularly marginal zone B cells, appear to be more resistant to killing. These differences in resistance to rituximab are neither due to lack of CD20 expression nor due to differences in drug bioavailability. Thus, the
8.2 Rituximab (Anti-CD20 Monoclonal Antibody) in the Treatment of Autoimmune Bullous Skin Disorders
Fig. 8.4. Mode of action of rituximab. B-cell killing is largely mediated by antibody-dependent cell mediated cytotoxicity (ADCC). Recent data indicates that the patient’s Fc * RIII allotype seems to influence the response to rituximab. In vitro studies have shown that rituximab effectively induces complement-dependent cytotoxicity (CDC) against B-cell lines and lymphoma cells. Induction of apoptosis may also contribute to B-cell killing
differences in kinetics and sensitivity to the B-cell cytolytic activity of rituximab seem to depend on protective microenvironmental factors. The expression of the CD20 antigen is not restricted to B cells. A small number of T cells and NK cells also express low levels of CD20. A recent study with 24 rheumatoid arthritis (RA) patients showed that these cell populations disappear for a mean of 5 months after rituximab therapy. The authors did not find significant changes in the total number or frequency of other T-cell subpopulations in the peripheral blood. 8.2.2 Clinical Experience with Rituximab Therapy In December 1997 the US Food and Drug Administration (FDA) approved rituximab for the treatment of relapsing or refractory indolent CD20+ B-cell nonHodgkin’s lymphoma (NHL). More recently, rituximab was also approved for the treatment of aggressive NHL in combination with standard chemotherapy in the US and in Europe. The use of rituximab in the treatment of RA was endorsed by the FDA approval in March 2006.
The current application of rituximab in autoantibody mediated autoimmune diseases was catalyzed by findings that treatment of B-cell NHL improved symptoms of lymphoma-associated autoimmune phenomena, since malignant B-cell clones are capable of secreting low-affinity self-reactive antibodies, for example autoantibodies specific for self antigens on red blood cells leading to autoimmune hemolytic anemia (Boye et al. 2003). Moreover, the rationale for applying rituximab in primary autoimmune disorders is the long-term depletion of pathogenic, autoantibody-secreting B-cell clones, thus restoring tolerance. Follow-up of rituximab-induced B-cell depletion in 24 patients with active RA showed that B-cell repopulation in the peripheral blood occurred around 8 months after rituximab treatment. Increased numbers of na¨ıve and immature B cells (CD19+, IgD+, CD38high, CD10low, CD24high) were identified during repopulation in the peripheral blood similar to the B-cell populations found following bonemarrow transplantation. In contrast, patients who experienced a relapse of RA tended to show higher numbers of memory B cells during repopulation (Edwards et al. 2006). Another report by Rouziere et al. (2005) demonstrated changes in the immunoglobulin heavy-chain repertoire after rituximab treatment, suggesting that new clones of B cells emerged from the bone-marrow dominating the repopulation process. In most clinical studies treating autoimmune disorders, the oncological regimen consisting of four weekly i.v. doses of 375 mg/m2 rituximab is adopted. However, different treatment protocols are reported with two single infusions, multiple courses including four weekly infusions or single doses with up to 1 g rituximab. Besides its use in RA, rituximab is being investigated in numerous autoimmune disorders including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, lupus erythematosus, myasthenia gravis, Sjögren’s syndrome and, finally, autoimmune bullous disorders. Within the latter group of disorders, mainly severe cases of paraneoplastic pemphigus, pemphigus vulgaris, pemphigus foliaceus and, to a lesser extent, epidermolysis bullosa acquisita have been successfully treated with rituximab. 8.2.3 Rituximab in Pemphigus There is a body of evidence demonstrating that rituximab treatment is highly beneficial in the treatment of
73
74
8 Treating Autoimmune Bullous Skin Disorders with Biologics
recalcitrant clinical variants of pemphigus. As reported for lymphoma patients and other autoimmune diseases, four i.v. treatments with rituximab at 375 mg/m2 over 4 weeks induced a complete and sustained B-cell depletion in the peripheral blood which usually lasted for 6 – 9 months. As recently reviewed, all clinical studies and case reports using rituximab in severe